Details of Disease

General Information of Disease (ID: DISQZ2X8)

• Disease Name: Renal cell carcinoma
• Synonyms: renal cell adenocarcinoma; kidney adenocarcinoma; hypernephroma; renal cell carcinoma; RCC; renal cell carcinoma (disease)
• Disease Class: 2C90: Renal cell carcinoma
• Definition: A carcinoma that arises from glandular epithelial cells of the kidney
• Disease Hierarchy:
  DIS3IHTY: Adenocarcinoma
  DISER9XT: Renal carcinoma
  DISQZ2X8: Renal cell carcinoma
• ICD Code:
  ICD-11: ICD-11: 2C90
  ICD-10: ICD-10: C64
  ICD-9: ICD-9: 189
  Expand ICD-9: 189
• Disease Identifiers:
  MONDO ID: MONDO_0005086
  MESH ID: D002292
  UMLS CUI: C0007134
  MedGen ID: 766
  HPO ID: HP:0005584
  Orphanet ID: 217071
  SNOMED CT ID: 41607009

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 19 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Aldesleukin	DM4YMIS	Approved	NA	[1]
Atezolizumab	DMMF8U0	Approved	Monoclonal antibody	[2]
Avelumab	DMSZLJR	Approved	Monoclonal antibody	[2]
Axitinib	DMGVH6N	Approved	Small molecular drug	[3]
Belzutifan	DML1KTO	Approved	NA	[4]
BOL-303259-X	DM2EXC5	Approved	Small molecular drug	[5]
CreaVax-RCC	DME7N5P	Approved	NA	[6]
Everolimus	DM8X2EH	Approved	Small molecular drug	[7]
Lenvatinib	DMB1IU4	Approved	Small molecular drug	[2]
Nivolumab	DMAB9QE	Approved	Monoclonal antibody	[2]
Pazopanib HCl	DM6U9CQ	Approved	Small molecular drug	[8]
Pembrolizumab	DMFQEA6	Approved	Monoclonal antibody	[2]
Reniale	DMJDDCV	Approved	NA	[9]
Romidepsin	DMT5GNL	Approved	Small molecular drug	[10]
Sifalimumab	DM1BS03	Approved	Antibody	[11]
Sorafenib	DMS8IFC	Approved	Small molecular drug	[12]
Temsirolimus	DMS104F	Approved	Small molecular drug	[13]
Tivozanib	DMUKC5L	Approved	Small molecular drug	[14]
HBI-8000	DMDWYUN	Registered	Small molecular drug	[2]

This Disease is Treated as An Indication in 51 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Human coagulation factor X	DMYA6TR	BLA submitted	NA	[15]
Abexinostat	DM91LGU	Phase 3	Small molecular drug	[16]
AM0010	DMGMNUE	Phase 3	NA	[17]
AMD-070	DMVOY6B	Phase 3	Small molecular drug	[2]
BMS-986205	DM3MAYQ	Phase 3	NA	[2]
Cotellic	DMF9M57	Phase 3	Small molecular drug	[2]
IMA-901	DMV5YI1	Phase 3	NA	[18]
NKTR 214	DM376WT	Phase 3	NA	[17]
Rocapuldencel-T	DMRRFLU	Phase 3	NA	[19]
Savolitinib	DMALFKX	Phase 3	NA	[2]
TKI258	DMYLT67	Phase 3	Small molecular drug	[20]
TRC105	DM1874J	Phase 3	Monoclonal antibody	[17]
Trebananib	DMOG2X1	Phase 3	Recombinant protein	[21]
Vitespen	DMZ8BZ2	Phase 3	NA	[22]
CAP-232	DMR6LXM	Phase 2a	Small molecular drug	[23]
AGS-003	DMMNLWI	Phase 2	NA	[24]
AGS-16C3F	DM2POHA	Phase 2	NA	[2]
Anti-LAG3	DMJO402	Phase 2	NA	[17]
ATN-161	DM4T9RS	Phase 2	Small molecular drug	[25]
Autologous renal cell carcinoma vaccine	DM28W2W	Phase 2	NA	[26]
CB-839	DM094UH	Phase 2	NA	[2]
CMN-001	DM5WD87	Phase 2	Cell therapy	[27]
CRLX101	DMQUWXY	Phase 2	NA	[2]
DS-3201b	DMI69E5	Phase 2	Small molecular drug	[28]
FolateImmune	DMB9ADM	Phase 2	Small molecular drug	[29]
Girentuximab I-124	DMG3O2Z	Phase 2	Monoclonal antibody	[30]
Human interleukin-2	DM0NJWG	Phase 2	NA	[31]
Ilixadencel	DMEUOWB	Phase 2	NA	[2]
IMO-2055	DM6IQ3V	Phase 2	NA	[32]
Ispinesib	DMP2BWX	Phase 2	Small molecular drug	[33]
OSI-027	DMJX3O8	Phase 2	Small molecular drug	[34]
RX-0201	DMTBAV3	Phase 2	NA	[2]
TV-Kidney-1	DMSWGCH	Phase 2	NA	[19]
TV1-Kidney-1	DMVH0SG	Phase 2	NA	[35]
TVI-Kidney-1	DMGYSZ0	Phase 2	Vaccine	[36]
Varlilumab	DMQSC5O	Phase 2	NA	[2]
XL880	DMHJTR2	Phase 2	Small molecular drug	[37]
Anti-C-met CAR-T cells	DMV5H0S	Phase 1/2	CAR T Cell Therapy	[38]
CCT301-38 (targeting ROR2)	DM2B1V0	Phase 1/2	CAR T Cell Therapy	[39]
CCT301-59 (targeting ROR2)	DM0F9CD	Phase 1/2	CAR T Cell Therapy	[39]
CDX-014	DMBRQ99	Phase 1/2	NA	[2]
IL-2 XL	DM1CG47	Phase 1/2	NA	[40]
LAG525	DMQX5SN	Phase 1/2	NA	[2]
AGS-16 mab	DMD284G	Phase 1	Monoclonal antibody	[41]
AMG 172	DMS72GN	Phase 1	NA	[42]
Anti-hCD70 CAR transduced PBL	DMK4GIS	Phase 1	CAR T Cell Therapy	[43]
ARO-HIF2	DMV5PEK	Phase 1	Antisense oligonucleotide	[44]
Biomed 101	DMQ9KZW	Phase 1	Small molecular drug	[45]
IL-7/CD80-expressing allogeneic RCC-26 tumor cell vaccine	DMW342G	Phase 1	NA	[46]
Neovastat	DMXTYWJ	Phase 1	NA	[47]
Veglin	DM931G7	Phase 1	NA	[48]

This Disease is Treated as An Indication in 1 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Vorsetuzumab mafodotin	DMATEL0	Discontinued in Phase 1	Antibody	[49]

This Disease is Treated as An Indication in 4 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
BCL-004	DMRKGMF	Investigative	NA	[50]
GM-CAIX	DMJHNBU	Investigative	NA	[50]
GS-168	DMKOA8S	Investigative	NA	[50]
STF-62247	DMPE7DQ	Investigative	Small molecular drug	[50]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 722 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
VHL	OT2C3JRN	Strong	Autosomal dominant	[51]
ACD	OTC54EPO	Limited	Biomarker	[491]
ACY1	OT9WU7X3	Limited	Biomarker	[492]
ADIPOR2	OT2HDTL8	Limited	Biomarker	[493]
AGFG1	OTI8ZKC4	Limited	Biomarker	[148]
AGO2	OT4JY32Q	Limited	Biomarker	[148]
APLP2	OTTFE53M	Limited	Altered Expression	[494]
ARL4C	OTQ3QNNU	Limited	Biomarker	[495]
ARNT	OTMSIEZY	Limited	Biomarker	[496]
CA8	OT9Y8GA8	Limited	Biomarker	[497]
CCN3	OTOW5YL4	Limited	Altered Expression	[498]
CD82	OTH8MC64	Limited	Biomarker	[499]
CDCP1	OTD7RRWK	Limited	Altered Expression	[500]
CHCHD2	OTL5PA3Y	Limited	Biomarker	[501]
CHI3L2	OT26R3HQ	Limited	Altered Expression	[502]
CMTM5	OTMS7NDP	Limited	Biomarker	[503]
COL5A1	OT24078H	Limited	Altered Expression	[65]
CORO1A	OTVAZOHC	Limited	Altered Expression	[504]
CORO1C	OTXDF9T3	Limited	Biomarker	[505]
CUL5	OTMTZD47	Limited	Biomarker	[506]
CXCL16	OTD49T9R	Limited	Biomarker	[507]
DCAF1	OT3ZDVOE	Limited	Biomarker	[148]
DCTN4	OTM7C943	Limited	Altered Expression	[316]
DEFB1	OT5SV0E4	Limited	Biomarker	[508]
EBAG9	OTTQLQCP	Limited	Biomarker	[509]
ELOC	OT0XHHWP	Limited	Genetic Variation	[510]
EN2	OT7EZCM2	Limited	Altered Expression	[511]
FAM107A	OTBG61YZ	Limited	Posttranslational Modification	[512]
FSD1	OT8P6PT3	Limited	Biomarker	[126]
FSD1L	OTBQ48RF	Limited	Biomarker	[126]
FSTL1	OT6KEZUD	Limited	Biomarker	[513]
GTF2H1	OTCRXC6B	Limited	Altered Expression	[316]
HAS1	OTJIAG1W	Limited	Biomarker	[514]
HAVCR1	OT184CRZ	Limited	Biomarker	[515]
HEPACAM	OT1MJ51D	Limited	Altered Expression	[516]
HILPDA	OTEID3ZM	Limited	Biomarker	[75]
ING4	OT0VVG4V	Limited	Altered Expression	[517]
KDM6A	OTZM3MJJ	Limited	Biomarker	[518]
KLLN	OTV3FPH0	Limited	Altered Expression	[519]
KPNA2	OTU7FOE6	Limited	Altered Expression	[520]
LAMA4	OTHI7TA0	Limited	Biomarker	[521]
LAT	OTZC1XZ1	Limited	Biomarker	[522]
LMLN	OTQF0JPY	Limited	Posttranslational Modification	[87]
MCM3	OTOOHQPM	Limited	Posttranslational Modification	[384]
MICA	OTPEIEAR	Limited	Biomarker	[523]
MOK	OTQK7M9V	Limited	Biomarker	[524]
MPC1	OT6DYFUO	Limited	Biomarker	[525]
MT1G	OTAV1OCR	Limited	Altered Expression	[526]
MT1M	OTVT8PLU	Limited	Posttranslational Modification	[526]
NDNF	OTCDL9PG	Limited	Biomarker	[527]
NOP53	OTA2YKO6	Limited	Altered Expression	[528]
NUP62	OTMN63DH	Limited	Altered Expression	[316]
OGT	OT1Z1ZXE	Limited	Altered Expression	[529]
PDCD4	OTZ6NXUX	Limited	Altered Expression	[530]
PNRC2	OTE7W7Y5	Limited	Biomarker	[531]
POLR2A	OTHJQ1DZ	Limited	Altered Expression	[532]
PRKAA1	OT7TNF0L	Limited	Biomarker	[92]
PRKAB1	OT1OG4QZ	Limited	Biomarker	[92]
RBM10	OTES2MES	Limited	Biomarker	[533]
RIN1	OTPBROUD	Limited	Biomarker	[534]
RIT1	OTVNOGOH	Limited	Biomarker	[535]
RPAIN	OTBMXAYK	Limited	Biomarker	[148]
RWDD3	OTE76DY5	Limited	Altered Expression	[536]
SCAMP1	OTFS4IKJ	Limited	Biomarker	[537]
SESN2	OT889IXY	Limited	Biomarker	[538]
SFRP1	OT0U9G41	Limited	Posttranslational Modification	[539]
SFRP5	OTLCVVSH	Limited	Posttranslational Modification	[540]
SOX4	OTSS40SS	Limited	Biomarker	[541]
SPAAR	OTWXG2R8	Limited	Altered Expression	[542]
SPINK13	OTEU2OSU	Limited	Altered Expression	[543]
SPINT2	OTQV7BKQ	Limited	Biomarker	[544]
SRA1	OTYOGMTG	Limited	Altered Expression	[83]
SRL	OT7IEBWZ	Limited	Genetic Variation	[545]
STX6	OTC5F5M6	Limited	Altered Expression	[546]
TIMP3	OTDGQAD1	Limited	Biomarker	[547]
TMPRSS13	OTMAOAP3	Limited	Posttranslational Modification	[87]
TNIP1	OTRAOTEW	Limited	Biomarker	[548]
TRIB3	OTG5OS7X	Limited	Altered Expression	[549]
APH1A	OT97F1TU	Disputed	Genetic Variation	[132]
COMMD5	OT6R7DXN	Disputed	Biomarker	[550]
SAG	OTDNS3ZQ	Disputed	Altered Expression	[551]
ACYP2	OTRB4S6X	moderate	Genetic Variation	[552]
ALDOA	OTWRFTIB	moderate	Altered Expression	[553]
ALDOB	OT7FR69A	moderate	Biomarker	[554]
AMPD1	OTU17BCI	moderate	Biomarker	[193]
ANXA6	OT9KIQ0Y	moderate	Biomarker	[483]
ARRDC1	OTMCTFHC	moderate	Biomarker	[555]
ARRDC3	OTAKW7R9	moderate	Biomarker	[555]
ASS1	OT4ZMG0Q	moderate	Biomarker	[148]
AVL9	OTZLRZ55	moderate	Biomarker	[556]
CAV2	OT1FGRQX	moderate	Biomarker	[557]
CCN4	OT69BER9	moderate	Altered Expression	[558]
CD151	OTF3UZS7	moderate	Biomarker	[559]
CDKN2B	OTAG24N1	Moderate	Autosomal dominant	[51]
CIRBP	OTXWTPBL	moderate	Altered Expression	[560]
CNPY2	OTGY8ESX	moderate	Altered Expression	[561]
COPS7B	OTZEPV2T	moderate	Biomarker	[562]
DAPK1	OTNCNUCO	moderate	Altered Expression	[211]
DIRAS1	OT07F6PE	moderate	Altered Expression	[563]
DLD	OT378CU9	moderate	Genetic Variation	[564]
EEF1A1	OT00THXS	moderate	Biomarker	[565]
ESM1	OT331Y8V	moderate	Biomarker	[566]
ESRP2	OTVTKJ4I	moderate	Genetic Variation	[139]
FAM83H	OTN0SF11	moderate	Altered Expression	[567]
FGB	OT6RKLI9	moderate	Altered Expression	[568]
FNDC5	OT5CSK9X	moderate	Biomarker	[569]
FNIP1	OTB1CC41	moderate	Biomarker	[570]
FOXK2	OTFXDZ3R	moderate	Biomarker	[571]
GAB2	OTBFN705	moderate	Altered Expression	[128]
GABPB1	OTEXDEJN	moderate	Biomarker	[572]
GPX4	OTRAFFX2	moderate	Biomarker	[573]
GTF2H4	OTPD1DIU	moderate	Altered Expression	[145]
HMGN5	OTUUAHVQ	moderate	Altered Expression	[574]
IGFN1	OTJIPVSM	moderate	Biomarker	[575]
KIFC1	OTNQDS00	moderate	Biomarker	[576]
KLF6	OTQY9S7F	moderate	Biomarker	[577]
LETM1	OT8N4MRU	moderate	Biomarker	[578]
LHX1	OT6WI2XS	moderate	Biomarker	[579]
MAGI1	OTMV4ASV	moderate	Biomarker	[580]
MAN1C1	OT44TM7D	moderate	Genetic Variation	[581]
MAP1LC3B	OTUYHB84	moderate	Biomarker	[582]
MCM2	OTGGORIQ	moderate	Altered Expression	[583]
MCM4	OT19PNNG	moderate	Altered Expression	[583]
MCM5	OTAHLB62	moderate	Altered Expression	[584]
MIP	OTEBLU3E	moderate	Biomarker	[579]
MITF	OT6XJCZH	Moderate	Autosomal dominant	[51]
MMUT	OTBBBV70	moderate	Biomarker	[583]
MT1E	OTXJKU4Y	moderate	Posttranslational Modification	[526]
MTA2	OTCCYIQJ	moderate	Biomarker	[585]
MUC13	OTWKS9MF	moderate	Altered Expression	[586]
MXD1	OTS5CTHX	moderate	Biomarker	[193]
NANOG	OTUEY1FM	moderate	Biomarker	[587]
NCR3	OT20M764	moderate	Altered Expression	[141]
NR2F2	OTJFS67N	moderate	Altered Expression	[124]
NRK	OTGR01FF	moderate	Biomarker	[588]
NRXN3	OTJ0I7HJ	moderate	Altered Expression	[134]
NSD2	OTQ6SW4R	moderate	Biomarker	[589]
NUCB2	OTHO6JWN	moderate	Biomarker	[590]
OPTN	OT2UXWH9	moderate	Biomarker	[591]
PAFAH1B1	OT9T2TCJ	moderate	Altered Expression	[592]
PANX2	OTAQ2S8R	moderate	Altered Expression	[567]
PCBP2	OTXCN9CG	moderate	Genetic Variation	[139]
PCLO	OTXJZZ98	moderate	Biomarker	[593]
PELP1	OTVXQNOT	moderate	Altered Expression	[594]
PIK3R2	OTZSUQK5	moderate	Biomarker	[595]
PLIN3	OT9ZA7MR	moderate	Altered Expression	[596]
PPP1R12C	OT9Q86JO	moderate	Biomarker	[595]
PPP1R13B	OTC88VQO	moderate	Biomarker	[595]
PRDX1	OTZ3BEC4	moderate	Biomarker	[597]
PTEN	OTOWDUNT	Moderate	Autosomal dominant	[51]
PYCR1	OTQHB52T	moderate	Altered Expression	[598]
RAB23	OTBAKFBR	moderate	Altered Expression	[599]
RASAL2	OTGMMX6W	moderate	Biomarker	[600]
RASSF6	OT25GVWY	moderate	Biomarker	[601]
RGN	OTD04KB1	moderate	Biomarker	[602]
RTCA	OTSJRVTD	moderate	Biomarker	[603]
SARS2	OTU4T99W	moderate	Biomarker	[604]
SCUBE1	OT4JY1UY	moderate	Biomarker	[605]
SDHC	OTC8G2MX	Moderate	Autosomal dominant	[51]
SDHD	OTYZ8XRH	Moderate	Autosomal dominant	[51]
SELENOW	OTVSKPAN	moderate	Biomarker	[606]
SGK2	OTCTVSHF	moderate	Altered Expression	[399]
SGK3	OTQ6QO99	moderate	Biomarker	[607]
SH3GL2	OTOE443G	moderate	Biomarker	[608]
SLC49A4	OTXL3KAM	moderate	Biomarker	[186]
STIP1	OT7TXLOX	moderate	Biomarker	[609]
TCEA1	OTBFO594	moderate	Biomarker	[610]
TMEM127	OTYHUXC1	Moderate	Autosomal dominant	[51]
TMEM52B	OTOC70IF	moderate	Altered Expression	[611]
TRPV5	OTWF4L0U	moderate	Altered Expression	[612]
A2ML1	OTWNUXIS	Strong	Biomarker	[613]
AADAC	OT8VACT2	Strong	Biomarker	[614]
ABCA13	OTTHTUQN	Strong	Altered Expression	[615]
ACAT2	OTZ092ZJ	Strong	Altered Expression	[616]
ACCS	OTHIHI9D	Strong	Genetic Variation	[617]
ACOT7	OT7C68YV	Strong	Biomarker	[618]
ACSS1	OT6C1WQD	Strong	Biomarker	[478]
ACTBL2	OTD6B81U	Strong	Biomarker	[618]
ACTG2	OTRDWUO0	Strong	Biomarker	[618]
ADAM28	OT3GBVHL	Strong	Altered Expression	[619]
ADAMTS2	OTTK22NO	Strong	Biomarker	[161]
AHNAK	OT6KH1WG	Strong	Biomarker	[231]
AIM2	OT86QUI8	Strong	Altered Expression	[620]
AKAP13	OTOZAR14	Strong	Biomarker	[231]
AKT1S1	OT4JHN4Y	Strong	Biomarker	[621]
ALPP	OTZU4G9W	Strong	Biomarker	[176]
AMBP	OTLU8GU8	Strong	Altered Expression	[622]
ANAPC16	OTG9MUYS	Strong	Genetic Variation	[150]
ANGPT4	OT881M3K	Strong	Altered Expression	[623]
ANKHD1	OTVYQ7ZL	Strong	Altered Expression	[624]
ANKRD2	OT4UYZ71	Strong	Biomarker	[625]
ANP32B	OT3SQMLU	Strong	Altered Expression	[444]
ANXA4	OTUCRYXL	Strong	Biomarker	[107]
AP1M2	OTUE5YLC	Strong	Biomarker	[391]
AP5M1	OTDLWEBL	Strong	Biomarker	[312]
APAF1	OTJWIVY0	Strong	Biomarker	[626]
APOBEC3B	OTHLNI51	Strong	Altered Expression	[627]
AQP6	OTXS6UYY	Strong	Genetic Variation	[628]
ARC	OTN2QQPG	Strong	Biomarker	[629]
ARHGAP24	OTCQCEZS	Strong	Biomarker	[630]
ARHGDIB	OT9PD6CS	Strong	Altered Expression	[631]
ARHGEF5	OTUVGFT9	Strong	Biomarker	[632]
ASB15	OTI0ZVLJ	Strong	Biomarker	[231]
ASPSCR1	OTXTOD10	Strong	Biomarker	[633]
ATF2	OTNIZPEA	Strong	Altered Expression	[634]
ATP1B1	OTTO6ZP4	Strong	Posttranslational Modification	[635]
ATP5MC2	OTA5F480	Strong	Genetic Variation	[636]
ATRNL1	OTY5JUX2	Strong	Biomarker	[176]
AXIN2	OTRMGQNU	Strong	Altered Expression	[637]
B3GAT1	OTXFP98E	Strong	Biomarker	[638]
BAP1	OTS8G0EN	Strong	Autosomal dominant	[51]
BAZ1A	OTWHOVZS	Strong	Genetic Variation	[314]
BBS2	OTPF9JIB	Strong	Genetic Variation	[639]
BCAR1	OTKT2C2N	Strong	Biomarker	[230]
BHLHE41	OTY9GJ1Y	Strong	Genetic Variation	[640]
BNC1	OTGJ5WUF	Strong	Biomarker	[641]
BNIP3	OT4SO7J4	Strong	Altered Expression	[642]
BSND	OTYWZWPD	Strong	Altered Expression	[643]
BTG3	OT9ANHVT	Strong	Altered Expression	[644]
BUB1B	OT8KME51	Strong	Altered Expression	[193]
C4orf46	OTXL7SLI	Strong	Posttranslational Modification	[645]
CABIN1	OT4G5CIK	Strong	Genetic Variation	[646]
CACYBP	OTJMZD2T	Strong	Biomarker	[647]
CADM2	OT45PVKC	Strong	Biomarker	[648]
CALB1	OTM7IXDG	Strong	Genetic Variation	[649]
CAMKMT	OTLJBRUW	Strong	Altered Expression	[650]
CAND1	OTGB6NU0	Strong	Biomarker	[651]
CAPG	OTJ86KI6	Strong	Biomarker	[228]
CARD10	OT2RPM4I	Strong	Altered Expression	[652]
CARD11	OTRCTLYC	Strong	Biomarker	[231]
CAVIN2	OTFHHDRU	Strong	Altered Expression	[653]
CBFA2T2	OTNOIB23	Strong	Biomarker	[595]
CBLL2	OTB4AD3V	Strong	Altered Expression	[654]
CCAR1	OTUXLQZZ	Strong	Biomarker	[410]
CCDC60	OT9GGLTH	Strong	Genetic Variation	[655]
CCDC8	OTO295IH	Strong	Genetic Variation	[636]
CCL18	OT7JYSK9	Strong	Altered Expression	[656]
CCL27	OTUZYC61	Strong	Biomarker	[176]
CCL7	OTDIS99H	Strong	Altered Expression	[657]
CCNC	OTMVK4K4	Strong	Biomarker	[219]
CCNG2	OTII38K2	Strong	Biomarker	[658]
CD1D	OT3ROU4J	Strong	Altered Expression	[659]
CD68	OTOYEY3J	Strong	Biomarker	[660]
CDH15	OTJ1TO02	Strong	Biomarker	[214]
CDH8	OTS3SRZ6	Strong	Biomarker	[661]
CDH9	OTV9N5XK	Strong	Altered Expression	[662]
CDHR5	OTTBWQMN	Strong	Biomarker	[663]
CDK2AP2	OTR99SJ8	Strong	Genetic Variation	[217]
CDKN3	OTBE3H07	Strong	Altered Expression	[664]
CEACAM7	OTKFDTZY	Strong	Biomarker	[222]
CEMIP	OTK80FYN	Strong	Altered Expression	[665]
CENPH	OTPOO9LK	Strong	Biomarker	[666]
CEP55	OTGSG2PA	Strong	Altered Expression	[667]
CETN1	OTGQ8JOZ	Strong	Altered Expression	[668]
CHAF1A	OTXSSY4H	Strong	Altered Expression	[669]
CHAF1B	OTOMK4KH	Strong	Altered Expression	[669]
CHD5	OTS5EVHH	Strong	Genetic Variation	[670]
CHMP1A	OTVQ5UWX	Strong	Biomarker	[671]
CHMP1B	OTP715L8	Strong	Biomarker	[672]
CHPT1	OT4FJ0K3	Strong	Biomarker	[673]
CIB1	OT4BVCRU	Strong	Biomarker	[651]
CIP2A	OTVS2GXA	Strong	Biomarker	[674]
CISD3	OT0MM1MW	Strong	Biomarker	[675]
CISH	OT8T5NYL	Strong	Altered Expression	[428]
CKS1B	OTNUPLUJ	Strong	Altered Expression	[676]
CLDN7	OTNE0XHQ	Strong	Biomarker	[677]
CLDN8	OT7IIWXG	Strong	Biomarker	[678]
CLIP4	OT75KVQK	Strong	Biomarker	[679]
CLTC	OTBFASMA	Strong	Genetic Variation	[680]
CMAS	OTFQJG3C	Strong	Altered Expression	[681]
CNN2	OTH3CSXA	Strong	Biomarker	[228]
CNOT7	OTJBKCPI	Strong	Altered Expression	[669]
CNOT8	OT6CMCS0	Strong	Altered Expression	[669]
COL14A1	OTLNJ13O	Strong	Biomarker	[641]
COL15A1	OTTFKK18	Strong	Genetic Variation	[641]
COL4A3	OT6SB8X5	Strong	Altered Expression	[682]
COP1	OT6J2K12	Strong	Biomarker	[683]
CORO6	OT9TFSVB	Strong	Genetic Variation	[636]
CPQ	OTTNZNLD	Strong	Biomarker	[265]
CRABP1	OTISDG5X	Strong	Biomarker	[684]
CRABP2	OTY01V9G	Strong	Altered Expression	[685]
CRADD	OT02TZ4S	Strong	Biomarker	[200]
CRISP2	OT8HLTV5	Strong	Altered Expression	[451]
CRYGD	OTW29JC4	Strong	Biomarker	[686]
CSMD3	OTAT75SW	Strong	Biomarker	[312]
CTHRC1	OTV88X2G	Strong	Biomarker	[687]
CTNNA1	OTFC725Z	Strong	Biomarker	[214]
CTNND1	OTUMPSHR	Strong	Biomarker	[230]
CUL1	OTXPE1UZ	Strong	Biomarker	[688]
CXCL5	OTZOUPCA	Strong	Biomarker	[689]
DAB2IP	OTF456VC	Strong	Altered Expression	[690]
DACH1	OTMKNAGG	Strong	Altered Expression	[437]
DCTN6	OTI8PIN9	Strong	Altered Expression	[691]
DDT	OTF5HTYL	Strong	Altered Expression	[692]
DDX31	OTNWY581	Strong	Altered Expression	[693]
DEF6	OTIRBYVK	Strong	Altered Expression	[694]
DEFA1	OT5N1B9B	Strong	Biomarker	[695]
DERL2	OTI3TUUZ	Strong	Biomarker	[696]
DERL3	OTRZRT6Q	Strong	Genetic Variation	[432]
DES	OTI09KBW	Strong	Biomarker	[222]
DHDDS	OTVLYBUS	Strong	Biomarker	[673]
DKC1	OTX7DJR6	Strong	Altered Expression	[697]
DKK4	OTWCCVF6	Strong	Genetic Variation	[97]
DLEC1	OTMKKBUW	Strong	Biomarker	[698]
DNAJB8	OT2CDBH6	Strong	Biomarker	[244]
DNHD1	OT4U3HUW	Strong	Biomarker	[312]
DPF3	OTEWLMNB	Strong	Genetic Variation	[310]
DSG2	OTJPB2TO	Strong	Biomarker	[699]
DVL2	OTMNYNCM	Strong	Genetic Variation	[700]
DYNLL1	OTR69LHT	Strong	Biomarker	[701]
EEF2	OTZ7SZ39	Strong	Biomarker	[228]
EIF3C	OTR8RF9X	Strong	Altered Expression	[702]
EIF3D	OTDOMP80	Strong	Biomarker	[703]
EIF4B	OTE8TXA8	Strong	Biomarker	[704]
ELF5	OTLRU8YF	Strong	Altered Expression	[705]
ELK1	OTH9MXD6	Strong	Biomarker	[706]
EOMES	OTB9VQFA	Strong	Altered Expression	[707]
EP400	OTVQ75NX	Strong	Altered Expression	[708]
ERCC4	OTFIOPG1	Strong	Altered Expression	[709]
ERCC6L	OTE9V7D9	Strong	Biomarker	[710]
ESRP1	OTNCS4SL	Strong	Biomarker	[391]
ETV1	OT6PMJIK	Strong	Altered Expression	[683]
FABP7	OTRE2H4G	Strong	Altered Expression	[711]
FAM111B	OT9IQ9NV	Strong	Biomarker	[231]
FAM20C	OTW5YZ7X	Strong	Biomarker	[712]
FBLN1	OT5MHHOP	Strong	Altered Expression	[713]
FBXO22	OTEJ5MO0	Strong	Biomarker	[714]
FBXW4	OTEGSZOX	Strong	Biomarker	[614]
FCGR3B	OTSLSPZG	Strong	Altered Expression	[715]
FERMT2	OTZNPWWX	Strong	Biomarker	[716]
FGF5	OTQXGHBY	Strong	Altered Expression	[717]
FHL5	OT6C00Z1	Strong	Biomarker	[618]
FLNB	OTPCOYL6	Strong	Biomarker	[392]
FMN2	OTUY7BSV	Strong	Biomarker	[231]
FOXH1	OTEXJ9SL	Strong	Altered Expression	[718]
FOXI1	OT2UFOE2	Strong	Altered Expression	[719]
FOXP4	OTHCGIEZ	Strong	Altered Expression	[720]
FPGT	OTVZJL3U	Strong	Biomarker	[312]
FRZB	OTTO3DPY	Strong	Biomarker	[721]
FZD5	OTXFFY56	Strong	Biomarker	[722]
FZD8	OTZ9IRFL	Strong	Altered Expression	[723]
GAL3ST1	OTSFFZRD	Strong	Altered Expression	[724]
GALNT2	OTZZ5386	Strong	Biomarker	[725]
GALNT3	OT7M67WT	Strong	Altered Expression	[726]
GATA5	OTO81B63	Strong	Posttranslational Modification	[727]
GATM	OTIJ4Z11	Strong	Altered Expression	[325]
GC	OTWS63BY	Strong	Biomarker	[728]
GCN1	OTBFVD7Z	Strong	Genetic Variation	[219]
GEMIN4	OTX7402E	Strong	Genetic Variation	[729]
GLIS3	OTBC960E	Strong	Altered Expression	[730]
GNA13	OTVDL515	Strong	Biomarker	[731]
GNG4	OTOXNDI9	Strong	Altered Expression	[732]
GOLPH3	OTDLGYM3	Strong	Altered Expression	[733]
GOT2	OT6XBWN0	Strong	Altered Expression	[734]
GPSM2	OT6RPMRM	Strong	Biomarker	[278]
GRB7	OTF8Y9XY	Strong	Biomarker	[312]
GRP	OT8JDFNI	Strong	Altered Expression	[284]
GSTK1	OTDNGWAF	Strong	Genetic Variation	[342]
GSTM2	OTG4WT05	Strong	Biomarker	[735]
H4C1	OTB71W46	Strong	Biomarker	[736]
HARS1	OTHOEOTS	Strong	Biomarker	[228]
HAVCR2	OTOL603T	Strong	Altered Expression	[737]
HIC1	OTI9TWY4	Strong	Posttranslational Modification	[738]
HIF3A	OTPWAAMC	Strong	Biomarker	[739]
HIVEP3	OTM3QT3L	Strong	Biomarker	[740]
HLA-E	OTX1CTFB	Strong	Biomarker	[741]
HMMR	OT4M0JTZ	Strong	Altered Expression	[742]
HNRNPK	OTNPRM8U	Strong	Biomarker	[743]
HNRNPUL1	OTJP4U7K	Strong	Altered Expression	[744]
HOXB1	OTGC0EKI	Strong	Genetic Variation	[745]
HOXB2	OTTD6HMV	Strong	Genetic Variation	[745]
HOXB3	OT9UC5PE	Strong	Genetic Variation	[745]
HOXB4	OTH1HRW5	Strong	Genetic Variation	[745]
HOXB5	OTU74TB8	Strong	Genetic Variation	[745]
HOXB6	OT3TFQ0U	Strong	Genetic Variation	[745]
HOXB7	OTC7WYU8	Strong	Genetic Variation	[745]
HOXB8	OTKHOD17	Strong	Genetic Variation	[745]
HOXB9	OTMVHQOU	Strong	Genetic Variation	[745]
HOXC11	OT8NMHM6	Strong	Biomarker	[746]
HSPA1A	OTKGIE76	Strong	Biomarker	[747]
HSPA2	OTSDET7B	Strong	Biomarker	[747]
HSPB7	OTLATAOV	Strong	Biomarker	[748]
HSPH1	OTVRR73T	Strong	Biomarker	[749]
HTRA2	OTC7616F	Strong	Altered Expression	[240]
HTRA3	OTXJ0H4X	Strong	Biomarker	[750]
IFI27	OTI2XGIT	Strong	Altered Expression	[691]
IFNA1	OTPMKY0L	Strong	Biomarker	[751]
IFNA17	OTHXRYG3	Strong	Genetic Variation	[752]
IGF2BP1	OT9G360P	Strong	Altered Expression	[753]
IGF2BP3	OTB97VIK	Strong	Altered Expression	[754]
IGFBP4	OT2HZRBD	Strong	Altered Expression	[755]
IL10RA	OTOX3D1D	Strong	Biomarker	[756]
IL6R	OTCQL07Z	Strong	Biomarker	[757]
INHA	OT7HWCO3	Strong	Altered Expression	[758]
INPP4B	OTLROA7G	Strong	Biomarker	[759]
INSRR	OT3F75WA	Strong	Biomarker	[760]
INTS1	OT7TY1M1	Strong	Genetic Variation	[761]
IRF9	OTK4MYQJ	Strong	Biomarker	[762]
ITGA2B	OT4Y17PY	Strong	Genetic Variation	[763]
ITGA7	OTTBTAYW	Strong	Altered Expression	[764]
JADE1	OTBPJIRI	Strong	Biomarker	[765]
JAM3	OTX0F9QL	Strong	Biomarker	[766]
KANK1	OT2E7A6W	Strong	Biomarker	[767]
KANK2	OT3SZIWM	Strong	Altered Expression	[768]
KAT8	OT5LPQTR	Strong	Altered Expression	[769]
KCNH4	OTHJ8WTU	Strong	Biomarker	[706]
KCNH8	OT3I5FLB	Strong	Biomarker	[706]
KCNIP4	OTB1BS0X	Strong	Genetic Variation	[770]
KDM5D	OTEKG0KD	Strong	Biomarker	[771]
KIF1B	OTI1XQTO	Strong	Biomarker	[772]
KIF22	OTY6X6BL	Strong	Biomarker	[773]
KLF8	OTUC5CDB	Strong	Biomarker	[774]
KLHL1	OTAX6SAD	Strong	Altered Expression	[469]
KLHL35	OT1DL3FY	Strong	Genetic Variation	[636]
KLK10	OTD573EL	Strong	Biomarker	[322]
KLK11	OT5PKX7Y	Strong	Altered Expression	[775]
KMT2B	OTMMAZQX	Strong	Genetic Variation	[80]
KRIT1	OT58AP1I	Strong	Altered Expression	[650]
KRT20	OT4RB40L	Strong	Biomarker	[776]
KRT32	OTZCGZYT	Strong	Biomarker	[312]
KRT72	OTAXW63A	Strong	Biomarker	[777]
KRT8	OTTM4X11	Strong	Biomarker	[228]
L2HGDH	OTW6C712	Strong	Altered Expression	[518]
LAMTOR2	OTHEDISB	Strong	Genetic Variation	[217]
LATS1	OTOOCG4R	Strong	Biomarker	[778]
LCN1	OT8BWXTV	Strong	Altered Expression	[779]
LDHB	OT9B1CT3	Strong	Biomarker	[228]
LGALS3BP	OT9AGQKH	Strong	Biomarker	[780]
LIG1	OTEEQS43	Strong	Altered Expression	[781]
LIMD1	OTN1CG6R	Strong	Altered Expression	[782]
LMAN2L	OTJ9FAWS	Strong	Biomarker	[312]
LRIG1	OTY5HZN5	Strong	Altered Expression	[781]
LRP1B	OT4YZG2N	Strong	Biomarker	[231]
LRPAP1	OT6DVD2Q	Strong	Biomarker	[783]
LRRC3B	OT9VDGPR	Strong	Posttranslational Modification	[784]
LRRFIP1	OTN7XAUD	Strong	Altered Expression	[359]
LSAMP	OTYXVQX2	Strong	Biomarker	[785]
LY6G6D	OTG75QOC	Strong	Biomarker	[786]
MACF1	OTVIHD77	Strong	Genetic Variation	[219]
MAD2L2	OT24ZO59	Strong	Biomarker	[193]
MAGEA9	OTWGX2SD	Strong	Biomarker	[787]
MAGEB2	OTAGUVU5	Strong	Altered Expression	[788]
MAGED1	OT6EOLFC	Strong	Altered Expression	[788]
MAGT1	OTQSAV5C	Strong	Altered Expression	[167]
MAK16	OTD546E5	Strong	Biomarker	[789]
MAL2	OTVPEI80	Strong	Altered Expression	[391]
MAML1	OTQA4DDN	Strong	Biomarker	[790]
MAP1S	OT5WUD4C	Strong	Biomarker	[791]
MARCHF8	OTH7PNN2	Strong	Biomarker	[792]
MARCKSL1	OT13J2FM	Strong	Biomarker	[793]
MAX	OTKZ0YKM	Strong	Biomarker	[794]
MB	OTYWYL2D	Strong	Altered Expression	[795]
MBD2	OTUQPP0R	Strong	Biomarker	[518]
MCF2L	OTEURA8N	Strong	Genetic Variation	[796]
MCPH1	OTYT3TT5	Strong	Biomarker	[797]
MCRS1	OT8K2X8P	Strong	Biomarker	[798]
MED12	OTQZ4D2X	Strong	Biomarker	[799]
MED15	OT0D0JVD	Strong	Genetic Variation	[800]
MED8	OTSIZ1I7	Strong	Altered Expression	[799]
METTL3	OTSXP1M3	Strong	Altered Expression	[801]
MFAP1	OTZN4FT3	Strong	Biomarker	[338]
MGP	OTZWU3FU	Strong	Altered Expression	[802]
MIB1	OT5C404P	Strong	Altered Expression	[350]
MINDY4	OTBZ2SZB	Strong	Altered Expression	[196]
MLLT10	OTURMDV7	Strong	Biomarker	[312]
MLXIP	OT30UNI7	Strong	Biomarker	[792]
MRPL41	OTG5URO4	Strong	Biomarker	[803]
MSGN1	OTZGNRKZ	Strong	Biomarker	[312]
MT1H	OT0MVBM6	Strong	Biomarker	[487]
MTG1	OTC9U1LI	Strong	Biomarker	[804]
MTHFD2	OT1LQSGX	Strong	Posttranslational Modification	[805]
MUC3A	OTI4XUDY	Strong	Altered Expression	[357]
MUC4	OTLT11V1	Strong	Biomarker	[312]
MUL1	OT2JC9YR	Strong	Biomarker	[806]
MXRA5	OTXZBWCU	Strong	Altered Expression	[807]
MYH9	OT94Z706	Strong	Biomarker	[808]
MYL2	OT78PC0C	Strong	Biomarker	[732]
MYL9	OT6B22JB	Strong	Biomarker	[732]
MYLIP	OTL0PFGV	Strong	Biomarker	[792]
MYO7B	OTOQ6S1H	Strong	Genetic Variation	[150]
NAPSA	OT6F8IAL	Strong	Altered Expression	[809]
NAV3	OT97M1TR	Strong	Biomarker	[231]
NBN	OT73B5MD	Strong	Genetic Variation	[810]
NCOA6	OTOMIGTV	Strong	Biomarker	[811]
ND3	OT1OC3K3	Strong	Biomarker	[812]
NDRG1	OTVO66BO	Strong	Biomarker	[228]
NDRG2	OT5L6KD7	Strong	Biomarker	[254]
NEFH	OTMSCW5I	Strong	Posttranslational Modification	[813]
NELL2	OTS4MJZ7	Strong	Biomarker	[814]
NEU1	OTH9BY8Y	Strong	Altered Expression	[815]
NEU3	OTQ5PQOW	Strong	Biomarker	[816]
NEURL1	OT2C4P70	Strong	Altered Expression	[815]
NFATC1	OT4TMERS	Strong	Biomarker	[104]
NFIA	OTDHQ9CG	Strong	Altered Expression	[817]
NFIC	OTLMCUIB	Strong	Altered Expression	[817]
NLRP12	OTGR132Z	Strong	Biomarker	[312]
NLRP2	OTJA81JU	Strong	Biomarker	[810]
NME2	OTCYGLHV	Strong	Altered Expression	[818]
NOL3	OT1K0L0D	Strong	Altered Expression	[819]
NONO	OTN36Q6U	Strong	Genetic Variation	[820]
NPC2	OTE9UEJC	Strong	Altered Expression	[821]
NSG1	OTRIMA50	Strong	Altered Expression	[822]
NT5C1A	OTS7UF36	Strong	Genetic Variation	[646]
NUB1	OTWA6RTX	Strong	Biomarker	[823]
NUDCD1	OT8DS3CX	Strong	Altered Expression	[592]
NUSAP1	OT85HIJ5	Strong	Biomarker	[824]
NXF1	OTEFHXG6	Strong	Biomarker	[392]
OBP2A	OTBIJ5TI	Strong	Biomarker	[773]
OSR1	OTB19LEQ	Strong	Biomarker	[825]
P3H4	OTZPXYSH	Strong	Biomarker	[826]
PACC1	OTKBS8CC	Strong	Biomarker	[827]
PARD3	OTH5BPLO	Strong	Biomarker	[264]
PAX8	OTRPD9MI	Strong	Biomarker	[828]
PCDH17	OTRK0M05	Strong	Biomarker	[829]
PCDH8	OTDDOQM2	Strong	Biomarker	[830]
PCLAF	OTMVIOUU	Strong	Altered Expression	[831]
PDC	OT1UUVYY	Strong	Genetic Variation	[832]
PDHB	OT2NHE5E	Strong	Biomarker	[265]
PDLIM3	OTVXQC81	Strong	Biomarker	[176]
PDXDC1	OTKH7U5Q	Strong	Biomarker	[265]
PDZD2	OTPPVRGY	Strong	Genetic Variation	[833]
PEA15	OTKCKTSX	Strong	Altered Expression	[834]
PFN1	OTHTGA1H	Strong	Altered Expression	[835]
PIAS2	OTJLSC3V	Strong	Altered Expression	[836]
PIDD1	OTWFM930	Strong	Biomarker	[200]
PIP	OTH719AH	Strong	Biomarker	[837]
PITX1	OTA0UN4C	Strong	Biomarker	[838]
PLA2G15	OT6VJTPA	Strong	Genetic Variation	[617]
PLCL1	OTJL2C79	Strong	Biomarker	[839]
PLIN2	OTRXJ9UN	Strong	Biomarker	[840]
PMAIP1	OTXEE550	Strong	Biomarker	[841]
PNKD	OT6G9UXN	Strong	Biomarker	[265]
PNO1	OT010GIS	Strong	Biomarker	[789]
POGLUT3	OTBTJI73	Strong	Genetic Variation	[150]
POT1	OTNBXJCQ	Strong	Genetic Variation	[150]
POTEM	OT7L2HGH	Strong	Biomarker	[618]
POU2F2	OTPV0J0C	Strong	Biomarker	[422]
POU3F2	OT30NFOC	Strong	Altered Expression	[817]
PPBP	OT1FHGQS	Strong	Biomarker	[842]
PPFIA4	OTWXG0DO	Strong	Altered Expression	[843]
PRDM2	OT8L7CGX	Strong	Altered Expression	[844]
PRKX	OTDAC6Z0	Strong	Altered Expression	[845]
PROM2	OTT8IVS7	Strong	Biomarker	[391]
PRPF31	OTSJ0Z1Y	Strong	Biomarker	[183]
PRSS55	OTXXWI5Y	Strong	Altered Expression	[451]
PSG2	OT2EIXAI	Strong	Biomarker	[222]
PSMD9	OT6Y5CC3	Strong	Altered Expression	[691]
PSME3	OTSTC4YY	Strong	Biomarker	[121]
PTHLH	OTI1JF13	Strong	Biomarker	[846]
PTPRG	OT9N2WOF	Strong	Genetic Variation	[471]
PTPRT	OTV5TXNN	Strong	Biomarker	[847]
PTPRU	OTHDO0QG	Strong	Genetic Variation	[471]
PVALB	OTZW1WVQ	Strong	Biomarker	[848]
PXN	OTVMMUOF	Strong	Altered Expression	[849]
PYROXD2	OTJIX22S	Strong	Altered Expression	[850]
QRSL1	OTJDU2UG	Strong	Genetic Variation	[727]
RAB25	OTW0W6NP	Strong	Biomarker	[225]
RAB37	OTRL8IUO	Strong	Biomarker	[851]
RAB5A	OTFR2KM4	Strong	Altered Expression	[852]
RAG2	OTG9UYTW	Strong	Biomarker	[853]
RALGAPB	OTY8CGA3	Strong	Biomarker	[613]
RALYL	OT232N7Q	Strong	Altered Expression	[854]
RAN	OT2TER5M	Strong	Altered Expression	[855]
RAP1B	OTHEIIMM	Strong	Biomarker	[856]
RAP1GAP	OTC31ONQ	Strong	Altered Expression	[857]
RAP2B	OTD2NDQP	Strong	Biomarker	[858]
RAPGEF5	OT53VS75	Strong	Biomarker	[859]
RARRES1	OTETUPP5	Strong	Altered Expression	[860]
RASSF5	OT6Q41I2	Strong	Biomarker	[785]
RBM14	OTO9GMBD	Strong	Altered Expression	[861]
RBM38	OTPO8EXU	Strong	Biomarker	[862]
RBMS3	OTFSC9MR	Strong	Biomarker	[789]
RBP1	OTRP1MFC	Strong	Biomarker	[684]
RBP2	OTR8QG5V	Strong	Altered Expression	[685]
RBX1	OTYA1UIO	Strong	Biomarker	[863]
RCC1	OT25AGMB	Strong	Altered Expression	[864]
RETN	OTW5Z1NH	Strong	Altered Expression	[865]
RGS5	OTUY0Q2I	Strong	Biomarker	[866]
RHEB	OTFLTSEC	Strong	Genetic Variation	[365]
RHOBTB2	OT2DATFX	Strong	Genetic Variation	[150]
RING1	OTCWTAX0	Strong	Biomarker	[867]
RIOX2	OT2YFPI2	Strong	Altered Expression	[868]
RIT2	OTSNYG0D	Strong	Biomarker	[869]
RNASE3	OTVE2XD1	Strong	Biomarker	[870]
RNASEH2A	OT8G3G7K	Strong	Altered Expression	[871]
RNF121	OTA0YMLW	Strong	Biomarker	[872]
RNF125	OTBD1Q3X	Strong	Biomarker	[873]
RNF139	OT0PR1X5	Strong	Biomarker	[874]
RPL14	OTZZW7TK	Strong	Biomarker	[312]
RPL17	OTTYMPS6	Strong	Altered Expression	[875]
RPP14	OT4OYFSK	Strong	Genetic Variation	[217]
RPS15A	OT0BUA12	Strong	Biomarker	[876]
RPS6	OTT4D1LN	Strong	Altered Expression	[877]
RTL10	OTHGB81W	Strong	Biomarker	[878]
S100A1	OT1F2G4J	Strong	Biomarker	[879]
S100A10	OTI71243	Strong	Biomarker	[276]
S100A11	OTI57KDN	Strong	Biomarker	[880]
S100A5	OTCGGL6K	Strong	Altered Expression	[881]
SAGE1	OT4H6FFA	Strong	Altered Expression	[882]
SART1	OTHMOGO1	Strong	Biomarker	[263]
SAV1	OTSAEV92	Strong	Altered Expression	[883]
SCNN1B	OT61QQTL	Strong	Posttranslational Modification	[437]
SCUBE3	OT2EADLC	Strong	Genetic Variation	[636]
SCYL1	OTQ0IN7P	Strong	Biomarker	[884]
SDC3	OT1P0LJM	Strong	Biomarker	[885]
SDF4	OTQ7WFYW	Strong	Altered Expression	[668]
SDHA	OTOJ8QFF	Strong	Genetic Variation	[429]
SDHB	OTRE1M1T	Strong	Autosomal dominant	[51]
SDS	OT5WTJ2M	Strong	Genetic Variation	[429]
SEC14L2	OTJST64D	Strong	Biomarker	[392]
SELENOM	OTJ7PORS	Strong	Biomarker	[886]
SEMG1	OT6Z4BPQ	Strong	Altered Expression	[887]
SERPINA5	OTTZXPGD	Strong	Genetic Variation	[888]
SET	OTGYYQJO	Strong	Altered Expression	[889]
SETDB2	OTBVVP9Q	Strong	Altered Expression	[868]
SF3B2	OTNW2U4Y	Strong	Genetic Variation	[365]
SF3B6	OTPRKS6S	Strong	Genetic Variation	[217]
SFMBT1	OTKMZIBW	Strong	Biomarker	[314]
SFPQ	OTLCIAPJ	Strong	Genetic Variation	[890]
SFRP2	OT8GZ0CA	Strong	Biomarker	[614]
SH3BP2	OT90JNBS	Strong	Altered Expression	[419]
SHANK1	OTK8PV0S	Strong	Biomarker	[231]
SHOX2	OTLCZZJW	Strong	Altered Expression	[891]
SIX2	OTYOVGSC	Strong	Altered Expression	[892]
SKA1	OTDYJ12A	Strong	Altered Expression	[893]
SLC12A9	OTR7VRAK	Strong	Biomarker	[894]
SLC16A4	OT1YXBKC	Strong	Altered Expression	[330]
SLC22A18	OT9C3KR4	Strong	Genetic Variation	[895]
SLC35G2	OTFBVS0P	Strong	Biomarker	[851]
SLFN5	OTT1AESL	Strong	Altered Expression	[896]
SLPI	OTUNFUU8	Strong	Biomarker	[176]
SMAD2	OTC6VB4K	Strong	Biomarker	[897]
SMARCA1	OT0Y6PTU	Strong	Altered Expression	[898]
SMARCB1	OT2LP7LJ	Strong	Biomarker	[899]
SMG1	OTTS3SXE	Strong	Altered Expression	[256]
SMUG1	OT2YIOCQ	Strong	Biomarker	[900]
SMURF2	OT3TRVL7	Strong	Biomarker	[901]
SNAI2	OT7Y8EJ2	Strong	Biomarker	[902]
SOX7	OTOZOFAG	Strong	Biomarker	[903]
SPAG4	OTVXS2SM	Strong	Biomarker	[904]
SPAG9	OT45AHMB	Strong	Biomarker	[905]
SPARCL1	OT74DWMV	Strong	Altered Expression	[906]
SPATA2	OTOA45GL	Strong	Altered Expression	[875]
SPEN	OT37A2MD	Strong	Biomarker	[675]
SPINK1	OTSUVAL2	Strong	Biomarker	[907]
SPINT1	OT1CLR5L	Strong	Biomarker	[287]
SPOP	OTP0107S	Strong	Biomarker	[908]
SPRY2	OTH0CRCZ	Strong	Biomarker	[909]
SPTBN4	OTAJAVP9	Strong	Biomarker	[231]
SPTLC1	OTN0Z98K	Strong	Biomarker	[910]
SPZ1	OTQH8HJ5	Strong	Altered Expression	[451]
SRRM2	OTSIMMC9	Strong	Biomarker	[789]
SRXN1	OTYDBO4L	Strong	Biomarker	[911]
SSH2	OT8NCK82	Strong	Altered Expression	[912]
ST3GAL2	OT8WM21E	Strong	Altered Expression	[913]
ST3GAL4	OTNENJZQ	Strong	Altered Expression	[914]
STAG1	OT564IX4	Strong	Altered Expression	[915]
STAMBPL1	OTI4CYTF	Strong	Altered Expression	[916]
STEAP3	OTS9GZK5	Strong	Genetic Variation	[310]
STK3	OTLNSCQD	Strong	Biomarker	[917]
STRN	OTLOZL5I	Strong	Biomarker	[153]
SUB1	OTK71JYU	Strong	Genetic Variation	[217]
SUSD2	OTSJTAZP	Strong	Biomarker	[918]
SYCE1L	OTXU44F3	Strong	Altered Expression	[469]
SYNE2	OTBUXGQ0	Strong	Biomarker	[231]
SYT6	OTE3F36L	Strong	Altered Expression	[437]
TAP2	OTWSYFI7	Strong	Posttranslational Modification	[919]
TAPBP	OTL81AVZ	Strong	Biomarker	[392]
TBC1D8	OT2011SS	Strong	Biomarker	[920]
TBC1D9	OTSSCTB5	Strong	Altered Expression	[465]
TBPL1	OT4I143E	Strong	Altered Expression	[436]
TBX3	OTM64N7K	Strong	Altered Expression	[921]
TCEAL1	OTAPG2L5	Strong	Altered Expression	[822]
TCF21	OT393IMA	Strong	Biomarker	[319]
TCHP	OTVDMHSY	Strong	Biomarker	[922]
TESC	OTI8C76M	Strong	Altered Expression	[99]
TET1	OTZDHT1D	Strong	Biomarker	[923]
TET2	OTKKT03T	Strong	Biomarker	[312]
TET3	OT76U3YF	Strong	Biomarker	[924]
TFAP2B	OTR1T8E9	Strong	Altered Expression	[925]
TFCP2L1	OT7QIJ0X	Strong	Altered Expression	[926]
TFDP2	OTKQFX5H	Strong	Genetic Variation	[150]
TFEB	OTJUJJQY	Strong	Genetic Variation	[927]
TGFBI	OTR443C5	Strong	Altered Expression	[928]
TGFBR3	OTQOOUC4	Strong	Altered Expression	[707]
TICAM2	OTK7GIJ5	Strong	Altered Expression	[691]
TIMELESS	OTD8DCBJ	Strong	Biomarker	[632]
TIMP4	OT8A68SW	Strong	Altered Expression	[929]
TM7SF2	OTILU5S7	Strong	Altered Expression	[930]
TMED7	OTONO8E6	Strong	Altered Expression	[691]
TMED9	OTYGAQS0	Strong	Genetic Variation	[217]
TMEFF2	OT1WZ2QO	Strong	Posttranslational Modification	[931]
TMEM176B	OTEGF2BV	Strong	Altered Expression	[694]
TMEM45A	OT54KJG6	Strong	Altered Expression	[932]
TMSB10	OTLVZ13T	Strong	Biomarker	[933]
TNFRSF6B	OTKAN9G7	Strong	Altered Expression	[934]
TNS3	OTPG2D8Z	Strong	Altered Expression	[935]
TP53I3	OTSCM68G	Strong	Biomarker	[803]
TP53INP1	OT2363Z9	Strong	Altered Expression	[768]
TP73	OT0LUO47	Strong	Altered Expression	[936]
TPD52	OTPKSK43	Strong	Biomarker	[937]
TPM1	OTD73X6R	Strong	Altered Expression	[938]
TPM3	OT5RU5G6	Strong	Genetic Variation	[939]
TPPP	OTCFMSUF	Strong	Genetic Variation	[217]
TRAF1	OTTLM5RU	Strong	Biomarker	[940]
TRAM1	OT3I0H8E	Strong	Altered Expression	[941]
TRIM33	OT0KS4J7	Strong	Altered Expression	[942]
TRIM9	OTKYG33W	Strong	Altered Expression	[943]
TRIP11	OT4FJEAR	Strong	Altered Expression	[102]
TSACC	OT3QW6PH	Strong	Altered Expression	[768]
TSC1	OTFF4YZ7	Strong	Genetic Variation	[146]
TTBK2	OT90YSM5	Strong	Altered Expression	[845]
DLC1	OTP8LMCR	Definitive	Biomarker	[701]
FNIP2	OT7EX8JJ	Definitive	Biomarker	[944]
MST1	OTOC4UNG	Definitive	Posttranslational Modification	[87]
NDUFS1	OTTIZDFR	Definitive	Altered Expression	[945]
PGK1	OT6V1ICH	Definitive	Altered Expression	[946]
PRCC	OTJ0KRYX	Definitive	Genetic Variation	[127]
RELA	OTUJP9CN	Definitive	Biomarker	[145]
SARDH	OTQ49Q27	Definitive	Genetic Variation	[545]
STK11	OT1YZSP3	Definitive	Biomarker	[947]
TSC2	OT47LWI9	Definitive	Genetic Variation	[146]

This Disease Is Related to 469 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
ABCC1	TTOI92F	Limited	Biomarker	[52]
ABCG2	TTIMJ02	Limited	Posttranslational Modification	[53]
ADAM10	TTVXEGU	Limited	Biomarker	[54]
ALOX12B	TTQ4QQH	Limited	Biomarker	[55]
AMACR	TTLN1AP	Limited	Biomarker	[56]
APLNR	TTJ8E43	Limited	Biomarker	[57]
AURKA	TTPS3C0	Limited	Altered Expression	[58]
BIRC5	TTTPU1G	Limited	Altered Expression	[59]
CDH2	TT1WS0T	Limited	Altered Expression	[60]
CDH5	TTXLCFO	Limited	Biomarker	[61]
CDH6	TT9QHUK	Limited	Altered Expression	[62]
CEBPB	TTUI35N	Limited	Altered Expression	[63]
CFLAR	TTJZQYH	Limited	Biomarker	[64]
COL6A3	TT5WCAH	Limited	Altered Expression	[65]
CTSG	TTQAJF1	Limited	Biomarker	[66]
DKK2	TTST5KX	Limited	Altered Expression	[67]
EDNRB	TT3ZTGU	Limited	Altered Expression	[68]
ESRRA	TTPNQAC	Limited	Biomarker	[69]
ESRRG	TT9ZRHB	Limited	Biomarker	[70]
FBXW7	TT29KY7	Limited	Biomarker	[71]
FGFR3	TTST7KB	Limited	Altered Expression	[72]
FKBP10	TT4P8O2	Limited	Biomarker	[73]
HIPK2	TTOB49C	Limited	Altered Expression	[74]
HLA-A	TTHONFT	Limited	Biomarker	[75]
HPGDS	TTCYE56	Limited	Genetic Variation	[76]
IFNB1	TT4TZ8J	Limited	Biomarker	[77]
IMP3	TTEJA2R	Limited	Altered Expression	[78]
KAT6A	TT6O1J0	Limited	Biomarker	[79]
KDM5C	TT94UCF	Limited	Genetic Variation	[80]
KIF20B	TTQECT2	Limited	Biomarker	[81]
LAIR1	TTSI7A8	Limited	Biomarker	[82]
LOXL2	TTFSUHX	Limited	Altered Expression	[83]
MAP4K1	TTSHWUP	Limited	Genetic Variation	[84]
MKNK1	TTEZAUX	Limited	Biomarker	[85]
MLH1	TTISG27	Limited	Biomarker	[86]
MSMB	TTYH1ZK	Limited	Posttranslational Modification	[87]
NEDD9	TT1UREA	Limited	Biomarker	[88]
NPTX2	TTNJ5A6	Limited	Altered Expression	[89]
NT5E	TTK0O6Y	Limited	Biomarker	[90]
PDK1	TTCZOF2	Limited	Altered Expression	[91]
PDPK1	TTYMGWX	Limited	Biomarker	[91]
PKM	TT4LOT8	Limited	Biomarker	[92]
PSMD10	TT2H4LN	Limited	Biomarker	[93]
RBCK1	TTIKUVC	Limited	Altered Expression	[94]
RCVRN	TTDQTEY	Limited	Altered Expression	[95]
S1PR1	TT9JZCK	Limited	Biomarker	[96]
SFRP4	TTX8I1Y	Limited	Genetic Variation	[97]
SLC5A2	TTF8JAT	Limited	Biomarker	[98]
SLC9A1	TTGSEFH	Limited	Biomarker	[99]
SOX5	TTXHSZK	Limited	Biomarker	[100]
SRPK1	TTU3WV6	Limited	Biomarker	[101]
THRB	TTGER3L	Limited	Biomarker	[102]
TLR1	TTW14D0	Limited	Biomarker	[103]
TRPC6	TTRBT3W	Limited	Biomarker	[104]
TSG101	TTHU7JA	Limited	Altered Expression	[105]
UCP1	TTI12YJ	Limited	Altered Expression	[106]
HSPB1	TT9AZWY	Disputed	Biomarker	[107]
IFNA2	TTSIUJ9	Disputed	Biomarker	[108]
PAK1	TTFN95D	Disputed	Altered Expression	[109]
SOD2	TT9O4C5	Disputed	Altered Expression	[110]
ACLY	TT0Z6Y2	moderate	Altered Expression	[111]
ACVRL1	TTGYPTC	moderate	Biomarker	[112]
ADORA2A	TTM2AOE	moderate	Biomarker	[113]
ALOX5	TTSJ6Q4	moderate	Biomarker	[55]
APLN	TT87D3J	moderate	Biomarker	[57]
ARG2	TTV1AG6	moderate	Biomarker	[114]
ARRB2	TT8SO2I	moderate	Biomarker	[115]
ASIC2	TTVMWLP	moderate	Biomarker	[116]
ATF4	TTQCKWT	moderate	Biomarker	[117]
BCL2A1	TTGT9C7	moderate	Altered Expression	[111]
CBL	TT7QT13	moderate	Altered Expression	[118]
CCND1	TTFCJ7S	moderate	Biomarker	[119]
CCNE1	TTCEJ4F	moderate	Altered Expression	[120]
CSNK1E	TTA8PLI	moderate	Biomarker	[121]
CXCR1	TTMWT8Z	moderate	Altered Expression	[122]
DCLK1	TTOHTCY	moderate	Biomarker	[123]
ESRRB	TTKF0XS	moderate	Biomarker	[124]
F2RL3	TTD0652	moderate	Biomarker	[125]
FN1	TTPJ921	moderate	Biomarker	[126]
GPNMB	TT7315J	moderate	Biomarker	[127]
GRB2	TTEYRJ9	moderate	Altered Expression	[128]
GRM4	TTICZ1O	moderate	Genetic Variation	[129]
HNF1A	TT01M3K	moderate	Biomarker	[130]
HOXA11	TTEX4ZA	moderate	Altered Expression	[131]
IGFBP7	TTUQ01B	moderate	Genetic Variation	[132]
IRF1	TT4TU3L	moderate	Biomarker	[133]
ITGB8	TTIF29E	moderate	Altered Expression	[134]
KDM1B	TT8VP2T	moderate	Biomarker	[135]
KDM5A	TTIG67W	moderate	Biomarker	[135]
KEAP1	TT3Z6Y9	moderate	Altered Expression	[136]
LAMP2	TTULDG7	moderate	Altered Expression	[137]
MAPK12	TTYT93M	moderate	Altered Expression	[138]
MBNL2	TTH9OLG	moderate	Biomarker	[139]
MCAM	TTHRE05	moderate	Biomarker	[140]
NCR1	TTQNRJM	moderate	Altered Expression	[141]
PDE10A	TTJW4LU	moderate	Altered Expression	[142]
PLD2	TTRLMKF	moderate	Biomarker	[143]
PPM1D	TTENJAB	moderate	Biomarker	[144]
PSIP1	TTH9LDP	moderate	Altered Expression	[145]
PTEN	TTEUQ4M	Moderate	Autosomal dominant	[51]
PTEN	TTXJ3W7	moderate	Altered Expression	[146]
RCE1	TT2AP5B	moderate	Altered Expression	[147]
RIPK1	TTVJHX8	moderate	Biomarker	[148]
RRM2	TT1S4LJ	moderate	Biomarker	[149]
SCARB1	TTRE324	moderate	Genetic Variation	[150]
SDHD	TTVH9W8	Moderate	Autosomal dominant	[51]
SENP1	TTW9HY5	moderate	Altered Expression	[151]
SETD2	TTPC3H4	moderate	Biomarker	[152]
SLC22A3	TTG2UMS	moderate	Altered Expression	[153]
ST8SIA4	TTDP8YM	moderate	Altered Expression	[154]
STC1	TTDLUER	moderate	Altered Expression	[155]
STK39	TTYQTIU	moderate	Altered Expression	[156]
ABCC2	TTFLHJV	Strong	Genetic Variation	[157]
ACR	TTAHE2N	Strong	Biomarker	[158]
ACVR1	TTJNBQA	Strong	Biomarker	[159]
ACVR2B	TTLFRKS	Strong	Biomarker	[160]
ADAM8	TTQWYMD	Strong	Altered Expression	[161]
ADAM9	TTTYQNS	Strong	Biomarker	[162]
ADAMTS1	TTS2TEI	Strong	Altered Expression	[161]
ADORA1	TTK25J1	Strong	Biomarker	[163]
AKR1C3	TT5ZWB6	Strong	Altered Expression	[164]
ALAD	TTJHKYD	Strong	Biomarker	[165]
ALOX12	TT12ABZ	Strong	Altered Expression	[166]
ALOX15	TTN9T81	Strong	Altered Expression	[166]
ALPI	TTHYMUV	Strong	Altered Expression	[167]
AMOT	TTI48OS	Strong	Biomarker	[168]
ANG	TTURHFP	Strong	Altered Expression	[169]
ANGPTL3	TT59GO7	Strong	Biomarker	[170]
ANGPTL4	TTWALY5	Strong	Biomarker	[171]
ANXA1	TTUCK4B	Strong	Biomarker	[172]
ANXA2	TT4YANI	Strong	Altered Expression	[173]
APEH	TTYWEDQ	Strong	Genetic Variation	[174]
APOL1	TTDB8PW	Strong	Biomarker	[175]
AR	TTKPW01	Strong	Biomarker	[148]
ASRGL1	TT4WT91	Strong	Biomarker	[176]
ATG7	TTLVB9Z	Strong	Altered Expression	[177]
ATIC	TT9NVXQ	Strong	Biomarker	[178]
ATP1A1	TTWK8D0	Strong	Biomarker	[179]
AXL	TTZPY6J	Strong	Altered Expression	[180]
B2M	TTY7FKA	Strong	Biomarker	[181]
BAP1	TT47RXJ	Strong	Autosomal dominant	[51]
BBC3	TT7JUKC	Strong	Altered Expression	[182]
BCL2L2	TTQ79W8	Strong	Altered Expression	[183]
BIRC2	TTQ5LRD	Strong	Altered Expression	[184]
BIRC7	TTHZ8TA	Strong	Biomarker	[185]
BMP6	TT07RIB	Strong	Biomarker	[186]
BMPR2	TTGKF90	Strong	Altered Expression	[187]
BMX	TTN2I9E	Strong	Altered Expression	[188]
BSG	TT5UJWD	Strong	Biomarker	[189]
BST2	TT90BJT	Strong	Altered Expression	[190]
BTG1	TTL7N2W	Strong	Biomarker	[191]
BTLA	TTER58P	Strong	Genetic Variation	[192]
BUB1	TT78309	Strong	Altered Expression	[193]
C1QBP	TTWTD7F	Strong	Biomarker	[194]
CA12	TTSYM0R	Strong	Altered Expression	[195]
CA4	TTZHA0O	Strong	Altered Expression	[196]
CA9	TT2LVK8	Strong	Biomarker	[197]
CAPN1	TT1WBIJ	Strong	Altered Expression	[198]
CAPN2	TTG5QB7	Strong	Altered Expression	[199]
CASP2	TT12VNG	Strong	Biomarker	[200]
CCNB1	TT9P6OW	Strong	Biomarker	[201]
CCND3	TT1JXNR	Strong	Biomarker	[202]
CCR3	TTD3XFU	Strong	Biomarker	[203]
CD209	TTBXIM9	Strong	Biomarker	[204]
CD24	TTCTYNP	Strong	Altered Expression	[205]
CD276	TT6CQUM	Strong	Altered Expression	[206]
CD38	TTPURFN	Strong	Biomarker	[207]
CD3E	TTZAT79	Strong	Altered Expression	[208]
CD70	TTNCIE0	Strong	Biomarker	[209]
CD74	TTCMYP9	Strong	Biomarker	[210]
CDC20	TTBKFDV	Strong	Altered Expression	[211]
CDC25B	TTR0SWN	Strong	Altered Expression	[212]
CDH11	TTRGWZC	Strong	Biomarker	[213]
CDH3	TTARMD9	Strong	Biomarker	[214]
CDK1	TTH6V3D	Strong	Biomarker	[215]
CDK2	TT7HF4W	Strong	Biomarker	[216]
CDK5R1	TTBYM6V	Strong	Genetic Variation	[217]
CDK7	TTQYF7G	Strong	Biomarker	[218]
CDK8	TTBJR4L	Strong	Genetic Variation	[219]
CDKN2A	TTFTWQ8	Strong	Altered Expression	[220]
CEACAM1	TTA9CK4	Strong	Altered Expression	[221]
CEACAM3	TTPX7I5	Strong	Biomarker	[222]
CGB3	TTUH273	Strong	Altered Expression	[223]
CLN3	TTORF9W	Strong	Altered Expression	[190]
COPS5	TTSTNJR	Strong	Biomarker	[224]
CRHBP	TT3PKZE	Strong	Biomarker	[225]
CRHR2	TTIY658	Strong	Biomarker	[226]
CRP	TTWRN6M	Strong	Altered Expression	[227]
CRYAB	TT7RUHB	Strong	Biomarker	[228]
CRYZ	TTP6UO8	Strong	Biomarker	[229]
CSE1L	TTTRULD	Strong	Biomarker	[230]
CTSB	TTF2LRI	Strong	Biomarker	[228]
CTSD	TTPT2QI	Strong	Biomarker	[228]
CUL7	TTI8R0P	Strong	Biomarker	[231]
CXCL11	TTWG0RE	Strong	Biomarker	[232]
CXCL9	TTWE5PB	Strong	Biomarker	[232]
CXCR2	TT30C9G	Strong	Altered Expression	[233]
CXCR3	TT1UCIJ	Strong	Biomarker	[234]
CYP1B1	TTI84H7	Strong	Altered Expression	[235]
CYP24A1	TT82UI1	Strong	Biomarker	[236]
CYP3A5	TTHS0OK	Strong	Biomarker	[237]
DAAM2	TTN0Z6H	Strong	Genetic Variation	[97]
DDC	TTN451K	Strong	Altered Expression	[238]
DFFA	TTYVQ9C	Strong	Altered Expression	[239]
DIABLO	TTN74LE	Strong	Altered Expression	[240]
DKK3	TTY2ZV6	Strong	Altered Expression	[241]
DLK1	TTF4AVB	Strong	Posttranslational Modification	[242]
DLL1	TT9CFQD	Strong	Altered Expression	[243]
DNAJB1	TTPXAWS	Strong	Biomarker	[244]
DRD1	TTZFYLI	Strong	Altered Expression	[245]
DUSP9	TT1GV6C	Strong	Altered Expression	[246]
E2F1	TTASI04	Strong	Biomarker	[247]
E2F3	TTWIJYH	Strong	Biomarker	[248]
EBP	TT4VQZX	Strong	Biomarker	[249]
ECE1	TTQ9RYT	Strong	Altered Expression	[250]
EDN2	TTMR0OP	Strong	Biomarker	[251]
EGFL7	TT7WD0H	Strong	Biomarker	[252]
EIF2AK3	TT79U1M	Strong	Altered Expression	[253]
EIF4EBP1	TTKGEBL	Strong	Altered Expression	[254]
ENPEP	TT9PBIL	Strong	Biomarker	[255]
ENPP2	TTSCIM2	Strong	Altered Expression	[256]
ENPP3	TTD4TKP	Strong	Biomarker	[257]
EPHA2	TTRJB2G	Strong	Altered Expression	[258]
EPHA3	TTHS2LR	Strong	Biomarker	[259]
EPHB4	TTI4ZX2	Strong	Altered Expression	[260]
EPOR	TTAUX24	Strong	Biomarker	[261]
ERAP2	TTVGS1C	Strong	Altered Expression	[262]
F12	TTRJSMV	Strong	Biomarker	[263]
F2RL2	TTVSEBF	Strong	Biomarker	[264]
FAAH2	TTWTES7	Strong	Biomarker	[265]
FAF1	TTSKL3G	Strong	Genetic Variation	[150]
FBXO11	TT6G10V	Strong	Altered Expression	[266]
FHIT	TTMS54D	Strong	Genetic Variation	[267]
FKBP1A	TTMW94E	Strong	Biomarker	[268]
FLT1	TT1VAUK	Strong	Biomarker	[269]
FOLH1	TT9G4N0	Strong	Genetic Variation	[270]
FSCN1	TTTRS9B	Strong	Biomarker	[271]
FTH1	TT975ZT	Strong	Altered Expression	[272]
FZD7	TTUQMO5	Strong	Biomarker	[273]
G3BP1	TTG0R8Z	Strong	Altered Expression	[274]
GAD1	TTKGEP3	Strong	Biomarker	[275]
GAS6	TT69QD2	Strong	Biomarker	[276]
GHSR	TTWDC17	Strong	Biomarker	[277]
GNAI1	TTL1HWR	Strong	Biomarker	[278]
GNAO1	TTAXD8Z	Strong	Biomarker	[278]
GNE	TT4DP5S	Strong	Biomarker	[279]
GPBAR1	TTSDVTR	Strong	Altered Expression	[280]
GPR182	TTT23CG	Strong	Biomarker	[281]
GRK5	TTTCXO0	Strong	Biomarker	[282]
GRM1	TTVBPDM	Strong	Biomarker	[283]
GRPR	TTC1MVT	Strong	Altered Expression	[284]
GSK3A	TTQWAU1	Strong	Biomarker	[285]
GSTO1	TTWO3SH	Strong	Genetic Variation	[286]
HDAC1	TT6R7JZ	Strong	Biomarker	[247]
HGFAC	TTD96RW	Strong	Altered Expression	[287]
HLA-G	TTLKFB3	Strong	Biomarker	[288]
HNF4A	TT2F3CD	Strong	Posttranslational Modification	[289]
HOXB13	TTZ6I58	Strong	Altered Expression	[290]
HPN	TT25MVL	Strong	Altered Expression	[291]
HSD11B2	TT9H85R	Strong	Biomarker	[292]
HSPA9	TTMTPG3	Strong	Biomarker	[228]
HSPD1	TT9HL5R	Strong	Biomarker	[228]
IAPP	TTHN8EM	Strong	Altered Expression	[167]
IDO1	TTZJYKH	Strong	Biomarker	[293]
IFNAR2	TTMQB37	Strong	Altered Expression	[294]
IGF1R	TTQFBMY	Strong	Biomarker	[295]
IGFBP2	TTU4QSN	Strong	Altered Expression	[296]
IGFBP5	TTDWEA8	Strong	Biomarker	[297]
IGFBP6	TTLAYV8	Strong	Altered Expression	[297]
IL17D	TTC5LTG	Strong	Biomarker	[298]
IL2	TTF89GD	Strong	Biomarker	[299]
IL24	TT1EPXZ	Strong	Biomarker	[300]
IL4R	TTDWHC3	Strong	Biomarker	[301]
ILK	TT7ALZG	Strong	Biomarker	[302]
INHBA	TTVB30D	Strong	Biomarker	[303]
INSR	TTCBFJO	Strong	Altered Expression	[304]
IRF8	TTHUBNK	Strong	Altered Expression	[305]
ITGA1	TTPERWV	Strong	Altered Expression	[306]
ITGA5	TTHIZP9	Strong	Altered Expression	[307]
ITGAV	TTT1R2L	Strong	Altered Expression	[307]
ITK	TT3C80U	Strong	Biomarker	[308]
ITPR1	TT5HWAT	Strong	Biomarker	[309]
ITPR2	TTK9OV3	Strong	Genetic Variation	[310]
JUP	TTREN0G	Strong	Biomarker	[311]
KCNMA1	TTE87WJ	Strong	Biomarker	[312]
KDM3A	TTKXS4A	Strong	Biomarker	[313]
KDM4C	TTV8CRH	Strong	Genetic Variation	[314]
KDM6B	TTDIJUQ	Strong	Biomarker	[315]
KHDRBS1	TTAT6C7	Strong	Altered Expression	[316]
KHK	TTPAFR9	Strong	Altered Expression	[317]
KIR2DL2	TTU0P73	Strong	Altered Expression	[318]
KIR2DL3	TTEX3SI	Strong	Altered Expression	[318]
KIR2DS2	TTV3CFI	Strong	Altered Expression	[318]
KISS1	TTU2O6T	Strong	Biomarker	[319]
KISS1R	TT3KBZY	Strong	Biomarker	[320]
KITLG	TTDJ51N	Strong	Altered Expression	[321]
KLK1	TT5T3P6	Strong	Biomarker	[322]
KLK2	TTJLNAW	Strong	Biomarker	[323]
KLK3	TTS78AZ	Strong	Altered Expression	[324]
KLK4	TT4319X	Strong	Altered Expression	[325]
KLK7	TTE6GTB	Strong	Altered Expression	[326]
KLRC1	TTC4IMS	Strong	Biomarker	[327]
L1CAM	TTC9D3K	Strong	Altered Expression	[194]
LAG3	TTNVXAW	Strong	Biomarker	[328]
LAPTM4B	TTEJQT0	Strong	Biomarker	[329]
LDHA	TTW76JE	Strong	Altered Expression	[330]
LGALS3	TTFPQV7	Strong	Altered Expression	[331]
LIFR	TTID542	Strong	Biomarker	[332]
LILRB1	TTC0QRJ	Strong	Altered Expression	[333]
LNPEP	TTY2KP7	Strong	Altered Expression	[334]
LRRK2	TTK0FEA	Strong	Biomarker	[231]
M6PR	TT95ICL	Strong	Biomarker	[312]
MAD1L1	TTNE9U7	Strong	Biomarker	[335]
MAGEA2	TTOZT28	Strong	Genetic Variation	[336]
MAGEA4	TT9EQUY	Strong	Altered Expression	[337]
MAGEA6	TTJIWMO	Strong	Altered Expression	[338]
MANF	TT56RYE	Strong	Genetic Variation	[339]
MAOB	TTGP7BY	Strong	Biomarker	[340]
MAP2K1	TTIDAPM	Strong	Altered Expression	[341]
MAP3K5	TTOQCD8	Strong	Biomarker	[342]
MAP3K8	TTGECUM	Strong	Biomarker	[343]
MAP3K9	TTUNSIX	Strong	Altered Expression	[344]
MAPKAP1	TTWDKCL	Strong	Altered Expression	[345]
MARK2	TTAJ45Y	Strong	Genetic Variation	[346]
MAT2A	TTSMPXQ	Strong	Biomarker	[347]
MCL1	TTL53M6	Strong	Altered Expression	[348]
MDM2	TT9TE0O	Strong	Biomarker	[349]
MKI67	TTB4UNG	Strong	Altered Expression	[350]
MME	TT5TKPM	Strong	Biomarker	[207]
MMP11	TTZW4MV	Strong	Biomarker	[351]
MMP16	TTNP4CU	Strong	Altered Expression	[352]
MST1R	TTBQ3OC	Strong	Altered Expression	[353]
MTDH	TTH6SA5	Strong	Altered Expression	[354]
MTNR1A	TT0WAIE	Strong	Altered Expression	[355]
MUC16	TTC1PS3	Strong	Altered Expression	[356]
MUC17	TTVO0JU	Strong	Altered Expression	[357]
MYC	TTNQ5ZP	Strong	Biomarker	[69]
NDUFA13	TTRU1NG	Strong	Altered Expression	[358]
NEDD8	TTNDC4K	Strong	Altered Expression	[359]
NEK1	TTO5QT2	Strong	Altered Expression	[360]
NELL1	TT7H4BF	Strong	Posttranslational Modification	[361]
NES	TTHZ752	Strong	Biomarker	[362]
NF2	TTZIK7P	Strong	Biomarker	[265]
NFKB2	TTKLNRV	Strong	Altered Expression	[145]
NR1H2	TTXA6PH	Strong	Genetic Variation	[363]
NR4A1	TTMXE2Q	Strong	Biomarker	[364]
NRAS	TTW2R9X	Strong	Genetic Variation	[365]
NRP1	TTIPJCB	Strong	Biomarker	[366]
NRP2	TTRXUVC	Strong	Biomarker	[367]
OGG1	TTRU01G	Strong	Genetic Variation	[368]
P2RY1	TTA93TL	Strong	Biomarker	[369]
PCNA	TTLG1PD	Strong	Altered Expression	[370]
PCSK7	TTD30LY	Strong	Biomarker	[371]
PDCD1	TTNBFWK	Strong	Biomarker	[372]
PDCD1LG2	TTW14O3	Strong	Biomarker	[373]
PDGFA	TTSM78N	Strong	Altered Expression	[169]
PDGFC	TTOABM9	Strong	Biomarker	[374]
PDGFD	TTSN0GA	Strong	Altered Expression	[375]
PDGFRB	TTI7421	Strong	Biomarker	[376]
PDZK1	TTDTBLM	Strong	Biomarker	[377]
PEBP1	TT1BGU8	Strong	Biomarker	[378]
PECAM1	TT4EZB2	Strong	Altered Expression	[379]
PGRMC1	TTY3LAZ	Strong	Biomarker	[179]
PHGDH	TT8DRCK	Strong	Biomarker	[380]
PIK3CA	TTEUNMR	Strong	Genetic Variation	[381]
PIK3CB	TT9H4P3	Strong	Genetic Variation	[381]
PINX1	TT4FJ3A	Strong	Biomarker	[382]
PLA2R1	TTHKW7D	Strong	Biomarker	[383]
PLK1	TTH4IP0	Strong	Altered Expression	[384]
PLOD2	TT8MEUD	Strong	Biomarker	[385]
POMC	TT21AKM	Strong	Altered Expression	[386]
PPAT	TTZFTY4	Strong	Biomarker	[387]
PRAME	TTPH7T0	Strong	Biomarker	[388]
PRKCH	TTONI0R	Strong	Altered Expression	[389]
PRKCZ	TTBSN0L	Strong	Altered Expression	[390]
PRSS8	TTT4N0Q	Strong	Biomarker	[391]
PSMB6	TT8EPLT	Strong	Altered Expression	[243]
PSMB8	TTEAD9J	Strong	Altered Expression	[392]
PSMB9	TTOUSTQ	Strong	Genetic Variation	[392]
PTBP1	TTWMX0U	Strong	Biomarker	[393]
PTGER4	TT79WV3	Strong	Biomarker	[394]
PTGS1	TT8NGED	Strong	Altered Expression	[395]
PTGS2	TTVKILB	Strong	Altered Expression	[396]
PTH1R	TTFPD47	Strong	Altered Expression	[397]
PTK2	TTON5IT	Strong	Altered Expression	[398]
PTK2B	TTTEFBV	Strong	Biomarker	[399]
PTPRZ1	TT4SEA8	Strong	Altered Expression	[400]
PYY	TTVFJLX	Strong	Genetic Variation	[401]
QPCT	TTJ7YTV	Strong	Posttranslational Modification	[402]
RAB22A	TTAJ746	Strong	Biomarker	[403]
RACK1	TTJ10AL	Strong	Biomarker	[404]
RALBP1	TTVSRUA	Strong	Biomarker	[405]
RARB	TTISP28	Strong	Altered Expression	[406]
RET	TT4DXQT	Strong	Biomarker	[127]
RHO	TTH0KSX	Strong	Biomarker	[407]
RHOB	TT6LPFO	Strong	Biomarker	[408]
RICTOR	TT143WL	Strong	Altered Expression	[409]
RNF34	TTEWDK1	Strong	Biomarker	[410]
RNPEP	TTD74YX	Strong	Altered Expression	[411]
ROBO1	TTND1YP	Strong	Genetic Variation	[412]
ROCK1	TTZN7RP	Strong	Biomarker	[413]
ROR2	TTUDPCI	Strong	Altered Expression	[414]
RPS6KA6	TT3KYWB	Strong	Biomarker	[415]
RSF1	TTMP86V	Strong	Altered Expression	[416]
RXRG	TTH029C	Strong	Altered Expression	[417]
RYR1	TTU5CIX	Strong	Biomarker	[231]
S100A9	TT0TMQG	Strong	Altered Expression	[418]
SELE	TT1PL7M	Strong	Altered Expression	[419]
SF3B1	TTL2WUI	Strong	Genetic Variation	[365]
SLC12A3	TTP362L	Strong	Biomarker	[420]
SLC15A1	TT5LF3C	Strong	Biomarker	[421]
SLC16A3	TTG6VD5	Strong	Altered Expression	[330]
SLC22A2	TT0XOJN	Strong	Biomarker	[422]
SLC2A1	TT79TKF	Strong	Altered Expression	[423]
SLC2A4	TTP6MT5	Strong	Biomarker	[423]
SLC34A2	TTQPZTM	Strong	Altered Expression	[424]
SLC3A2	TT5CZSM	Strong	Biomarker	[425]
SLC8A1	TTCF82X	Strong	Altered Expression	[426]
SMYD2	TT7YJFO	Strong	Biomarker	[427]
SOCS3	TTI0ME6	Strong	Altered Expression	[428]
SORD	TTLSRBZ	Strong	Genetic Variation	[429]
SRC	TT6PKBN	Strong	Biomarker	[123]
ST14	TTPRO7W	Strong	Altered Expression	[430]
SULF2	TTLQTHB	Strong	Biomarker	[431]
SYVN1	TT8XKYM	Strong	Genetic Variation	[432]
TAGLN2	TTP6BIJ	Strong	Biomarker	[228]
TEC	TT1ZV49	Strong	Biomarker	[433]
TEK	TT9VGXW	Strong	Biomarker	[434]
TEP1	TTQGAVX	Strong	Altered Expression	[435]
TERF1	TT1Y6J2	Strong	Altered Expression	[436]
TERF2	TT5XSLT	Strong	Altered Expression	[436]
TFAP2A	TTDY4BS	Strong	Biomarker	[437]
TGFA	TTTLQFR	Strong	Biomarker	[438]
TIAM1	TTNU6I5	Strong	Biomarker	[439]
TIE1	TTT4236	Strong	Biomarker	[440]
TMSB4X	TTMVAIU	Strong	Altered Expression	[441]
TNFRSF10A	TT5WLRX	Strong	Biomarker	[442]
TNFRSF10B	TTW20TU	Strong	Biomarker	[443]
TNFRSF12A	TTKPS7V	Strong	Altered Expression	[444]
TNFSF12	TTBTDM1	Strong	Altered Expression	[444]
TNFSF15	TTEST6I	Strong	Altered Expression	[445]
TPBG	TT70MLA	Strong	Altered Expression	[446]
TPT1	TT3PTB6	Strong	Altered Expression	[447]
TREM2	TTQRMSJ	Strong	Altered Expression	[448]
TRIM59	TT613U4	Strong	Biomarker	[449]
TRIP10	TTKHTGE	Strong	Biomarker	[450]
TRPC4	TTX0H5W	Strong	Biomarker	[451]
TXNIP	TTTLDZK	Strong	Biomarker	[452]
UBE2T	TT0A1R8	Strong	Altered Expression	[453]
UCHL1	TTX9IFP	Strong	Altered Expression	[454]
USP1	TTG9MT5	Strong	Posttranslational Modification	[454]
VEGFB	TTPJQHE	Strong	Altered Expression	[455]
VEGFC	TT0QUFV	Strong	Biomarker	[456]
VHL	TTEMWSD	Strong	Autosomal dominant	[51]
VTCN1	TTCK85E	Strong	Biomarker	[457]
WNT7A	TT8NARC	Strong	Biomarker	[458]
XIAP	TTK3WBU	Strong	Altered Expression	[459]
ZEB2	TTT2WK4	Strong	Genetic Variation	[150]
ACHE	TT1RS9F	Definitive	Altered Expression	[460]
ATM	TTKBM7V	Definitive	Genetic Variation	[461]
BCHE	TT3MSAO	Definitive	Altered Expression	[460]
CCK	TT90CMU	Definitive	Biomarker	[402]
CLU	TTRL76H	Definitive	Biomarker	[462]
COL18A1	TT63DI9	Definitive	Biomarker	[463]
CUBN	TT9YLCR	Definitive	Altered Expression	[464]
GJB1	TTSJIRP	Definitive	Biomarker	[465]
NUF2	TTIXBFP	Definitive	Altered Expression	[466]
PBRM1	TTH8ZRL	Definitive	Biomarker	[467]
TGM2	TT2F4OL	Definitive	Biomarker	[468]

This Disease Is Related to 12 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
ABCC6	DT582KR	Strong	Altered Expression	[469]
ABCD1	DTKM9DZ	Strong	Altered Expression	[470]
SLC25A3	DTCRIWV	Strong	Genetic Variation	[471]
SLC25A5	DTL1TRY	Strong	Biomarker	[472]
SLC2A2	DTUJPOL	Strong	Altered Expression	[473]
SLC2A3	DT9SQ3L	Strong	Altered Expression	[474]
SLC39A10	DTK02RZ	Strong	Biomarker	[475]
SLC39A11	DTEOAND	Strong	Genetic Variation	[476]
SLC4A4	DTWDEIL	Strong	Altered Expression	[477]
SLC50A1	DTI9CQU	Strong	Biomarker	[275]
SLC5A3	DT8ACN1	Strong	Biomarker	[265]
SLCO6A1	DTIFXNS	Strong	Genetic Variation	[342]

This Disease Is Related to 18 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
ACSS2	DEE76VW	Limited	Biomarker	[478]
AKR1A1	DED2FW3	Limited	Genetic Variation	[479]
ALDH1A1	DE2JP1Y	Limited	Biomarker	[480]
CYP1A1	DE6OQ3W	moderate	Biomarker	[481]
LDHC	DEQG7F9	moderate	Biomarker	[482]
UBASH3B	DE10BJ5	moderate	Biomarker	[483]
AGMAT	DEG5L6E	Strong	Biomarker	[484]
APRT	DE2MV1R	Strong	Biomarker	[338]
CYP2R1	DEBIHM3	Strong	Biomarker	[236]
GPT	DER5HFI	Strong	Biomarker	[485]
GSTO2	DEHMPZR	Strong	Genetic Variation	[286]
HIF1AN	DEY1CBW	Strong	Altered Expression	[486]
MT1A	DE5ME8A	Strong	Altered Expression	[487]
NAT1	DE7OAB3	Strong	Genetic Variation	[488]
NAT10	DEZV4AP	Strong	Biomarker	[176]
NNMT	DECVGJ3	Strong	Altered Expression	[489]
PARK7	DEPOVCH	Strong	Biomarker	[490]
GSTT1	DE3PKUG	Definitive	Genetic Variation	[76]

References

• [1] Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5659).
• [4] ClinicalTrials.gov (NCT04586231) A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011). U.S. National Institutes of Health.
• [5] ClinicalTrials.gov (NCT01895972) A Study Evaluating the Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024%, in Japanese Subjects With Open-Angle Glaucoma or Ocular Hypertension. U.S.National Institutes of Health.
• [6] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [7] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5889).
• [8] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [9] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026173)
• [10] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7006).
• [11] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8257).
• [12] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5711).
• [13] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5892).
• [14] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services
• [15] FDA Accepts BPL's Amended BLA Submission for Coagadex (Coagulation Factor X, Human). BPL Bio Products Laboratory USA, Inc.
• [16] ClinicalTrials.gov (NCT03592472) A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV). U.S. National Institutes of Health.
• [17] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [18] ClinicalTrials.gov (NCT01265901) IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma. U.S. National Institutes of Health.
• [19] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [20] ClinicalTrials.gov (NCT01223027) Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma. U.S. National Institutes of Health.
• [21] ClinicalTrials.gov (NCT00467025) AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib. U.S. National Institutes of Health.
• [22] ClinicalTrials.gov (NCT00033904) Survival Study Of Oncophage vs. Observation In Patients With Kidney Cancer. U.S. National Institutes of Health.
• [23] ClinicalTrials.gov (NCT00735332) Efficacy Study of TLN-232 in Patients With Recurring Metastatic Melanoma. U.S. National Institutes of Health.
• [24] ClinicalTrials.gov (NCT01482949) A Rollover Protocol for Subjects Previously Treated With AGS-003. U.S. National Institutes of Health.
• [25] ClinicalTrials.gov (NCT00131651) ATN-161 in Advanced Renal Cell Cancer. U.S. National Institutes of Health.
• [26] Clinical pipeline report, company report or official report of Dartmouth-Hitchcock Medical Center.
• [27] ClinicalTrials.gov (NCT04203901) A Phase 2b Randomized Trial of Autologous Dendritic Cell Immunotherapy (CMN-001) Plus Standard Treatment of Advanced Renal Cell Carcinoma. U.S.National Institutes of Health.
• [28] ClinicalTrials.gov (NCT04388852) DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers. U.S. National Institutes of Health.
• [29] ClinicalTrials.gov (NCT01511055) Intra-op Detection of Occult Ovarian Carcinoma Using a Folate-Alpha Receptor Specific Fluorescent Ligand. U.S. National Institutes of Health.
• [30] ClinicalTrials.gov (NCT00717587) Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer. U.S. National Institutes of Health.
• [31] Clinical pipeline report, company report or official report of Immunservice GmbH.
• [32] Clinical pipeline report, company report or official report of Idera Pharmaceuticals (2011).
• [33] ClinicalTrials.gov (NCT00095628) SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer. U.S. National Institutes of Health.
• [34] Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin. Mol Cancer Ther. 2011 Aug;10(8):1394-406.
• [35] Rethinking Immunotherapy for Brain Tumors. Michael D. Becker, MDB Communications LLC. February 22, 2012.
• [36] Clinical pipeline report, company report or official report of TVAX Biomedical.
• [37] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5679).
• [38] ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
• [39] ClinicalTrials.gov (NCT03393936) Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma
• [40] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020218)
• [41] ClinicalTrials.gov (NCT00816686) A Phase 1 Study of the Safety and Pharmacokinetics of AGS-16M18 in Subjects With Advanced Renal Cell Cancer. U.S. National Institutes of Health.
• [42] ClinicalTrials.gov (NCT01497821) AMG 172 First in Human Study in Patients With Kidney Cancer. U.S. National Institutes of Health.
• [43] ClinicalTrials.gov (NCT02830724) Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
• [44] ClinicalTrials.gov (NCT04169711) Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma. U.S. National Institutes of Health.
• [45] ClinicalTrials.gov (NCT00004890) Biomed 101 and Interleukin-2 in Treating Patients With Kidney Cancer. U.S. National Institutes of Health.
• [46] Allogeneic gene-modified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study. Gene Ther. 2011 Apr;18(4):354-63.
• [47] Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
• [48] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020056)
• [49] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020387)
• [50] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [51] The Gene Curation Coalition: A global effort to harmonize gene-disease evidence resources. Genet Med. 2022 Aug;24(8):1732-1742. doi: 10.1016/j.gim.2022.04.017. Epub 2022 May 4.
• [52] Down-regulation of miR-210-3p encourages chemotherapy resistance of renal cell carcinoma via modulating ABCC1.Cell Biosci. 2018 Feb 7;8:9. doi: 10.1186/s13578-018-0209-3. eCollection 2018.
• [53] A novel miR-203-DNMT3b-ABCG2 regulatory pathway predisposing colorectal cancer development.Mol Carcinog. 2017 Feb;56(2):464-477. doi: 10.1002/mc.22508. Epub 2016 Jun 10.
• [54] The transcription factor PAX2 regulates ADAM10 expression in renal cell carcinoma.Carcinogenesis. 2011 Nov;32(11):1713-23. doi: 10.1093/carcin/bgr195. Epub 2011 Aug 30.
• [55] Mitochondrial uncoupling reveals a novel therapeutic opportunity for p53-defective cancers. Nat Commun. 2018 Sep 26;9(1):3931.
• [56] Do clear cell papillary renal cell carcinomas have malignant potential? Diolombi ML, Cheng L, Argani P, Epstein JI.Am J Surg Pathol. December 2015;39(12):1621-1634.Urol Oncol. 2017 Jun;35(6):451-452. doi: 10.1016/j.urolonc.2017.03.020. Epub 2017 Apr 14.
• [57] Apelin and apelin receptor expression in renal cell carcinoma.Br J Cancer. 2019 Mar;120(6):633-639. doi: 10.1038/s41416-019-0396-7. Epub 2019 Feb 20.
• [58] Bexarotene - a novel modulator of AURKA and the primary cilium in VHL-deficient cells.J Cell Sci. 2018 Dec 14;131(24):jcs219923. doi: 10.1242/jcs.219923.
• [59] MALAT1 accelerates the development and progression of renal cell carcinoma by decreasing the expression of miR-203 and promoting the expression of BIRC5.Cell Prolif. 2019 Sep;52(5):e12640. doi: 10.1111/cpr.12640. Epub 2019 Jun 27.
• [60] Down-Regulation of Circular RNA_000926 Attenuates Renal Cell Carcinoma Progression through miRNA-411-Dependent CDH2 Inhibition.Am J Pathol. 2019 Dec;189(12):2469-2486. doi: 10.1016/j.ajpath.2019.06.016. Epub 2019 Aug 30.
• [61] sE-cadherin is upregulated in serum of patients with renal cell carcinoma and promotes tumor cell dissemination in vitro.Urol Oncol. 2019 Jun;37(6):355.e1-355.e9. doi: 10.1016/j.urolonc.2019.03.001. Epub 2019 Apr 18.
• [62] Cadherin-6 gene expression in conventional renal cell carcinoma: a useful marker to detect circulating tumor cells.Anticancer Res. 2005 Jan-Feb;25(1A):377-81.
• [63] TMIGD1 acts as a tumor suppressor through regulation of p21Cip1/p27Kip1 in renal cancer.Oncotarget. 2017 Dec 26;9(11):9672-9684. doi: 10.18632/oncotarget.23822. eCollection 2018 Feb 9.
• [64] c-FLIP and CD95 signaling are essential for survival of renal cell carcinoma.Cell Death Dis. 2019 May 16;10(6):384. doi: 10.1038/s41419-019-1609-y.
• [65] Identification of potential core genes in metastatic renal cell carcinoma using bioinformatics analysis.Am J Transl Res. 2019 Nov 15;11(11):6812-6825. eCollection 2019.
• [66] Up-regulation of 5-lipoxygenase by inhibition of cathepsin G enhances TRAIL-induced apoptosis through down-regulation of survivin.Oncotarget. 2017 Nov 20;8(63):106672-106684. doi: 10.18632/oncotarget.22508. eCollection 2017 Dec 5.
• [67] Wnt antagonist gene DKK2 is epigenetically silenced and inhibits renal cancer progression through apoptotic and cell cycle pathways.Clin Cancer Res. 2009 Sep 15;15(18):5678-87. doi: 10.1158/1078-0432.CCR-09-0558.
• [68] Are primary renal cell carcinoma and metastases of renal cell carcinoma the same cancer?.Urol Oncol. 2016 May;34(5):215-20. doi: 10.1016/j.urolonc.2015.12.013. Epub 2016 Feb 2.
• [69] Molecular profiling of transcription factors pinpoints MYC-estrogen related receptor -regulatory factor X5 panel for characterizing the immune microenvironment and predicting the efficacy of immune checkpoint inhibitors in renal cell carcinoma.Oncol Lett. 2019 Aug;18(2):1895-1903. doi: 10.3892/ol.2019.10523. Epub 2019 Jun 24.
• [70] Integrative Epigenetic and Gene Expression Analysis of Renal Tumor Progression to Metastasis.Mol Cancer Res. 2019 Jan;17(1):84-96. doi: 10.1158/1541-7786.MCR-17-0636. Epub 2018 Aug 21.
• [71] Fbxw7 regulates renal cell carcinoma migration and invasion via suppression of the epithelial-mesenchymal transition.Oncol Lett. 2018 Mar;15(3):3694-3702. doi: 10.3892/ol.2018.7744. Epub 2018 Jan 8.
• [72] Mutational activation of FGFR3: no involvement in the development of renal cell carcinoma.J Cancer Res Clin Oncol. 2012 Feb;138(2):359-61. doi: 10.1007/s00432-011-1130-x. Epub 2011 Dec 28.
• [73] FK506 Binding Protein 10 Is Overexpressed and Promotes Renal Cell Carcinoma.Urol Int. 2017;98(2):169-176. doi: 10.1159/000448338. Epub 2016 Sep 8.
• [74] Homeodomain interacting protein kinase-2 phosphorylates FOXM1 and promotes FOXM1-mediated tumor growth in renal cell carcinoma.J Cell Biochem. 2019 Jun;120(6):10391-10401. doi: 10.1002/jcb.28323. Epub 2019 Jan 4.
• [75] Effective induction of cytotoxic T cells recognizing an epitope peptide derived from hypoxia-inducible protein 2 (HIG2) in patients with metastatic renal cell carcinoma.Cancer Immunol Immunother. 2017 Jan;66(1):17-24. doi: 10.1007/s00262-016-1915-5. Epub 2016 Oct 18.
• [76] A systematic review and meta-analyses of the relationship between glutathione S-transferase gene polymorphisms and renal cell carcinoma susceptibility.BMC Med Genet. 2018 Jun 8;19(1):98. doi: 10.1186/s12881-018-0620-y.
• [77] Significant induction of apoptosis in renal cell carcinoma cells transfected with cationic multilamellar liposomes containing the human interferon- gene through activation of the intracellular type 1 interferon signal pathway.Int J Oncol. 2012 May;40(5):1441-6. doi: 10.3892/ijo.2012.1377. Epub 2012 Feb 16.
• [78] Circulating and tissue IMP3 levels are correlated with poor survival in renal cell carcinoma.Int J Cancer. 2019 Jul 15;145(2):531-539. doi: 10.1002/ijc.32124. Epub 2019 Jan 31.
• [79] NEAT1-TFE3 and KAT6A-TFE3 renal cell carcinomas, new members of MiT family translocation renal cell carcinoma.Mod Pathol. 2019 May;32(5):710-716. doi: 10.1038/s41379-018-0191-7. Epub 2019 Jan 8.
• [80] Epigenetic modifiers: activities in renal cell carcinoma.Nat Rev Urol. 2018 Oct;15(10):599-614. doi: 10.1038/s41585-018-0052-7.
• [81] KIF20B promotes the progression of clear cell renal cell carcinoma by stimulating cell proliferation.J Cell Physiol. 2019 Sep;234(9):16517-16525. doi: 10.1002/jcp.28322. Epub 2019 Feb 25.
• [82] Leukocyteassociated immunoglobulinlike receptor1 promotes tumorigenesis in RCC.Oncol Rep. 2019 Feb;41(2):1293-1303. doi: 10.3892/or.2018.6875. Epub 2018 Nov 20.
• [83] Silencing of lysyl oxidaselike 2 inhibits the migration, invasion and epithelialtomesenchymal transition of renal cell carcinoma cells through the Src/FAK signaling pathway.Int J Oncol. 2019 May;54(5):1676-1690. doi: 10.3892/ijo.2019.4726. Epub 2019 Feb 27.
• [84] Multiple conformational states of the HPK1 kinase domain in complex with sunitinib reveal the structural changes accompanying HPK1 trans-regulation.J Biol Chem. 2019 Jun 7;294(23):9029-9036. doi: 10.1074/jbc.AC119.007466. Epub 2019 Apr 24.
• [85] Design, synthesis and biological evaluation of 4-aniline-thieno[2,3-d]pyrimidine derivatives as MNK1 inhibitors against renal cell carcinoma and nasopharyngeal carcinoma.Bioorg Med Chem. 2019 Jun 1;27(11):2268-2279. doi: 10.1016/j.bmc.2019.04.022. Epub 2019 Apr 17.
• [86] Extracellular vesicles transmitted miR-31-5p promotes sorafenib resistance by targeting MLH1 in renal cell carcinoma.Int J Cancer. 2020 Feb 15;146(4):1052-1063. doi: 10.1002/ijc.32543. Epub 2019 Jul 16.
• [87] The Silencing of CCND2 by Promoter Aberrant Methylation in Renal Cell Cancer and Analysis of the Correlation between CCND2 Methylation Status and Clinical Features.PLoS One. 2016 Sep 1;11(9):e0161859. doi: 10.1371/journal.pone.0161859. eCollection 2016.
• [88] Overexpression of NEDD9 in renal cell carcinoma is associated with tumor migration and invasion.Oncol Lett. 2017 Dec;14(6):8021-8027. doi: 10.3892/ol.2017.7231. Epub 2017 Oct 20.
• [89] MicroRNA-96 is a potential tumor repressor by inhibiting NPTX2 in renal cell carcinoma.J Cell Biochem. 2020 Feb;121(2):1504-1513. doi: 10.1002/jcb.29385. Epub 2019 Sep 9.
• [90] NT5E inhibition suppresses the growth of sunitinib-resistant cells and EMT course and AKT/GSK-3 signaling pathway in renal cell cancer.IUBMB Life. 2019 Jan;71(1):113-124. doi: 10.1002/iub.1942. Epub 2018 Oct 3.
• [91] Low expression of PDK1 inhibits renal cell carcinoma cell proliferation, migration, invasion and epithelial mesenchymal transition through inhibition of the PI3K-PDK1-Akt pathway.Cell Signal. 2019 Apr;56:1-14. doi: 10.1016/j.cellsig.2018.11.016. Epub 2018 Nov 20.
• [92] Activation of AMPK by metformin promotes renal cancer cell proliferation under glucose deprivation through its interaction with PKM2.Int J Biol Sci. 2019 Jan 1;15(3):617-627. doi: 10.7150/ijbs.29689. eCollection 2019.
• [93] Gankyrin is a novel biomarker for disease progression and prognosis of patients with renal cell carcinoma.EBioMedicine. 2019 Jan;39:255-264. doi: 10.1016/j.ebiom.2018.12.011. Epub 2018 Dec 14.
• [94] RBCK1 promotes p53 degradation via ubiquitination in renal cell carcinoma.Cell Death Dis. 2019 Mar 15;10(4):254. doi: 10.1038/s41419-019-1488-2.
• [95] The cancer-retina antigen recoverin as a potential biomarker for renal tumors.Tumour Biol. 2016 Jul;37(7):9899-907. doi: 10.1007/s13277-016-4885-5. Epub 2016 Jan 26.
• [96] Inhibition of Sphingosine Phosphate Receptor 1 Signaling Enhances the Efficacy of VEGF Receptor Inhibition.Mol Cancer Ther. 2019 Apr;18(4):856-867. doi: 10.1158/1535-7163.MCT-18-0548. Epub 2019 Feb 20.
• [97] Wnt antagonist gene polymorphisms and renal cancer.Cancer. 2009 Oct 1;115(19):4488-503. doi: 10.1002/cncr.24491.
• [98] Immunohistochemical expressionof sodium-dependent glucose transporter - 2 (SGLT-2) in clear cell renal carcinoma: possible prognostic implications.Int Braz J Urol. 2019 Jan-Feb;45(1):169-178. doi: 10.1590/S1677-5538.IBJU.2018.0271.
• [99] Suppression of Tescalcin inhibits growth and metastasis in renal cell carcinoma via downregulating NHE1 and NF-kB signaling.Exp Mol Pathol. 2019 Apr;107:110-117. doi: 10.1016/j.yexmp.2018.12.004. Epub 2018 Dec 27.
• [100] Long non-coding RNA GAS5 sensitizes renal cell carcinoma to sorafenib via miR-21/SOX5 pathway.Cell Cycle. 2019 Feb;18(3):257-263. doi: 10.1080/15384101.2018.1475826. Epub 2019 Jan 29.
• [101] Knockdown of Serine-Arginine Protein Kinase 1 Inhibits the Growth and Migration in Renal Cell Carcinoma Cells.Oncol Res. 2017 Mar 13;25(3):389-395. doi: 10.3727/096504016X14743324568129. Epub 2016 Sep 22.
• [102] The significance of TRIP11 and T3 signalling pathway in renal cancer progression and survival of patients.Endokrynol Pol. 2017;68(6):631-641. doi: 10.5603/EP.a2017.0052. Epub 2017 Oct 12.
• [103] Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250.Int J Cancer. 2000 Mar 15;85(6):865-70. doi: 10.1002/(sici)1097-0215(20000315)85:6<865::aid-ijc21>3.0.co;2-q.
• [104] WNK1 promotes renal tumor progression by activating TRPC6-NFAT pathway.FASEB J. 2019 Jul;33(7):8588-8599. doi: 10.1096/fj.201802019RR. Epub 2019 Apr 25.
• [105] siRNA against TSG101 reduces proliferation and induces G0/G1 arrest in renal cell carcinoma - involvement of c-myc, cyclin E1, and CDK2.Cell Mol Biol Lett. 2019 Jan 15;24:7. doi: 10.1186/s11658-018-0124-y. eCollection 2019.
• [106] Increased UCP1 expression in the perirenal adipose tissue of patients with renal cell carcinoma.Oncol Rep. 2019 Nov;42(5):1972-1980. doi: 10.3892/or.2019.7306. Epub 2019 Sep 10.
• [107] Genomic and proteomic approaches to renal cell carcinoma.J Nephrol. 2011 Mar-Apr;24(2):155-64. doi: 10.5301/jn.2010.90.
• [108] Development of a novel interferon-2b gene construct with a repetitive hypoxia-inducible factor binding site and its suppressive effects on human renal cell carcinoma cell lines in vitro.Int J Clin Oncol. 2014;19(3):497-504. doi: 10.1007/s10147-013-0568-z. Epub 2013 Jun 6.
• [109] p21-activated kinase 1 determines stem-like phenotype and sunitinib resistance via NF-B/IL-6 activation in renal cell carcinoma.Cell Death Dis. 2015 Feb 12;6(2):e1637. doi: 10.1038/cddis.2015.2.
• [110] Superoxide dismutase 2 expression can predict prognosis of renal cell carcinoma patients.Cancer Biomark. 2018;22(4):755-761. doi: 10.3233/CBM-181308.
• [111] Overexpression of ATP citrate lyase in renal cell carcinoma tissues and its effect on the human renal carcinoma cells in vitro.Oncol Lett. 2018 May;15(5):6967-6974. doi: 10.3892/ol.2018.8211. Epub 2018 Mar 8.
• [112] A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma.Cancer. 2019 Jul 15;125(14):2400-2408. doi: 10.1002/cncr.32061. Epub 2019 Apr 5.
• [113] Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer.Cancer Discov. 2020 Jan;10(1):40-53. doi: 10.1158/2159-8290.CD-19-0980. Epub 2019 Nov 15.
• [114] Arginase 2 Suppresses Renal Carcinoma Progression via Biosynthetic Cofactor Pyridoxal Phosphate Depletion and Increased Polyamine Toxicity.Cell Metab. 2018 Jun 5;27(6):1263-1280.e6. doi: 10.1016/j.cmet.2018.04.009. Epub 2018 May 10.
• [115] Arrestin2 Mediates Renal Cell Carcinoma Tumor Growth.Sci Rep. 2018 Mar 20;8(1):4879. doi: 10.1038/s41598-018-23212-w.
• [116] Discovery and validation of methylated-differentially expressed genes in Helicobacter pylori-induced gastric cancer.Cancer Gene Ther. 2020 Jun;27(6):473-485. doi: 10.1038/s41417-019-0125-7. Epub 2019 Jul 16.
• [117] Sorafenib induces renal cell carcinoma apoptosis via upregulating activating transcription factor 4.Pharmazie. 2018 Mar 5;73(3):156-160. doi: 10.1691/ph.2018.7855.
• [118] Decreased miR-200a-3p is a key regulator of renal carcinoma growth and migration by directly targeting CBL.J Cell Biochem. 2018 Dec;119(12):9974-9985. doi: 10.1002/jcb.27326. Epub 2018 Sep 1.
• [119] 6-Gingerol induces cell-cycle G1-phase arrest through AKT-GSK 3-cyclin D1 pathway in renal-cell carcinoma.Cancer Chemother Pharmacol. 2020 Feb;85(2):379-390. doi: 10.1007/s00280-019-03999-9. Epub 2019 Dec 12.
• [120] LINC01510 suppresses cell proliferation and invasion by inhibiting Wnt/-catenin signaling in renal cell carcinoma.Biochem Biophys Res Commun. 2018 Oct 20;505(1):7-12. doi: 10.1016/j.bbrc.2018.08.167. Epub 2018 Sep 14.
• [121] REG deficiency suppresses tumor progression via stabilizing CK1 in renal cell carcinoma.Cell Death Dis. 2018 May 24;9(6):627. doi: 10.1038/s41419-018-0646-2.
• [122] IL-8 and CXCR1 expression is associated with cancer stem cell-like properties of clear cell renal cancer.J Pathol. 2019 Jul;248(3):377-389. doi: 10.1002/path.5267. Epub 2019 Apr 11.
• [123] Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer.Int J Cancer. 2018 Sep 1;143(5):1162-1175. doi: 10.1002/ijc.31400. Epub 2018 Apr 16.
• [124] Orphan nuclear receptor COUP-TFII is an oncogenic gene in renal cell carcinoma.Clin Transl Oncol. 2020 May;22(5):772-781. doi: 10.1007/s12094-019-02190-z. Epub 2019 Jul 31.
• [125] High expression of F2RL3 correlates with aggressive features and poor survival in clear cell renal cell carcinoma.J Cancer. 2018 Sep 8;9(18):3400-3406. doi: 10.7150/jca.23923. eCollection 2018.
• [126] miR-1-3p suppresses the epithelial-mesenchymal transition property in renal cell cancer by downregulating Fibronectin 1.Cancer Manag Res. 2019 Jun 21;11:5573-5587. doi: 10.2147/CMAR.S200707. eCollection 2019.
• [127] TFE3 Xp11.2 Translocation Renal Cell Carcinoma Mouse Model Reveals Novel Therapeutic Targets and Identifies GPNMB as a Diagnostic Marker for Human Disease.Mol Cancer Res. 2019 Aug;17(8):1613-1626. doi: 10.1158/1541-7786.MCR-18-1235. Epub 2019 May 1.
• [128] microRNA-302c-3p inhibits renal cell carcinoma cell proliferation by targeting Grb2-associated binding 2 (Gab2).Oncotarget. 2017 Apr 18;8(16):26334-26343. doi: 10.18632/oncotarget.15463.
• [129] Clinical significance of glutamate metabotropic receptors in renal cell carcinoma risk and survival.Cancer Med. 2018 Dec;7(12):6104-6111. doi: 10.1002/cam4.1901. Epub 2018 Nov 28.
• [130] Loss of function of the tissue specific transcription factor HNF1 alpha in renal cell carcinoma and clinical prognosis.Anticancer Res. 1999 May-Jun;19(3A):2105-10.
• [131] Epigenetic inactivation of HOXA11, a novel functional tumor suppressor for renal cell carcinoma, is associated with RCC TNM classification.Oncotarget. 2017 Mar 28;8(13):21861-21870. doi: 10.18632/oncotarget.15668.
• [132] SFPQ/PSF-TFE3 renal cell carcinoma: a clinicopathologic study emphasizing extended morphology and reviewing the differences between SFPQ-TFE3 RCC and the corresponding mesenchymal neoplasm despite an identical gene fusion.Hum Pathol. 2017 May;63:190-200. doi: 10.1016/j.humpath.2017.02.022. Epub 2017 Mar 14.
• [133] Interferon-alpha enhances CD317 expression and the antitumor activity of anti-CD317 monoclonal antibody in renal cell carcinoma xenograft models.Cancer Sci. 2008 Dec;99(12):2461-6. doi: 10.1111/j.1349-7006.2008.00968.x. Epub 2008 Nov 20.
• [134] The Role of YB1 in Renal Cell Carcinoma Cell Adhesion.Int J Med Sci. 2018 Aug 6;15(12):1304-1311. doi: 10.7150/ijms.25580. eCollection 2018.
• [135] Reduction in H3K4me patterns due to aberrant expression of methyltransferases and demethylases in renal cell carcinoma: prognostic and therapeutic implications.Sci Rep. 2019 Jun 3;9(1):8189. doi: 10.1038/s41598-019-44733-y.
• [136] Downregulation of Keap1 contributes to poor prognosis and Axitinib resistance of renal cell carcinoma via upregulation of Nrf2 expression.Int J Mol Med. 2019 May;43(5):2044-2054. doi: 10.3892/ijmm.2019.4134. Epub 2019 Mar 14.
• [137] Lysosome-associated membrane protein 2 (LAMP-2) expression induced by miR-194-5p downregulation contributes to sunitinib resistance in human renal cell carcinoma cells.Oncol Lett. 2018 Jan;15(1):893-900. doi: 10.3892/ol.2017.7423. Epub 2017 Nov 15.
• [138] p38gamma overexpression promotes renal cell carcinoma cell growth, proliferation and migration.Biochem Biophys Res Commun. 2019 Aug 20;516(2):466-473. doi: 10.1016/j.bbrc.2019.06.056. Epub 2019 Jun 20.
• [139] A General Framework for Interrogation of mRNA Stability Programs Identifies RNA-Binding Proteins that Govern Cancer Transcriptomes.Cell Rep. 2018 May 8;23(6):1639-1650. doi: 10.1016/j.celrep.2018.04.031.
• [140] Expression of CK19, CD105 and CD146 are associated with early metastasis in patients with renal cell carcinoma.Oncol Lett. 2018 Apr;15(4):4229-4234. doi: 10.3892/ol.2018.7871. Epub 2018 Jan 26.
• [141] Mutated Von Hippel-Lindau-renal cell carcinoma (RCC) promotes patients specific natural killer (NK) cytotoxicity.J Exp Clin Cancer Res. 2018 Dec 4;37(1):297. doi: 10.1186/s13046-018-0952-7.
• [142] Phosphodiesterase 10A IgG: A novel biomarker of paraneoplastic neurologic autoimmunity.Neurology. 2019 Aug 20;93(8):e815-e822. doi: 10.1212/WNL.0000000000007971. Epub 2019 Jul 17.
• [143] Phospholipase D2 promotes disease progression of renal cell carcinoma through the induction of angiogenin.Cancer Sci. 2018 Jun;109(6):1865-1875. doi: 10.1111/cas.13609. Epub 2018 May 25.
• [144] Expression of Wip1 in kidney carcinoma and its correlation with tumor metastasis and clinical significance.Pathol Oncol Res. 2015 Jan;21(1):219-24. doi: 10.1007/s12253-014-9811-9. Epub 2014 Jun 28.
• [145] Nuclear factor-kappa B subunits and their prognostic cancer-specific survival value in renal cell carcinoma patients.Pathology. 2018 Aug;50(5):511-518. doi: 10.1016/j.pathol.2018.03.003. Epub 2018 Jun 21.
• [146] PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma.Int J Cancer. 2020 Mar 1;146(5):1435-1444. doi: 10.1002/ijc.32579. Epub 2019 Aug 9.
• [147] Rce1 expression in renal cell carcinoma and its regulatory effect on 786-O cell apoptosis through endoplasmic reticulum stress.Acta Biochim Biophys Sin (Shanghai). 2017 Mar 1;49(3):254-261. doi: 10.1093/abbs/gmx002.
• [148] Androgen receptor regulates ASS1P3/miR-34a-5p/ASS1 signaling to promote renal cell carcinoma cell growth.Cell Death Dis. 2019 Apr 18;10(5):339. doi: 10.1038/s41419-019-1330-x.
• [149] Ribonucleotide reductase subunit M2 as a novel target for clear-cell renal cell carcinoma.Onco Targets Ther. 2019 Apr 30;12:3267-3275. doi: 10.2147/OTT.S196347. eCollection 2019.
• [150] Genome-wide association study identifies multiple risk loci for renal cell carcinoma.Nat Commun. 2017 Jun 9;8:15724. doi: 10.1038/ncomms15724.
• [151] MicroRNA-186 Suppresses Cell Proliferation and Metastasis Through Targeting Sentrin-Specific Protease 1 in Renal Cell Carcinoma.Oncol Res. 2018 Mar 5;26(2):249-259. doi: 10.3727/096504017X14953948675430. Epub 2017 May 21.
• [152] Integrated Genomic and Proteomic Analyses Reveal Novel Mechanisms of the Methyltransferase SETD2 in Renal Cell Carcinoma Development.Mol Cell Proteomics. 2019 Mar;18(3):437-447. doi: 10.1074/mcp.RA118.000957. Epub 2018 Nov 28.
• [153] Clinicopathologic and Molecular Pathology of Collecting Duct Carcinoma and Related Renal Cell Carcinomas.Adv Anat Pathol. 2017 Mar;24(2):65-77. doi: 10.1097/PAP.0000000000000138.
• [154] Long noncoding RNA HOTAIR promotes renal cell carcinoma malignancy through alpha-2, 8-sialyltransferase 4 by sponging microRNA-124.Cell Prolif. 2018 Dec;51(6):e12507. doi: 10.1111/cpr.12507. Epub 2018 Aug 13.
• [155] The importance of serum osteopontin and stanniocalcin-1 in renal cell carcinoma.Neoplasma. 2018 Nov 15;65(6):958-964. doi: 10.4149/neo_2018_171123N759. Epub 2018 Jun 18.
• [156] STK39 blockage by RNA interference inhibits the proliferation and induces the apoptosis of renal cell carcinoma.Onco Targets Ther. 2018 Mar 16;11:1511-1519. doi: 10.2147/OTT.S153806. eCollection 2018.
• [157] Risk factors for sorafenib-induced high-grade skin rash in Japanese patients with advanced renal cell carcinoma. Anticancer Drugs. 2013 Mar;24(3):310-4.
• [158] Racial/ethnic disparities in renal cell carcinoma: Increased risk of early-onset and variation in histologic subtypes.Cancer Med. 2019 Nov;8(15):6780-6788. doi: 10.1002/cam4.2552. Epub 2019 Sep 11.
• [159] Establishment of two human renal cell carcinoma cell lines with different chemosensitivity.Hum Cell. 1996 Jun;9(2):101-8.
• [160] LncRNA MALAT1 modified progression of clear cell kidney carcinoma (KIRC) by regulation of miR-194-5p/ACVR2B signaling.Mol Carcinog. 2019 Feb;58(2):279-292. doi: 10.1002/mc.22926. Epub 2018 Oct 31.
• [161] Increased mRNA expression of ADAMs in renal cell carcinoma and their association with clinical outcome.Oncol Rep. 2004 Feb;11(2):529-36.
• [162] Changes in expressions of ADAM9, 10, and 17 as well as -secretase activity in renal cell carcinoma.Urol Oncol. 2017 Jan;35(1):36.e15-36.e22. doi: 10.1016/j.urolonc.2016.08.010. Epub 2016 Sep 28.
• [163] The Adenosine A1 Receptor Antagonist DPCPX Inhibits Tumor Progression via the ERK/JNK Pathway in Renal Cell Carcinoma.Cell Physiol Biochem. 2017;43(2):733-742. doi: 10.1159/000481557. Epub 2017 Sep 27.
• [164] Identification of Novel Proteins Interacting with Vascular Endothelial Growth Inhibitor 174 in Renal Cell Carcinoma.Anticancer Res. 2017 Aug;37(8):4379-4388. doi: 10.21873/anticanres.11832.
• [165] Comprehensive analysis of 5-aminolevulinic acid dehydrogenase (ALAD) variants and renal cell carcinoma risk among individuals exposed to lead.PLoS One. 2011;6(7):e20432. doi: 10.1371/journal.pone.0020432. Epub 2011 Jul 20.
• [166] 5-Lipoxygenase inhibitors attenuate growth of human renal cell carcinoma and induce apoptosis through arachidonic acid pathway.Oncol Rep. 2005 Jul;14(1):73-9.
• [167] Overexpression of integrin-associated protein (CD47) in rat kidney treated with a renal carcinogen, ferric nitrilotriacetate.Jpn J Cancer Res. 1997 Feb;88(2):120-8. doi: 10.1111/j.1349-7006.1997.tb00356.x.
• [168] Angiomotin Family Members: Oncogenes or Tumor Suppressors?.Int J Biol Sci. 2017 Jun 1;13(6):772-781. doi: 10.7150/ijbs.19603. eCollection 2017.
• [169] Determination of angiogenic factors in serum by protein array in patients with renal cell carcinoma.Folia Biol (Praha). 2008;54(4):134-40.
• [170] ANGPTL3 inhibits renal cell carcinoma metastasis by inhibiting VASP phosphorylation.Biochem Biophys Res Commun. 2019 Aug 27;516(3):880-887. doi: 10.1016/j.bbrc.2019.06.120. Epub 2019 Jun 30.
• [171] Serum level of ANGPTL4 as a potential biomarker in renal cell carcinoma.Urol Oncol. 2017 May;35(5):279-285. doi: 10.1016/j.urolonc.2016.12.017. Epub 2017 Jan 19.
• [172] AnnexinA1 expression is correlated with malignant potential of renal cell carcinoma.Int J Urol. 2019 Feb;26(2):284-290. doi: 10.1111/iju.13869. Epub 2018 Dec 2.
• [173] Annexin A2 in renal cell carcinoma: expression, function, and prognostic significance.Urol Oncol. 2015 Jan;33(1):22.e11-22.e21. doi: 10.1016/j.urolonc.2014.08.015. Epub 2014 Oct 3.
• [174] PCR-based RFLP screening of the commonly deleted 3p loci in renal cortical neoplasms.Diagn Mol Pathol. 1993 Dec;2(4):269-76.
• [175] Human apolipoprotein L1 (ApoL1) in cancer and chronic kidney disease.FEBS Lett. 2012 Apr 5;586(7):947-55. doi: 10.1016/j.febslet.2012.03.002. Epub 2012 Mar 8.
• [176] Reduced L/B/K alkaline phosphatase gene expression in renal cell carcinoma: plausible role in tumorigenesis.Biochimie. 2014 Sep;104:27-35. doi: 10.1016/j.biochi.2014.05.011. Epub 2014 Jun 5.
• [177] Autophagy suppresses the proliferation of renal carcinoma cell.Eur Rev Med Pharmacol Sci. 2018 Jan;22(2):343-350. doi: 10.26355/eurrev_201801_14178.
• [178] AMPK as a therapeutic target in renal cell carcinoma.Cancer Biol Ther. 2010 Dec 1;10(11):1168-77. doi: 10.4161/cbt.10.11.13629. Epub 2010 Dec 1.
• [179] Combined assessment of low PGRMC1/positive ATP1A1 levels has enhanced prognostic value for renal cell carcinoma.Oncol Rep. 2018 Sep;40(3):1467-1476. doi: 10.3892/or.2018.6541. Epub 2018 Jul 2.
• [180] Targeting the TR4 nuclear receptor-mediated lncTASR/AXL signaling with tretinoin increases the sunitinib sensitivity to better suppress the RCC progression.Oncogene. 2020 Jan;39(3):530-545. doi: 10.1038/s41388-019-0962-8. Epub 2019 Sep 9.
• [181] Targeting beta2-microglobulin mediated signaling as a novel therapeutic approach for human renal cell carcinoma.J Urol. 2007 Jul;178(1):292-300. doi: 10.1016/j.juro.2007.03.007. Epub 2007 May 17.
• [182] Clinical significance and expression of PUMA, MCL-1, and p53 in human renal cell carcinoma and para-carcinoma tissues.Genet Mol Res. 2017 Jul 6;16(3). doi: 10.4238/gmr16039278.
• [183] LncRNA RP11-436H11.5, functioning as a competitive endogenous RNA, upregulates BCL-W expression by sponging miR-335-5p and promotes proliferation and invasion in renal cell carcinoma.Mol Cancer. 2017 Oct 25;16(1):166. doi: 10.1186/s12943-017-0735-3.
• [184] Expression parameters of the inhibitors of apoptosis cIAP1 and cIAP2 in renal cell carcinomas and their prognostic relevance.Int J Cancer. 2007 Mar 1;120(5):1081-6. doi: 10.1002/ijc.22416.
• [185] Expression of Livin and PlGF in human osteosarcoma is associated with tumor progression and clinical outcome.Oncol Lett. 2018 Oct;16(4):4953-4960. doi: 10.3892/ol.2018.9239. Epub 2018 Jul 31.
• [186] Different Cytokine and Chemokine Expression Patterns in Malignant Compared to Those in Nonmalignant Renal Cells.Anal Cell Pathol (Amst). 2017;2017:7190546. doi: 10.1155/2017/7190546. Epub 2017 Jul 9.
• [187] Decreased expression of bone morphogenetic protein (BMP) receptor type II correlates with insensitivity to BMP-6 in human renal cell carcinoma cells.Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):6046-51.
• [188] The expression and role of tyrosine kinase ETK/BMX in renal cell carcinoma.J Exp Clin Cancer Res. 2014 Mar 7;33(1):25. doi: 10.1186/1756-9966-33-25.
• [189] Expression and clinical significance of CD147 in renal cell carcinoma: a meta-analysis.Oncotarget. 2017 Apr 10;8(31):51331-51344. doi: 10.18632/oncotarget.17376. eCollection 2017 Aug 1.
• [190] The Expression of BTS-2 Enhances Cell Growth and Invasiveness in Renal Cell Carcinoma.Anticancer Res. 2017 Jun;37(6):2853-2860. doi: 10.21873/anticanres.11637.
• [191] B cell translocation gene 1 reduces the biological outcome of kidney cancer through induction of cell proliferation, cell cycle arrest, cell apoptosis and cell metastasis.Int J Mol Med. 2015 Mar;35(3):777-83. doi: 10.3892/ijmm.2014.2058. Epub 2014 Dec 31.
• [192] Association of 3' nearby gene BTLA polymorphisms with the risk of renal cell carcinoma in the Polish population.Urol Oncol. 2016 Sep;34(9):419.e13-9. doi: 10.1016/j.urolonc.2016.04.010. Epub 2016 May 24.
• [193] Overexpression of the mitotic checkpoint genes BUB1 and BUBR1 is associated with genomic complexity in clear cell kidney carcinomas.Cell Oncol. 2008;30(5):389-95. doi: 10.3233/clo-2008-0439.
• [194] C1QBP suppresses cell adhesion and metastasis of renal carcinoma cells.Sci Rep. 2017 Apr 20;7(1):999. doi: 10.1038/s41598-017-01084-w.
• [195] Effects of von Hippel-Lindau gene mutation and methylation status on expression of transmembrane carbonic anhydrases in renal cell carcinoma.J Cancer Res Clin Oncol. 2002 Oct;128(10):561-8. doi: 10.1007/s00432-002-0374-x. Epub 2002 Aug 30.
• [196] Transcript levels of aquaporin 1 and carbonic anhydrase IV as predictive indicators for prognosis of renal cell carcinoma patients after nephrectomy.Int J Cancer. 1998 Feb 20;79(1):1-7. doi: 10.1002/(sici)1097-0215(19980220)79:1<1::aid-ijc1>3.0.co;2-5.
• [197] CAIX-specific CAR-T Cells and Sunitinib Show Synergistic Effects Against Metastatic Renal Cancer Models.J Immunother. 2020 Jan;43(1):16-28. doi: 10.1097/CJI.0000000000000301.
• [198] Expression of calpain I messenger RNA in human renal cell carcinoma: correlation with lymph node metastasis and histological type.Int J Cancer. 1999 Feb 19;84(1):6-9. doi: 10.1002/(sici)1097-0215(19990219)84:1<6::aid-ijc2>3.0.co;2-t.
• [199] Overexpression of CAPN2 promotes cell metastasis and proliferation via AKT/mTOR signaling in renal cell carcinoma.Oncotarget. 2017 Oct 26;8(58):97811-97821. doi: 10.18632/oncotarget.22083. eCollection 2017 Nov 17.
• [200] PIDDosome expression and the role of caspase-2 activation for chemotherapy-induced apoptosis in RCCs.Cell Oncol. 2010;32(1-2):29-42. doi: 10.3233/CLO-2009-0492.
• [201] Improvement of doxorubicin efficacy using liposomal anti-polo-like kinase 1 siRNA in human renal cell carcinomas.Mol Pharm. 2014 Aug 4;11(8):2713-9. doi: 10.1021/mp500245z. Epub 2014 May 12.
• [202] Overexpression of cyclin D1, D3, and p21 in an infantile renal carcinoma with Xp11.2 TFE3-gene fusion.Pathol Res Pract. 2008;204(8):589-97. doi: 10.1016/j.prp.2008.01.010. Epub 2008 Mar 20.
• [203] Up-regulation of functional chemokine receptor CCR3 in human renal cell carcinoma.Clin Cancer Res. 2005 Apr 1;11(7):2459-65. doi: 10.1158/1078-0432.CCR-04-0405.
• [204] Human renal cell carcinoma induces a dendritic cell subset that uses T-cell crosstalk for tumor-permissive milieu alterations.Am J Pathol. 2011 Jul;179(1):436-51. doi: 10.1016/j.ajpath.2011.03.011. Epub 2011 May 18.
• [205] Prostaglandin E2 receptor 4 mediates renal cell carcinoma intravasation and metastasis.Cancer Lett. 2017 Apr 10;391:50-58. doi: 10.1016/j.canlet.2017.01.007. Epub 2017 Jan 17.
• [206] Relationship of B7-H3 expression in tumor cells and tumor vasculature with FOXP3+ regulatory T cells in renal cell carcinoma.Cancer Manag Res. 2019 Jul 25;11:7021-7030. doi: 10.2147/CMAR.S209205. eCollection 2019.
• [207] Proximal CD13 Versus Distal GATA-3 Expression in Renal Neoplasia According to WHO 2016 Classification.Appl Immunohistochem Mol Morphol. 2018 May/Jun;26(5):316-323. doi: 10.1097/PAI.0000000000000435.
• [208] Expression of CD3 antigens in renal tubule epithelium and renal oncocytomas.Pathol Res Pract. 2005;201(12):803-8. doi: 10.1016/j.prp.2005.09.003. Epub 2005 Nov 3.
• [209] First-in-human study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-CD27L antibody-drug conjugate AMG 172 in patients with relapsed/refractory renal cell carcinoma.Cancer Chemother Pharmacol. 2019 Jun;83(6):1057-1063. doi: 10.1007/s00280-019-03796-4. Epub 2019 Mar 26.
• [210] Up-regulation of vascular endothelial growth factor-D expression in clear cell renal cell carcinoma by CD74: a critical role in cancer cell tumorigenesis.J Immunol. 2008 Nov 1;181(9):6584-94. doi: 10.4049/jimmunol.181.9.6584.
• [211] CYP1B1 promotes tumorigenesis via altered expression of CDC20 and DAPK1 genes in renal cell carcinoma.BMC Cancer. 2015 Dec 1;15:942. doi: 10.1186/s12885-015-1951-0.
• [212] Knockdown of Cdc25B in renal cell carcinoma is associated with decreased malignant features.Asian Pac J Cancer Prev. 2012;13(3):931-5. doi: 10.7314/apjcp.2012.13.3.931.
• [213] Functional loss of E-cadherin and cadherin-11 alleles on chromosome 16q22 in colonic cancer.J Pathol. 1999 Apr;187(5):530-4. doi: 10.1002/(SICI)1096-9896(199904)187:5<530::AID-PATH293>3.0.CO;2-C.
• [214] MicroRNA-720 Regulates E-cadherin-E-catenin Complex and Promotes Renal Cell Carcinoma.Mol Cancer Ther. 2017 Dec;16(12):2840-2848. doi: 10.1158/1535-7163.MCT-17-0400. Epub 2017 Aug 11.
• [215] MiR-31-5p acts as a tumor suppressor in renal cell carcinoma by targeting cyclin-dependent kinase 1 (CDK1).Biomed Pharmacother. 2019 Mar;111:517-526. doi: 10.1016/j.biopha.2018.12.102. Epub 2018 Dec 28.
• [216] Wilms' tumor 1-associating protein promotes renal cell carcinoma proliferation by regulating CDK2 mRNA stability.J Exp Clin Cancer Res. 2018 Feb 27;37(1):40. doi: 10.1186/s13046-018-0706-6.
• [217] Major role for a 3p21 region and lack of involvement of the t(3;8) breakpoint region in the development of renal cell carcinoma suggested by loss of heterozygosity analysis.Genes Chromosomes Cancer. 1996 Jan;15(1):64-72. doi: 10.1002/(SICI)1098-2264(199601)15:1<64::AID-GCC9>3.0.CO;2-2.
• [218] The covalent CDK7 inhibitor THZ1 enhances temsirolimus-induced cytotoxicity via autophagy suppression in human renal cell carcinoma.Cancer Lett. 2020 Feb 28;471:27-37. doi: 10.1016/j.canlet.2019.12.005. Epub 2019 Dec 6.
• [219] Multilayer-omics analysis of renal cell carcinoma, including the whole exome, methylome and transcriptome.Int J Cancer. 2014 Sep 15;135(6):1330-42. doi: 10.1002/ijc.28768. Epub 2014 May 2.
• [220] Immunohistochemical study of cyclin A and p16 expression in patients with renal cell carcinoma.J BUON. 2017 Sep-Oct;22(5):1322-1327.
• [221] The tumour suppressor gene CEACAM1 is completely but reversibly downregulated in renal cell carcinoma.J Pathol. 2004 Nov;204(3):258-67. doi: 10.1002/path.1657.
• [222] Protein gene product 9.5 is diagnostically helpful in delineating high-grade renal cell cancer involving the renal medullary/sinus region from invasive urothelial cell carcinoma of the renal pelvis.Hum Pathol. 2013 May;44(5):712-7. doi: 10.1016/j.humpath.2012.07.024. Epub 2012 Nov 14.
• [223] Expression of the free beta-subunit of human chorionic gonadotropin in renal cell carcinoma: prognostic study on tissue and serum.Int J Cancer. 2003 May 1;104(5):631-5. doi: 10.1002/ijc.11000.
• [224] CSN5 promotes renal cell carcinoma metastasis and EMT by inhibiting ZEB1 degradation.Biochem Biophys Res Commun. 2017 Jun 17;488(1):101-108. doi: 10.1016/j.bbrc.2017.05.016. Epub 2017 May 4.
• [225] Integrative analysis reveals CRHBP inhibits renal cell carcinoma progression by regulating inflammation and apoptosis.Cancer Gene Ther. 2020 Aug;27(7-8):607-618. doi: 10.1038/s41417-019-0138-2. Epub 2019 Oct 1.
• [226] Urocortin and corticotropin-releasing factor receptor 2 in human renal cell carcinoma: disruption of an endogenous inhibitor of angiogenesis and proliferation.World J Urol. 2009 Dec;27(6):825-30. doi: 10.1007/s00345-009-0417-x.
• [227] The Vitamin D status is associated with serum C-reactive protein and adhesion molecules in patients with renal cell carcinoma.Sci Rep. 2019 Nov 13;9(1):16719. doi: 10.1038/s41598-019-53395-9.
• [228] Differential protein profiling in renal-cell carcinoma.Mol Carcinog. 2004 May;40(1):47-61. doi: 10.1002/mc.20015.
• [229] Expression of NAD(P)H:quinone oxidoreductase and glutathione S-transferases alpha and pi in human renal cell carcinoma and in kidney cancer-derived cell lines.Carcinogenesis. 1994 Feb;15(2):219-25. doi: 10.1093/carcin/15.2.219.
• [230] DNA ploidy of oncocytic-granular renal cell carcinomas and renal oncocytomas by image analysis.Arch Pathol Lab Med. 1992 Feb;116(2):154-8.
• [231] Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma.Nat Genet. 2011 Dec 4;44(1):17-9. doi: 10.1038/ng.1014.
• [232] CXCR3-B expression correlates with tumor necrosis extension in renal cell carcinoma.J Urol. 2009 Feb;181(2):843-8. doi: 10.1016/j.juro.2008.10.063. Epub 2008 Dec 17.
• [233] Galectin-3 promotes CXCR2 to augment the stem-like property of renal cell carcinoma.J Cell Mol Med. 2018 Dec;22(12):5909-5918. doi: 10.1111/jcmm.13860. Epub 2018 Sep 24.
• [234] Immunohistochemical distinction of metastases of renal cell carcinoma with molecular analysis of overexpression of the chemokines CXCR2 and CXCR3 as independent positive prognostic factors for the tumorigenesis.IUBMB Life. 2016 Aug;68(8):629-33. doi: 10.1002/iub.1520. Epub 2016 Jun 6.
• [235] Loss of miR-200c up-regulates CYP1B1 and confers docetaxel resistance in renal cell carcinoma. Oncotarget. 2015 Apr 10;6(10):7774-87.
• [236] Vitamin D hydroxylases CYP2R1, CYP27B1 and CYP24A1 in renal cell carcinoma.Eur J Clin Invest. 2013 Dec;43(12):1282-90. doi: 10.1111/eci.12176. Epub 2013 Oct 12.
• [237] Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study.Lancet Oncol. 2011 Nov;12(12):1143-50. doi: 10.1016/S1470-2045(11)70266-2. Epub 2011 Oct 17.
• [238] L-DOPA decarboxylase mRNA levels provide high diagnostic accuracy and discrimination between clear cell and non-clear cell subtypes in renal cell carcinoma.Clin Biochem. 2015 Jun;48(9):590-5. doi: 10.1016/j.clinbiochem.2015.02.007. Epub 2015 Feb 23.
• [239] Renal carcinoma cells undergo apoptosis without oligonucleosomal DNA fragmentation.Biochem Biophys Res Commun. 2004 Jun 4;318(3):710-3. doi: 10.1016/j.bbrc.2004.04.086.
• [240] Expression levels of the mitochondrial IAP antagonists Smac/DIABLO and Omi/HtrA2 in clear-cell renal cell carcinomas and their prognostic value.J Cancer Res Clin Oncol. 2008 May;134(5):543-50. doi: 10.1007/s00432-007-0317-7. Epub 2007 Oct 9.
• [241] MicroRNA-183 promotes the proliferation and metastasis of renal cell carcinoma through targeting Dickkopf-related protein 3.Oncol Lett. 2018 Apr;15(4):6003-6008. doi: 10.3892/ol.2018.7998. Epub 2018 Feb 8.
• [242] Imprinted DLK1 is a putative tumor suppressor gene and inactivated by epimutation at the region upstream of GTL2 in human renal cell carcinoma.Hum Mol Genet. 2006 Mar 15;15(6):821-30. doi: 10.1093/hmg/ddl001. Epub 2006 Jan 26.
• [243] Characterisation of gamma delta T cells in renal cell carcinoma patients by polymerase chain reaction analysis of T cell receptor transcripts.Cancer Immunol Immunother. 1997 Mar;44(1):27-34. doi: 10.1007/s002620050351.
• [244] HSP DNAJB8 controls tumor-initiating ability in renal cancer stem-like cells.Cancer Res. 2012 Jun 1;72(11):2844-54. doi: 10.1158/0008-5472.CAN-11-3062. Epub 2012 May 2.
• [245] Serotonin and Dopamine Receptor Expression in Solid Tumours Including Rare Cancers.Pathol Oncol Res. 2020 Jul;26(3):1539-1547. doi: 10.1007/s12253-019-00734-w. Epub 2019 Sep 2.
• [246] Decreased expression of dual-specificity phosphatase 9 is associated with poor prognosis in clear cell renal cell carcinoma.BMC Cancer. 2011 Sep 26;11:413. doi: 10.1186/1471-2407-11-413.
• [247] A novel human lncRNA SANT1 cis-regulates the expression of SLC47A2 by altering SFPQ/E2F1/HDAC1 binding to the promoter region in renal cell carcinoma. RNA Biol. 2019 Jul;16(7):940-949.
• [248] MicroRNA-429 suppresses cell proliferation, epithelial-mesenchymal transition, and metastasis by direct targeting of BMI1 and E2F3 in renal cell carcinoma.Urol Oncol. 2015 Jul;33(7):332.e9-18. doi: 10.1016/j.urolonc.2015.03.016. Epub 2015 May 4.
• [249] Modality of tumor endothelial VEGFR2 silencing-mediated improvement in intratumoral distribution of lipid nanoparticles.J Control Release. 2017 Apr 10;251:1-10. doi: 10.1016/j.jconrel.2017.02.010. Epub 2017 Feb 10.
• [250] Endothelin axis expression is markedly different in the two main subtypes of renal cell carcinoma.Cancer. 2004 May 15;100(10):2118-24. doi: 10.1002/cncr.20222.
• [251] Cloning and sequencing of a human endothelin converting enzyme in renal adenocarcinoma (ACHN) cells producing endothelin-2.Biochem Biophys Res Commun. 1995 Mar 17;208(2):721-7. doi: 10.1006/bbrc.1995.1397.
• [252] Targeting EGFL7 expression through RNA interference suppresses renal cell carcinoma growth by inhibiting angiogenesis.Asian Pac J Cancer Prev. 2014;15(7):3045-50. doi: 10.7314/apjcp.2014.15.7.3045.
• [253] Protein Kinase RNA-Like Endoplasmic Reticulum Kinase-Mediated Bcl-2 Protein Phosphorylation Contributes to Evodiamine-Induced Apoptosis of Human Renal Cell Carcinoma Cells.PLoS One. 2016 Aug 2;11(8):e0160484. doi: 10.1371/journal.pone.0160484. eCollection 2016.
• [254] The tumor suppressor NDRG2 cooperates with an mTORC1 inhibitor to suppress the Warburg effect in renal cell carcinoma.Invest New Drugs. 2020 Aug;38(4):956-966. doi: 10.1007/s10637-019-00839-8. Epub 2019 Aug 28.
• [255] Molecular cloning of the human kidney differentiation antigen gp160: human aminopeptidase A.Proc Natl Acad Sci U S A. 1993 Aug 1;90(15):7069-73. doi: 10.1073/pnas.90.15.7069.
• [256] Overexpression of autotaxin is associated with human renal cell carcinoma and bladder carcinoma and their progression.Med Oncol. 2016 Nov;33(11):131. doi: 10.1007/s12032-016-0836-7. Epub 2016 Oct 18.
• [257] Phase I Trials of Anti-ENPP3 Antibody-Drug Conjugates in Advanced Refractory Renal Cell Carcinomas.Clin Cancer Res. 2018 Sep 15;24(18):4399-4406. doi: 10.1158/1078-0432.CCR-18-0481. Epub 2018 May 30.
• [258] EphA2 Is a Potential Player of Malignant Cellular Behavior in Non-Metastatic Renal Cell Carcinoma Cells but Not in Metastatic Renal Cell Carcinoma Cells.PLoS One. 2015 Jul 15;10(7):e0130975. doi: 10.1371/journal.pone.0130975. eCollection 2015.
• [259] miR?5a?p acts as an oncogene in renal cell carcinoma.Mol Med Rep. 2017 Mar;15(3):1379-1386. doi: 10.3892/mmr.2017.6121. Epub 2017 Jan 16.
• [260] Expression of the EPHB4 receptor tyrosine kinase in head and neck and renal malignancies--implications for solid tumors and potential for therapeutic inhibition.Growth Factors. 2014 Dec;32(6):202-6. doi: 10.3109/08977194.2014.980904. Epub 2014 Nov 13.
• [261] Identification of erythropoietin receptor-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from HLA-A24(+) patients with renal cell carcinoma.Int Immunopharmacol. 2014 May;20(1):59-65. doi: 10.1016/j.intimp.2014.02.018. Epub 2014 Feb 26.
• [262] Comparative expression profiling for human endoplasmic reticulum-resident aminopeptidases 1 and 2 in normal kidney versus distinct renal cell carcinoma subtypes.Int J Clin Exp Pathol. 2013 May 15;6(6):998-1008. Print 2013.
• [263] HAF mediates the evasive resistance of anti-angiogenesis TKI through disrupting HIF-1 and HIF-2 balance in renal cell carcinoma.Oncotarget. 2017 Jul 25;8(30):49713-49724. doi: 10.18632/oncotarget.17923.
• [264] PAR-1- and PAR-3-type thrombin receptor expression in primary cultures of human renal cell carcinoma cells.Int J Oncol. 2002 Jan;20(1):177-80.
• [265] Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes.Nat Genet. 2015 Jan;47(1):13-21. doi: 10.1038/ng.3146. Epub 2014 Nov 17.
• [266] Prevalence and prognostic value of FBXO11 expression in patients with clear cell renal cell carcinoma.BMC Cancer. 2019 Jun 3;19(1):534. doi: 10.1186/s12885-019-5736-8.
• [267] Deletion of chromosome 3p14.2-p25 involving the VHL and FHIT genes in conventional renal cell carcinoma.Cancer Res. 2003 Jan 15;63(2):455-7.
• [268] FKBP-12 exhibits an inhibitory activity on calcium oxalate crystal growth in vitro.J Korean Med Sci. 2002 Feb;17(1):41-8. doi: 10.3346/jkms.2002.17.1.41.
• [269] Impact of tivozanib on patient outcomes in treatment of advanced renal cell carcinoma.Cancer Manag Res. 2019 Aug 16;11:7779-7785. doi: 10.2147/CMAR.S206105. eCollection 2019.
• [270] PET imaging in renal cancer.Curr Opin Oncol. 2019 May;31(3):216-221. doi: 10.1097/CCO.0000000000000518.
• [271] FSCN1 predicts survival and is regulated by a PI3K-dependent mechanism in renal cell carcinoma.J Cell Physiol. 2018 Jun;233(6):4748-4758. doi: 10.1002/jcp.26264. Epub 2018 Jan 15.
• [272] Value of Ferritin Heavy Chain (FTH1) Expression in Diagnosis and Prognosis of Renal Cell Carcinoma.Med Sci Monit. 2019 May 19;25:3700-3715. doi: 10.12659/MSM.914162.
• [273] MicroRNA?13 inhibits proliferation and invasion of renal cell carcinoma cells through targeting FZD7.Mol Med Rep. 2017 Oct;16(4):4279-4286. doi: 10.3892/mmr.2017.7076. Epub 2017 Jul 24.
• [274] The interaction of YBX1 with G3BP1 promotes renal cell carcinoma cell metastasis via YBX1/G3BP1-SPP1- NF-B signaling axis.J Exp Clin Cancer Res. 2019 Sep 3;38(1):386. doi: 10.1186/s13046-019-1347-0.
• [275] SCP phosphatases suppress renal cell carcinoma by stabilizing PML and inhibiting mTOR/HIF signaling.Cancer Res. 2014 Dec 1;74(23):6935-46. doi: 10.1158/0008-5472.CAN-14-1330. Epub 2014 Oct 7.
• [276] S100A10 Is a Critical Mediator of GAS6/AXL-Induced Angiogenesis in Renal Cell Carcinoma.Cancer Res. 2019 Nov 15;79(22):5758-5768. doi: 10.1158/0008-5472.CAN-19-1366. Epub 2019 Oct 4.
• [277] Ghrelin promotes renal cell carcinoma metastasis via Snail activation and is associated with poor prognosis.J Pathol. 2015 Sep;237(1):50-61. doi: 10.1002/path.4552. Epub 2015 May 28.
• [278] Identification of key genes and pathways in renal cell carcinoma through expression profiling data.Kidney Blood Press Res. 2015;40(3):288-97. doi: 10.1159/000368504. Epub 2015 May 27.
• [279] VHL-dependent regulation of a -dystroglycan glycoform and glycogene expression in renal cancer.Int J Oncol. 2013 Nov;43(5):1368-76. doi: 10.3892/ijo.2013.2066. Epub 2013 Aug 21.
• [280] TGR5 expression in normal kidney and renal neoplasms.Diagn Pathol. 2018 Apr 2;13(1):22. doi: 10.1186/s13000-018-0700-5.
• [281] Adrenomedullin blockade suppresses sunitinib-resistant renal cell carcinoma growth by targeting the ERK/MAPK pathway.Oncotarget. 2016 Sep 27;7(39):63374-63387. doi: 10.18632/oncotarget.11463.
• [282] GRK5 promotes tumor progression in renal cell carcinoma.Neoplasma. 2019 Feb 6;66(2):261-270. doi: 10.4149/neo_2018_180621N409.
• [283] Metabotropic glutamate receptor 1 (Grm1) is an oncogene in epithelial cells.Oncogene. 2013 Sep 12;32(37):4366-76. doi: 10.1038/onc.2012.471. Epub 2012 Oct 22.
• [284] Expression of gastrin releasing Peptide receptor in renal cell carcinomas: a potential function for the regulation of neoangiogenesis and microvascular perfusion.J Urol. 2005 Jun;173(6):2154-9. doi: 10.1097/01.ju.0000158135.26893.bc.
• [285] Signal integration and gene induction by a functionally distinct STAT3 phosphoform.Mol Cell Biol. 2014 May;34(10):1800-11. doi: 10.1128/MCB.00034-14. Epub 2014 Mar 10.
• [286] Concomitance of Polymorphisms in Glutathione Transferase Omega Genes Is Associated with Risk of Clear Cell Renal Cell Carcinoma.Tohoku J Exp Med. 2018 Sep;246(1):35-44. doi: 10.1620/tjem.246.35.
• [287] Hepatocyte growth factor activator inhibitor types 1 and 2 are expressed by tubular epithelium in kidney and down-regulated in renal cell carcinoma.J Urol. 2004 Feb;171(2 Pt 1):890-6. doi: 10.1097/01.ju.0000092861.21122.d2.
• [288] Identification of novel microRNAs regulating HLA-G expression and investigating their clinical relevance in renal cell carcinoma.Oncotarget. 2016 May 3;7(18):26866-78. doi: 10.18632/oncotarget.8567.
• [289] Silencing of tumor-suppressive NR_023387 in renal cell carcinoma via promoter hypermethylation and HNF4A deficiency.J Cell Physiol. 2020 Mar;235(3):2113-2128. doi: 10.1002/jcp.29115. Epub 2019 Aug 20.
• [290] Tumor-suppressive function and mechanism of HOXB13 in right-sided colon cancer.Signal Transduct Target Ther. 2019 Nov 29;4:51. doi: 10.1038/s41392-019-0086-1. eCollection 2019.
• [291] Antibodies neutralizing hepsin protease activity do not impact cell growth but inhibit invasion of prostate and ovarian tumor cells in culture.Cancer Res. 2006 Apr 1;66(7):3611-9. doi: 10.1158/0008-5472.CAN-05-2983.
• [292] Mineralocorticoid receptor and 11beta-hydroxysteroid dehydrogenase type II expression in renal cell neoplasms: a tissue microarray and quantitative RT-PCR study.Am J Surg Pathol. 2008 Jun;32(6):874-83. doi: 10.1097/PAS.0b013e31815f2362.
• [293] Recent developments in small molecule therapies for renal cell carcinoma.Eur J Med Chem. 2017 Dec 15;142:383-392. doi: 10.1016/j.ejmech.2017.08.007. Epub 2017 Aug 9.
• [294] Serum interferon alpha receptor 2 mRNA may predict efficacy of interferon alpha with/without low-dose sorafenib for metastatic clear cell renal cell carcinoma.Cancer Immunol Immunother. 2011 Jun;60(6):793-808. doi: 10.1007/s00262-011-0989-3. Epub 2011 Feb 25.
• [295] Targeting the insulin-like growth factor-1 receptor in MTAP-deficient renal cell carcinoma.Signal Transduct Target Ther. 2019 Jan 25;4:2. doi: 10.1038/s41392-019-0035-z. eCollection 2019.
• [296] Long non-coding RNA HOTAIR promotes cell migration by upregulating insulin growth factor-binding protein 2 in renal cell carcinoma.Sci Rep. 2017 Sep 20;7(1):12016. doi: 10.1038/s41598-017-12191-z.
• [297] Altered messenger RNA and protein expressions for insulin-like growth factor family members in clear cell and papillary renal cell carcinomas.Int J Urol. 2005 Jan;12(1):17-28. doi: 10.1111/j.1442-2042.2004.00993.x.
• [298] Mechanisms regulating PD-L1 expression on tumor and immune cells.J Immunother Cancer. 2019 Nov 15;7(1):305. doi: 10.1186/s40425-019-0770-2.
• [299] Immunotherapy for genitourinary tumors.Int J Urol. 2019 Mar;26(3):326-333. doi: 10.1111/iju.13902. Epub 2019 Feb 1.
• [300] Enhancing mda-7/IL-24 therapy in renal carcinoma cells by inhibiting multiple protective signaling pathways using sorafenib and by Ad.5/3 gene delivery.Cancer Biol Ther. 2010 Dec 15;10(12):1290-305. doi: 10.4161/cbt.10.12.13497. Epub 2010 Dec 15.
• [301] Polymorphism rs4787951 in IL-4R contributes to the increased risk of renal cell carcinoma in a Chinese population.Gene. 2019 Feb 15;685:242-247. doi: 10.1016/j.gene.2018.11.070. Epub 2018 Nov 23.
• [302] Oleic acid promotes cell invasion through an integrin-linked kinase signaling pathway in renal cell carcinoma.Nutr Cancer. 2020;72(6):968-975. doi: 10.1080/01635581.2019.1669672. Epub 2019 Oct 1.
• [303] Key role for activin B in cellular transformation after loss of the von Hippel-Lindau tumor suppressor.Mol Cell Biol. 2009 Apr;29(7):1707-18. doi: 10.1128/MCB.01184-07. Epub 2009 Jan 21.
• [304] Inverse relationship between insulin receptor expression and progression in renal cell carcinoma.Oncol Rep. 2017 May;37(5):2929-2941. doi: 10.3892/or.2017.5552. Epub 2017 Apr 5.
• [305] Tumor-associated macrophage expression of interferon regulatory Factor-8 (IRF8) is a predictor of progression and patient survival in renal cell carcinoma.J Immunother Cancer. 2019 Jun 20;7(1):155. doi: 10.1186/s40425-019-0630-0.
• [306] Altered expression of beta 1 integrins in renal carcinoma cell lines exposed to vinblastine.Anticancer Res. 1999 Mar-Apr;19(2C):1509-12.
• [307] Integrin signaling potentiates transforming growth factor-beta 1 (TGF-1) dependent down-regulation of E-Cadherin expression - Important implications for epithelial to mesenchymal transition (EMT) in renal cell carcinoma.Exp Cell Res. 2017 Jun 15;355(2):57-66. doi: 10.1016/j.yexcr.2017.03.051. Epub 2017 Mar 29.
• [308] miR-17 inhibition enhances the formation of kidney cancer spheres with stem cell/ tumor initiating cell properties.Oncotarget. 2015 Mar 20;6(8):5567-81. doi: 10.18632/oncotarget.1901.
• [309] ITPR1 protects renal cancer cells against natural killer cells by inducing autophagy.Cancer Res. 2014 Dec 1;74(23):6820-32. doi: 10.1158/0008-5472.CAN-14-0303. Epub 2014 Oct 8.
• [310] Sex specific associations in genome wide association analysis of renal cell carcinoma.Eur J Hum Genet. 2019 Oct;27(10):1589-1598. doi: 10.1038/s41431-019-0455-9. Epub 2019 Jun 23.
• [311] Methylation of the gamma-catenin gene is associated with poor prognosis of renal cell carcinoma.Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):557-64.
• [312] Integrated molecular analysis of clear-cell renal cell carcinoma.Nat Genet. 2013 Aug;45(8):860-7. doi: 10.1038/ng.2699. Epub 2013 Jun 24.
• [313] KDM3A is not associated with metastasis and prognosis of breast cancer.Oncol Lett. 2018 Jun;15(6):9751-9756. doi: 10.3892/ol.2018.8578. Epub 2018 Apr 25.
• [314] Renal cell neoplasms contain shared tumor type-specific copy number variations.Am J Pathol. 2012 Jun;180(6):2427-39. doi: 10.1016/j.ajpath.2012.01.044. Epub 2012 Apr 3.
• [315] Different expression patterns of histone H3K27 demethylases in renal cell carcinoma and bladder cancer.Cancer Biomark. 2017;18(2):125-131. doi: 10.3233/CBM-160003.
• [316] Discovery of a novel 2,5-dihydroxycinnamic acid-based 5-lipoxygenase inhibitor that induces apoptosis and may impair autophagic flux in RCC4 renal cancer cells.Eur J Med Chem. 2019 Oct 1;179:347-357. doi: 10.1016/j.ejmech.2019.06.060. Epub 2019 Jun 23.
• [317] The expression of ketohexokinase is diminished in human clear cell type of renal cell carcinoma.Proteomics. 2006 Feb;6(3):1077-84. doi: 10.1002/pmic.200401345.
• [318] Killer inhibitory receptor (CD158b) modulates the lytic activity of tumor-specific T lymphocytes infiltrating renal cell carcinomas.Blood. 2000 May 1;95(9):2883-9.
• [319] miR-21 downregulated TCF21 to inhibit KISS1 in renal cancer.Urology. 2012 Dec;80(6):1298-302.e1. doi: 10.1016/j.urology.2012.08.013.
• [320] Lack of KISS1R expression is associated with rapid progression of conventional renal cell carcinomas.J Pathol. 2011 Jan;223(1):46-53. doi: 10.1002/path.2764.
• [321] Expression of KIT (CD117) in renal cell carcinoma and renal oncocytoma.Oncology. 2005;68(2-3):269-75. doi: 10.1159/000086783. Epub 2005 Jul 7.
• [322] Dysregulation of kallikrein-related peptidases in renal cell carcinoma: potential targets of miRNAs.Biol Chem. 2010 Apr;391(4):411-23. doi: 10.1515/BC.2010.041.
• [323] The human tissue kallikreins (KLKs 1-3) and a novel KLK1 mRNA transcript are expressed in a renal cell carcinoma cDNA library.Immunopharmacology. 1999 Dec;45(1-3):83-8. doi: 10.1016/s0162-3109(99)00059-4.
• [324] Incidental Detection of Thyroid Metastases From Renal Cell Carcinoma Using 68Ga-PSMA PET/CT to Assess Prostate Cancer Recurrence.Clin Nucl Med. 2017 Mar;42(3):221-222. doi: 10.1097/RLU.0000000000001522.
• [325] Functional characterization of BC039389-GATM and KLK4-KRSP1 chimeric read-through transcripts which are up-regulated in renal cell cancer.BMC Genomics. 2015 Mar 27;16(1):247. doi: 10.1186/s12864-015-1446-z.
• [326] Immunohistochemical analysis of kallikrein-related peptidases in the normal kidney and renal tumors: potential clinical implications.Biol Chem. 2010 Apr;391(4):403-9. doi: 10.1515/BC.2010.025.
• [327] Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma.Oncogene. 2011 Jun 9;30(23):2622-32. doi: 10.1038/onc.2010.638. Epub 2011 Jan 24.
• [328] PD-1 and LAG-3 Dominate Checkpoint Receptor-Mediated T-cell Inhibition in Renal Cell Carcinoma.Cancer Immunol Res. 2019 Nov;7(11):1891-1899. doi: 10.1158/2326-6066.CIR-19-0146. Epub 2019 Sep 4.
• [329] Detection of urinary survivin using a magnetic particles-based chemiluminescence immunoassay for the preliminary diagnosis of bladder cancer and renal cell carcinoma combined with LAPTM4B.Oncol Lett. 2018 May;15(5):7923-7933. doi: 10.3892/ol.2018.8317. Epub 2018 Mar 22.
• [330] Non-Invasive Assessment of Lactate Production and Compartmentalization in Renal Cell Carcinomas Using Hyperpolarized (13)C Pyruvate MRI.Cancers (Basel). 2018 Sep 5;10(9):313. doi: 10.3390/cancers10090313.
• [331] Expression and Distribution of Galectin-3 in Chromophobe and Papillary Carcinomas.Anticancer Res. 2018 Jan;38(1):259-263. doi: 10.21873/anticanres.12216.
• [332] Detection of dysregulated competing endogenous RNA modules associated with clear cell kidney carcinoma.Mol Med Rep. 2018 Aug;18(2):1963-1972. doi: 10.3892/mmr.2018.9189. Epub 2018 Jun 19.
• [333] Combined Influence of EGF+61G>A and TGFB+869T>C Functional Polymorphisms in Renal Cell Carcinoma Progression and Overall Survival: The Link to Plasma Circulating MiR-7 and MiR-221/222 Expression.PLoS One. 2015 Apr 24;10(4):e0103258. doi: 10.1371/journal.pone.0103258. eCollection 2014.
• [334] Cystinyl aminopeptidase activity is decreased in renal cell carcinomas.Regul Pept. 2007 Dec 4;144(1-3):56-61. doi: 10.1016/j.regpep.2007.06.002. Epub 2007 Jun 21.
• [335] Expression changes of the MAD mitotic checkpoint gene family in renal cell carcinomas characterized by numerical chromosome changes.Virchows Arch. 2007 Apr;450(4):379-85. doi: 10.1007/s00428-007-0386-7. Epub 2007 Feb 28.
• [336] Below Safety Limits, Every Unit of Glomerular Filtration Rate Counts: Assessing the Relationship Between Renal Function and Cancer-specific Mortality in Renal Cell Carcinoma.Eur Urol. 2018 Nov;74(5):661-667. doi: 10.1016/j.eururo.2018.07.029. Epub 2018 Aug 10.
• [337] Expression of MAGE genes in renal cell carcinoma.Int J Mol Med. 1998 Jul;2(1):57-60. doi: 10.3892/ijmm.2.1.57.
• [338] Knockdown of MAGEA6 Activates AMP-Activated Protein Kinase (AMPK) Signaling to Inhibit Human Renal Cell Carcinoma Cells.Cell Physiol Biochem. 2018;45(3):1205-1218. doi: 10.1159/000487452. Epub 2018 Feb 9.
• [339] Normal polymorphism in the incomplete trinucleotide repeat of the arginine-rich protein gene.Cancer Res. 1997 Jul 15;57(14):2888-9.
• [340] Monoamine Oxidase B in Renal Cell Carcinoma.Med Sci Monit. 2018 Aug 4;24:5422-5426. doi: 10.12659/MSM.909507.
• [341] The selective MEK1 inhibitor Selumetinib enhances the antitumor activity of everolimus against renal cell carcinoma in vitro and in vivo.Oncotarget. 2017 Mar 28;8(13):20825-20833. doi: 10.18632/oncotarget.15346.
• [342] GSTM1 genotype is an independent prognostic factor in clear cell renal cell carcinoma.Urol Oncol. 2017 Jun;35(6):409-417. doi: 10.1016/j.urolonc.2017.02.005. Epub 2017 Mar 9.
• [343] miR-144-3p serves as a tumor suppressor for renal cell carcinoma and inhibits its invasion and metastasis by targeting MAP3K8.Biochem Biophys Res Commun. 2016 Nov 4;480(1):87-93. doi: 10.1016/j.bbrc.2016.10.004. Epub 2016 Oct 4.
• [344] MicroRNA-148b enhances proliferation and apoptosis in human renal cancer cells via directly targeting MAP3K9.Mol Med Rep. 2016 Jan;13(1):83-90. doi: 10.3892/mmr.2015.4555. Epub 2015 Nov 11.
• [345] Macrophage inflammatory protein-1 delta: a novel osteoclast stimulating factor secreted by renal cell carcinoma bone metastasis.Cancer Res. 2008 Mar 1;68(5):1261-6. doi: 10.1158/0008-5472.CAN-07-6122.
• [346] The protease activated receptor 1 gene variation IVSn -14 A>T is associated with distant metastasis and cancer specific survival in renal cell carcinoma.J Urol. 2013 Oct;190(4):1392-7. doi: 10.1016/j.juro.2013.03.041. Epub 2013 Mar 19.
• [347] Expression of methionine adenosyltransferase 2A in renal cell carcinomas and potential mechanism for kidney carcinogenesis.BMC Cancer. 2014 Mar 17;14:196. doi: 10.1186/1471-2407-14-196.
• [348] Aspirin restores ABT-737-mediated apoptosis in human renal carcinoma cells.Biochem Biophys Res Commun. 2018 Jul 12;502(2):187-193. doi: 10.1016/j.bbrc.2018.05.142. Epub 2018 May 24.
• [349] MDM2-positive papillary sarcomatoid renal cell carcinoma: a potential diagnostic pitfall.Virchows Arch. 2020 May;476(5):783-786. doi: 10.1007/s00428-019-02703-9. Epub 2019 Nov 16.
• [350] Prognostic and clinicopathological value of Ki-67/MIB-1 expression in renal cell carcinoma: a meta-analysis based on 4579 individuals.Cancer Manag Res. 2017 Nov 21;9:679-689. doi: 10.2147/CMAR.S141670. eCollection 2017.
• [351] microRNA?45 inhibits cell proliferation, migration and invasion by targeting matrix metallopeptidase-11 in renal cell carcinoma.Mol Med Rep. 2014 Jul;10(1):393-8. doi: 10.3892/mmr.2014.2149. Epub 2014 Apr 15.
• [352] Expression of messenger RNAs for membrane-type 1, 2, and 3 matrix metalloproteinases in human renal cell carcinomas.J Urol. 1999 Sep;162(3 Pt 1):905-9. doi: 10.1097/00005392-199909010-00088.
• [353] Expression of RON Proto-oncogene in Renal Oncocytoma and Chromophobe Renal Cell Carcinoma.Am J Surg Pathol. 2004 Aug;28(8):1045-50. doi: 10.1097/01.pas.0000128661.58697.7d.
• [354] MicroRNA-384 Inhibits the Growth and Invasion of Renal Cell Carcinoma Cells by Targeting Astrocyte Elevated Gene 1.Oncol Res. 2018 Apr 10;26(3):457-466. doi: 10.3727/096504017X15035025554553. Epub 2017 Aug 25.
• [355] Melatonin inhibits MMP-9 transactivation and renal cell carcinoma metastasis by suppressing Akt-MAPKs pathway and NF-B DNA-binding activity.J Pineal Res. 2016 Apr;60(3):277-90. doi: 10.1111/jpi.12308. Epub 2016 Feb 3.
• [356] An analysis of five clear cell papillary cystadenomas of mesosalpinx and broad ligament: four associated with von Hippel-Lindau disease and one aggressive sporadic type.Histopathology. 2012 Apr;60(5):748-57. doi: 10.1111/j.1365-2559.2011.04151.x. Epub 2012 Feb 1.
• [357] Expression of human mucin genes in normal kidney and renal cell carcinoma.Histopathology. 2002 May;40(5):450-7. doi: 10.1046/j.1365-2559.2002.01408.x.
• [358] The effect of a gene associated with retinoid-interferon-induced mortality 19 (GRIM-19) on STAT3-induced gene expression in renal carcinoma.J Biochem. 2018 Oct 1;164(4):285-294. doi: 10.1093/jb/mvy052.
• [359] MLN4924 (Pevonedistat), a protein neddylation inhibitor, suppresses proliferation and migration of human clear cell renal cell carcinoma.Sci Rep. 2017 Jul 17;7(1):5599. doi: 10.1038/s41598-017-06098-y.
• [360] Increased Nek1 expression in renal cell carcinoma cells is associated with decreased sensitivity to DNA-damaging treatment.Oncotarget. 2014 Jun 30;5(12):4283-94. doi: 10.18632/oncotarget.2005.
• [361] DNA methylation of neural EGFL like1 (NELL1) is associated with advanced disease and the metastatic state of renal cell cancer patients.Oncol Rep. 2018 Dec;40(6):3861-3868. doi: 10.3892/or.2018.6732. Epub 2018 Sep 24.
• [362] Metastatic renal cell carcinoma cells growing in 3D on polyDlysine or laminin present a stemlike phenotype and drug resistance.Oncol Rep. 2019 Nov;42(5):1878-1892. doi: 10.3892/or.2019.7321. Epub 2019 Sep 18.
• [363] Case-control analysis of nucleotide excision repair pathway and the risk of renal cell carcinoma.Carcinogenesis. 2008 Nov;29(11):2112-9. doi: 10.1093/carcin/bgn189. Epub 2008 Aug 18.
• [364] Nuclear Receptor 4A1 (NR4A1) as a Drug Target for Renal Cell Adenocarcinoma.PLoS One. 2015 Jun 2;10(6):e0128308. doi: 10.1371/journal.pone.0128308. eCollection 2015.
• [365] Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.Nat Biotechnol. 2016 Feb;34(2):155-63. doi: 10.1038/nbt.3391. Epub 2015 Nov 30.
• [366] Potential effect of tumor-specific Treg-targeted antibodies in the treatment of human cancers: A bioinformatics analysis.Oncoimmunology. 2017 Nov 9;7(2):e1387705. doi: 10.1080/2162402X.2017.1387705. eCollection 2018.
• [367] The impact of immunohistochemical staining with ezrin-carbonic anhydrase IX and neuropilin-2 on prognosis in patients with metastatic renal cell cancer receiving tyrosine kinase inhibitors.Tumour Biol. 2015 Nov;36(11):8471-8. doi: 10.1007/s13277-015-3589-6. Epub 2015 May 31.
• [368] hOGG1 Ser326Cys polymorphism and renal cell carcinoma risk in a Chinese population.DNA Cell Biol. 2011 May;30(5):317-21. doi: 10.1089/dna.2010.1135. Epub 2010 Dec 17.
• [369] LncRNA-SARCC suppresses renal cell carcinoma (RCC) progression via altering the androgen receptor(AR)/miRNA-143-3p signals.Cell Death Differ. 2017 Sep;24(9):1502-1517. doi: 10.1038/cdd.2017.74. Epub 2017 Jun 23.
• [370] microRNA-505 negatively regulates HMGB1 to suppress cell proliferation in renal cell carcinoma.J Cell Physiol. 2019 Sep;234(9):15025-15034. doi: 10.1002/jcp.28142. Epub 2019 Jan 15.
• [371] Tumor efficacy and biodistribution of linear polyethylenimine-cholesterol/DNA complexes.Mol Ther. 2004 Jun;9(6):837-45. doi: 10.1016/j.ymthe.2004.02.014.
• [372] Negative prognostic significance of primary cilia, CD8+ tumor infiltrating lymphocytes and PD1+ cells expression in clear cell renal cancer.J BUON. 2019 Jul-Aug;24(4):1644-1651.
• [373] Differential expressions of PD-1, PD-L1 and PD-L2 between primary and metastatic sites in renal cell carcinoma.BMC Cancer. 2019 Apr 16;19(1):360. doi: 10.1186/s12885-019-5578-4.
• [374] Identification and expression analysis of an N-terminally truncated isoform of human PDGF-C.Exp Cell Res. 2008 Aug 15;314(14):2529-43. doi: 10.1016/j.yexcr.2008.06.007. Epub 2008 Jun 13.
• [375] Blocking platelet-derived growth factor-D/platelet-derived growth factor receptor beta signaling inhibits human renal cell carcinoma progression in an orthotopic mouse model.Cancer Res. 2005 Jul 1;65(13):5711-9. doi: 10.1158/0008-5472.CAN-04-4313.
• [376] Targeting Tyrosine kinases in Renal Cell Carcinoma: "New Bullets against Old Guys".Int J Mol Sci. 2019 Apr 17;20(8):1901. doi: 10.3390/ijms20081901.
• [377] PDZK1 inhibits the development and progression of renal cell carcinoma by suppression of SHP-1 phosphorylation.Oncogene. 2017 Nov 2;36(44):6119-6131. doi: 10.1038/onc.2017.199. Epub 2017 Jul 10.
• [378] Genetic variants in RKIP are associated with clear cell renal cell carcinoma risk in a Chinese population.PLoS One. 2014 Oct 16;9(10):e109285. doi: 10.1371/journal.pone.0109285. eCollection 2014.
• [379] Suppression of Angiogenesis by Targeting Cyclin-Dependent Kinase 7 in Human Umbilical Vein Endothelial Cells and Renal Cell Carcinoma: An In Vitro and In Vivo Study.Cells. 2019 Nov 19;8(11):1469. doi: 10.3390/cells8111469.
• [380] PHGDH as a Key Enzyme for Serine Biosynthesis in HIF2-Targeting Therapy for Renal Cell Carcinoma.Cancer Res. 2017 Nov 15;77(22):6321-6329. doi: 10.1158/0008-5472.CAN-17-1589. Epub 2017 Sep 26.
• [381] SETD2 loss sensitizes cells to PI3K and AKT inhibition.Oncotarget. 2019 Jan 18;10(6):647-659. doi: 10.18632/oncotarget.26567. eCollection 2019 Jan 18.
• [382] PinX1 represses renal cancer angiogenesis via the mir-125a-3p/VEGF signaling pathway.Angiogenesis. 2019 Nov;22(4):507-519. doi: 10.1007/s10456-019-09675-z. Epub 2019 Jun 28.
• [383] Repression of PLA2R1 by c-MYC and HIF-2alpha promotes cancer growth.Oncotarget. 2014 Feb 28;5(4):1004-13. doi: 10.18632/oncotarget.1681.
• [384] PLK1 promotes proliferation and suppresses apoptosis of renal cell carcinoma cells by phosphorylating MCM3.Cancer Gene Ther. 2020 Jun;27(6):412-423. doi: 10.1038/s41417-019-0094-x. Epub 2019 Jun 12.
• [385] Regulation of the collagen cross-linking enzymes LOXL2 and PLOD2 by tumor-suppressive microRNA-26a/b in renal cell carcinoma.Int J Oncol. 2016 May;48(5):1837-46. doi: 10.3892/ijo.2016.3440. Epub 2016 Mar 15.
• [386] Nivolumab-induced hypophysitis causing secondary adrenal insufficiency after transient ACTH elevation.Endocr J. 2019 Oct 28;66(10):937-941. doi: 10.1507/endocrj.EJ19-0076. Epub 2019 Jun 19.
• [387] Glutamine-phosphoribosylpyrophosphate amidotransferase (amidophosphoribosyltransferase, EC 2.4.2.14) activity in normal, differentiating, and neoplastic kidney.Cancer Res. 1979 Oct;39(10):3909-14.
• [388] The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell. 2005 Sep 23;122(6):835-47. doi: 10.1016/j.cell.2005.07.003.
• [389] Protein kinase C eta is associated with progression of renal cell carcinoma (RCC).Anticancer Res. 2003 Sep-Oct;23(5A):4001-6.
• [390] Down-regulation of PKC in renal cell carcinoma and its clinicopathological implications.J Biomed Sci. 2012 Apr 5;19(1):39. doi: 10.1186/1423-0127-19-39.
• [391] Gene expression profiling separates chromophobe renal cell carcinoma from oncocytoma and identifies vesicular transport and cell junction proteins as differentially expressed genes.Clin Cancer Res. 2006 Dec 1;12(23):6937-45. doi: 10.1158/1078-0432.CCR-06-1268.
• [392] Characterization of human lymphocyte antigen class I antigen-processing machinery defects in renal cell carcinoma lesions with special emphasis on transporter-associated with antigen-processing down-regulation.Clin Cancer Res. 2003 May;9(5):1721-7.
• [393] PTBP1 knockdown in renal cell carcinoma inhibits cell migration, invasion and angiogenesis in vitro and metastasis in vivo via the hypoxia inducible factor-1 pathway.Int J Oncol. 2018 May;52(5):1613-1622. doi: 10.3892/ijo.2018.4296. Epub 2018 Mar 2.
• [394] Prostaglandin E2 regulates renal cell carcinoma invasion through the EP4 receptor-Rap GTPase signal transduction pathway.J Biol Chem. 2011 Sep 30;286(39):33954-62. doi: 10.1074/jbc.M110.187344. Epub 2011 Aug 10.
• [395] Overexpression of cyclooxygenase-1 correlates with poor prognosis in renal cell carcinoma.Asian Pac J Cancer Prev. 2013;14(6):3729-34. doi: 10.7314/apjcp.2013.14.6.3729.
• [396] Significance of cyclooxygenase-2, prostaglandin E2 and CD133 levels in sunitinib-resistant renal cell carcinoma.Oncol Lett. 2019 Aug;18(2):1442-1450. doi: 10.3892/ol.2019.10442. Epub 2019 Jun 6.
• [397] Antitumor effect of parathyroid hormone-related protein neutralizing antibody in human renal cell carcinoma in vitro and in vivo.Carcinogenesis. 2006 Jan;27(1):73-83. doi: 10.1093/carcin/bgi203. Epub 2005 Aug 4.
• [398] Kinomic profiling identifies focal adhesion kinase 1 as a therapeutic target in advanced clear cell renal cell carcinoma.Oncotarget. 2017 Apr 25;8(17):29220-29232. doi: 10.18632/oncotarget.16352.
• [399] SGK2 promotes renal cancer progression via enhancing ERK 1/2 and AKT phosphorylation.Eur Rev Med Pharmacol Sci. 2019 Apr;23(7):2756-2767. doi: 10.26355/eurrev_201904_17549.
• [400] Protein tyrosine phosphatase enhances proliferation by increasing -catenin nuclear expression in VHL-inactive human renal cell carcinoma cells.World J Urol. 2013 Dec;31(6):1547-54. doi: 10.1007/s00345-013-1077-4. Epub 2013 Apr 16.
• [401] Neuropeptide Y receptors in renal cell carcinomas and nephroblastomas.Int J Cancer. 2005 Jul 10;115(5):734-41. doi: 10.1002/ijc.20948.
• [402] DNA methylation-regulated QPCT promotes sunitinib resistance by increasing HRAS stability in renal cell carcinoma.Theranostics. 2019 Aug 14;9(21):6175-6190. doi: 10.7150/thno.35572. eCollection 2019.
• [403] MiR-204 inhibits the proliferation and invasion of renal cell carcinoma by inhibiting RAB22A expression.Oncol Rep. 2016 May;35(5):3000-8. doi: 10.3892/or.2016.4624. Epub 2016 Feb 16.
• [404] Regulation of receptor for activated C kinase 1 protein by the von Hippel-Lindau tumor suppressor in IGF-I-induced renal carcinoma cell invasiveness.Oncogene. 2011 Feb 3;30(5):535-47. doi: 10.1038/onc.2010.427. Epub 2010 Sep 27.
• [405] RIP1-dependent reactive oxygen species production executes artesunate-induced cell death in renal carcinoma Caki cells.Mol Cell Biochem. 2017 Nov;435(1-2):15-24. doi: 10.1007/s11010-017-3052-7. Epub 2017 May 2.
• [406] Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model.Clin Cancer Res. 2005 May 1;11(9):3558-66. doi: 10.1158/1078-0432.CCR-04-1155.
• [407] HIF-1alpha mRNA and protein upregulation involves Rho GTPase expression during hypoxia in renal cell carcinoma.J Cell Sci. 2003 Jun 1;116(Pt 11):2247-60. doi: 10.1242/jcs.00427. Epub 2003 Apr 15.
• [408] Identification of gene markers associated with metastasis in clear cell renal cell carcinoma.Oncol Lett. 2017 Jun;13(6):4755-4761. doi: 10.3892/ol.2017.6084. Epub 2017 Apr 24.
• [409] Upregulation of RICTOR gene transcription by the proinflammatory cytokines through NF-B pathway contributes to the metastasis of renal cell carcinoma.Tumour Biol. 2016 Apr;37(4):4457-66. doi: 10.1007/s13277-015-4296-z. Epub 2015 Oct 25.
• [410] A CARP-1 functional mimetic loaded vitamin E-TPGS micellar nano-formulation for inhibition of renal cell carcinoma.Oncotarget. 2017 Sep 5;8(62):104928-104945. doi: 10.18632/oncotarget.20650. eCollection 2017 Dec 1.
• [411] Acid, basic, and neutral peptidases present different profiles in chromophobe renal cell carcinoma and in oncocytoma.Am J Physiol Renal Physiol. 2008 Apr;294(4):F850-8. doi: 10.1152/ajprenal.00469.2007. Epub 2008 Jan 23.
• [412] Tumour specific promoter region methylation of the human homologue of the Drosophila Roundabout gene DUTT1 (ROBO1) in human cancers.Oncogene. 2002 May 2;21(19):3020-8. doi: 10.1038/sj.onc.1205421.
• [413] MiR-199a targeting ROCK1 to affect kidney cell proliferation, invasion and apoptosis.Artif Cells Nanomed Biotechnol. 2018 Dec;46(8):1920-1925. doi: 10.1080/21691401.2017.1396224. Epub 2017 Nov 13.
• [414] Expression of Ror2 mediates invasive phenotypes in renal cell carcinoma.PLoS One. 2014 Dec 26;9(12):e116101. doi: 10.1371/journal.pone.0116101. eCollection 2014.
• [415] Ribosomal s6 protein kinase 4: a prognostic factor for renal cell carcinoma.Br J Cancer. 2013 Sep 3;109(5):1137-46. doi: 10.1038/bjc.2013.463. Epub 2013 Aug 13.
• [416] Remodeling and spacing factor 1 overexpression is associated with poor prognosis in renal cell carcinoma. Oncol Lett. 2018 Mar;15(3):3852-3857.
• [417] Prognostic significance of vitamin D receptor and retinoid X receptor expression in renal cell carcinoma.J Urol. 2007 Oct;178(4 Pt 1):1497-503. doi: 10.1016/j.juro.2007.05.119. Epub 2007 Aug 16.
• [418] Proteins S100A8 and S100A9 are potential biomarkers for renal cell carcinoma in the early stages: results from a proteomic study integrated with bioinformatics analysis.Mol Med Rep. 2015 Jun;11(6):4093-100. doi: 10.3892/mmr.2015.3321. Epub 2015 Feb 9.
• [419] Immunogenic properties of renal cell carcinoma and the pathogenesis of osteolytic bone metastases.Int J Oncol. 2009 May;34(5):1387-93.
• [420] Somatic Bi-allelic Loss of TSC Genes in Eosinophilic Solid and Cystic Renal Cell Carcinoma.Eur Urol. 2018 Oct;74(4):483-486. doi: 10.1016/j.eururo.2018.06.007. Epub 2018 Jun 23.
• [421] Expression of Genes Involved in Porphyrin Biosynthesis Pathway in the Human Renal Cell Carcinoma.J Fluoresc. 2015 Sep;25(5):1363-9. doi: 10.1007/s10895-015-1626-x. Epub 2015 Aug 6.
• [422] Upregulation of miR-489-3p and miR-630 inhibits oxaliplatin uptake in renal cell carcinoma by targeting OCT2.Acta Pharm Sin B. 2019 Sep;9(5):1008-1020. doi: 10.1016/j.apsb.2019.01.002. Epub 2019 Jan 8.
• [423] The prospect of precision therapy for renal cell carcinoma.Cancer Treat Rev. 2016 Sep;49:37-44. doi: 10.1016/j.ctrv.2016.07.003. Epub 2016 Jul 12.
• [424] Genome-wide CpG island methylation analysis implicates novel genes in the pathogenesis of renal cell carcinoma.Epigenetics. 2012 Mar;7(3):278-90. doi: 10.4161/epi.7.3.19103.
• [425] CD98hc (SLC3A2) drives integrin-dependent renal cancer cell behavior.Mol Cancer. 2013 Dec 21;12:169. doi: 10.1186/1476-4598-12-169.
• [426] Knockdown of sodium-calcium exchanger 1 induces epithelial-to-mesenchymal transition in kidney epithelial cells. J Biol Chem. 2017 Jul 7;292(27):11388-11399.
• [427] Inhibition of SMYD2 suppresses tumor progression by down-regulating microRNA-125b and attenuates multi-drug resistance in renal cell carcinoma.Theranostics. 2019 Oct 22;9(26):8377-8391. doi: 10.7150/thno.37628. eCollection 2019.
• [428] Suppression of SOCS3 enhances TRAIL-induced cell growth inhibition through the upregulation of DR4 expression in renal cell carcinoma cells.Oncotarget. 2018 Aug 3;9(60):31697-31708. doi: 10.18632/oncotarget.25851. eCollection 2018 Aug 3.
• [429] The Impact Of Succinate Dehydrogenase Gene (SDH) Mutations In Renal Cell Carcinoma (RCC): A Systematic Review.Onco Targets Ther. 2019 Sep 26;12:7929-7940. doi: 10.2147/OTT.S207460. eCollection 2019.
• [430] Matriptase and MET are prominently expressed at the site of bone metastasis in renal cell carcinoma: immunohistochemical analysis.Hum Cell. 2015 Jan;28(1):44-50. doi: 10.1007/s13577-014-0101-3. Epub 2014 Sep 4.
• [431] Impact of Sulfatase-2 on cancer progression and prognosis in patients with renal cell carcinoma.Cancer Sci. 2016 Nov;107(11):1632-1641. doi: 10.1111/cas.13074.
• [432] Molecular analysis of a familial case of renal cell cancer and a t(3;6)(q12;q15).Genes Chromosomes Cancer. 2001 May;31(1):23-32. doi: 10.1002/gcc.1114.
• [433] The F-prostaglandin receptor is a novel marker for tumor endothelial cells in renal cell carcinoma.Pathol Int. 2013 Jan;63(1):37-44. doi: 10.1111/pin.12031.
• [434] Dual Inhibition of Angiopoietin-TIE2 and MET Alters the Tumor Microenvironment and Prolongs Survival in a Metastatic Model of Renal Cell Carcinoma.Mol Cancer Ther. 2020 Jan;19(1):147-156. doi: 10.1158/1535-7163.MCT-18-1202. Epub 2019 Oct 3.
• [435] Emerging immunotherapeutic strategies targeting telomerases in genitourinary tumors.Crit Rev Oncol Hematol. 2018 Nov;131:1-6. doi: 10.1016/j.critrevonc.2018.07.008. Epub 2018 Aug 1.
• [436] Over-expression of telomere binding factors (TRF1 & TRF2) in renal cell carcinoma and their inhibition by using SiRNA induce apoptosis, reduce cell proliferation and migration invitro.PLoS One. 2015 Mar 2;10(3):e0115651. doi: 10.1371/journal.pone.0115651. eCollection 2015.
• [437] Identification of novel epigenetic markers for clear cell renal cell carcinoma.J Urol. 2008 Sep;180(3):1126-30. doi: 10.1016/j.juro.2008.04.137. Epub 2008 Jul 18.
• [438] TGF-alpha as a candidate tumor antigen for renal cell carcinomas.Cancer Immunol Immunother. 2009 Aug;58(8):1207-18. doi: 10.1007/s00262-008-0630-2. Epub 2008 Dec 4.
• [439] Rac affects invasion of human renal cell carcinomas by up-regulating tissue inhibitor of metalloproteinases (TIMP)-1 and TIMP-2 expression.J Biol Chem. 2001 Nov 9;276(45):41889-97. doi: 10.1074/jbc.M105049200. Epub 2001 Sep 10.
• [440] Identification of receptor genes in renal cell carcinoma associated with angiogenesis by differential hybridization technique.Biochem Biophys Res Commun. 1999 Apr 21;257(3):855-9. doi: 10.1006/bbrc.1999.0465.
• [441] Differential expression of thymosin genes in human tumors and in the developing human kidney.Int J Cancer. 1991 Jul 9;48(5):672-7. doi: 10.1002/ijc.2910480507.
• [442] Enhancement of death receptor 4-mediated apoptosis and cytotoxicity in renal cell carcinoma cells by anisomycin.Anticancer Drugs. 2017 Feb;28(2):180-186. doi: 10.1097/CAD.0000000000000450.
• [443] Triptolide enhances the tumoricidal activity of TRAIL against renal cell carcinoma.FEBS J. 2015 Dec;282(24):4747-4765. doi: 10.1111/febs.13532. Epub 2015 Oct 18.
• [444] Detection of the TNFSF members BAFF, APRIL, TWEAK and their receptors in normal kidney and renal cell carcinomas.Anal Cell Pathol (Amst). 2011;34(1-2):49-60. doi: 10.3233/ACP-2011-0001.
• [445] Suppression of renal cell carcinoma growth in vivo by forced expression of vascular endothelial growth inhibitor.Int J Oncol. 2013 May;42(5):1664-73. doi: 10.3892/ijo.2013.1877. Epub 2013 Mar 29.
• [446] Preclinical development of T-cell receptor-engineered T-cell therapy targeting the 5T4 tumor antigen on renal cell carcinoma.Cancer Immunol Immunother. 2019 Dec;68(12):1979-1993. doi: 10.1007/s00262-019-02419-4. Epub 2019 Nov 4.
• [447] Expression of Translationally Controlled Tumor Protein in Human Kidney and in Renal Cell Carcinoma.Biomed Res Int. 2015;2015:730390. doi: 10.1155/2015/730390. Epub 2015 Sep 3.
• [448] Depletion of the triggering receptor expressed on myeloid cells 2 inhibits progression of renal cell carcinoma via regulating related protein expression and PTEN-PI3K/Akt pathway.Int J Oncol. 2016 Dec;49(6):2498-2506. doi: 10.3892/ijo.2016.3740. Epub 2016 Oct 19.
• [449] TRIM59 is a key regulator of growth and migration inrenal cell carcinoma.Cell Mol Biol (Noisy-le-grand). 2017 May 20;63(5):68-74. doi: 10.14715/cmb/2017.63.5.13.
• [450] Splicing variant of Cdc42 interacting protein-4 disrupts beta-catenin-mediated cell-cell adhesion: expression and function in renal cell carcinoma.Biochem Biophys Res Commun. 2006 Jan 27;339(4):1083-8. doi: 10.1016/j.bbrc.2005.11.117. Epub 2005 Dec 5.
• [451] Transient potential receptor channel 4 controls thrombospondin-1 secretion and angiogenesis in renal cell carcinoma.FEBS J. 2007 Dec;274(24):6365-77. doi: 10.1111/j.1742-4658.2007.06159.x. Epub 2007 Nov 15.
• [452] CircRNA cRAPGEF5 inhibits the growth and metastasis of renal cell carcinoma via the miR-27a-3p/TXNIP pathway.Cancer Lett. 2020 Jan 28;469:68-77. doi: 10.1016/j.canlet.2019.10.017. Epub 2019 Oct 17.
• [453] UBE2T promotes proliferation and regulates PI3K/Akt signaling in renal cell carcinoma.Mol Med Rep. 2019 Aug;20(2):1212-1220. doi: 10.3892/mmr.2019.10322. Epub 2019 Jun 3.
• [454] Epigenetic control of the ubiquitin carboxyl terminal hydrolase 1 in renal cell carcinoma.J Transl Med. 2009 Oct 26;7:90. doi: 10.1186/1479-5876-7-90.
• [455] Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: regulation by the von Hippel-Lindau gene and hypoxia.Cancer Res. 2001 Apr 1;61(7):3206-11.
• [456] VEGFC acts as a double-edged sword in renal cell carcinoma aggressiveness.Theranostics. 2019 Jan 21;9(3):661-675. doi: 10.7150/thno.27794. eCollection 2019.
• [457] Serum soluble B7-H4 is a prognostic marker for patients with non-metastatic clear cell renal cell carcinoma.PLoS One. 2018 Jul 25;13(7):e0199719. doi: 10.1371/journal.pone.0199719. eCollection 2018.
• [458] Alterations of the WNT7A gene in clear cell renal cell carcinomas.PLoS One. 2012;7(10):e47012. doi: 10.1371/journal.pone.0047012. Epub 2012 Oct 8.
• [459] Potential biological process of X-linked inhibitor of apoptosis protein in renal cell carcinoma based upon differential protein expression analysis.Oncol Lett. 2018 Jan;15(1):821-832. doi: 10.3892/ol.2017.7383. Epub 2017 Nov 9.
• [460] Expression of cholinesterases in human kidney and its variation in renal cell carcinoma types.FEBS J. 2010 Nov;277(21):4519-29. doi: 10.1111/j.1742-4658.2010.07861.x. Epub 2010 Sep 30.
• [461] Germline genetic variants in somatically significantly mutated genes in tumors are associated with renal cell carcinoma risk and outcome.Carcinogenesis. 2018 May 28;39(6):752-757. doi: 10.1093/carcin/bgy021.
• [462] Clusterin promotes growth and invasion of clear cell renal carcinoma cell by upregulation of S100A4 expression.Cancer Biomark. 2018;21(4):915-923. doi: 10.3233/CBM-171018.
• [463] Endostatin Effects on Tumor Cells and Vascular Network of Human Renal Cell Carcinoma Implanted on Chick Embryo Chorioallantoic Membrane.Anticancer Res. 2015 Dec;35(12):6521-8.
• [464] A systematic search strategy identifies cubilin as independent prognostic marker for renal cell carcinoma.BMC Cancer. 2017 Jan 4;17(1):9. doi: 10.1186/s12885-016-3030-6.
• [465] Induction of the connexin 32 gene by epigallocatechin-3-gallate potentiates vinblastine-induced cytotoxicity in human renal carcinoma cells.Chemotherapy. 2013;59(3):192-9. doi: 10.1159/000354715. Epub 2013 Dec 3.
• [466] HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL.Int J Cancer. 2008 Dec 1;123(11):2616-25. doi: 10.1002/ijc.23823.
• [467] Linking Binary Gene Relationships to Drivers of Renal Cell Carcinoma Reveals Convergent Function in Alternate Tumor Progression Paths.Sci Rep. 2019 Feb 27;9(1):2899. doi: 10.1038/s41598-019-39875-y.
• [468] Transglutaminase 2 Promotes Autophagy by LC3 Induction through p53 Depletion in Cancer Cell.Biomol Ther (Seoul). 2019 Jan 1;27(1):34-40. doi: 10.4062/biomolther.2018.140.
• [469] Involvement of ABC transporters in chemosensitivity of human renal cell carcinoma, and regulation of MRP2 expression by conjugated bilirubin.Anticancer Res. 2005 Jul-Aug;25(4):2729-35.
• [470] Downregulation of ABCD1 in human renal cell carcinoma.Int J Biol Markers. 2009 Jul-Sep;24(3):171-8. doi: 10.1177/172460080902400307.
• [471] Structure of the human receptor tyrosine phosphatase gamma gene (PTPRG) and relation to the familial RCC t(3;8) chromosome translocation.Genomics. 1996 Mar 1;32(2):225-35. doi: 10.1006/geno.1996.0109.
• [472] Coordinate expression of nuclear and mitochondrial genes involved in energy production in carcinoma and oncocytoma.Biochim Biophys Acta. 1996 Aug 23;1316(3):203-9. doi: 10.1016/0925-4439(96)00026-9.
• [473] Differential expression of facilitative glucose transporters in normal and tumour kidney tissues.BJU Int. 2007 May;99(5):1143-9. doi: 10.1111/j.1464-410X.2007.06765.x.
• [474] Hypoxia drives glucose transporter 3 expression through hypoxia-inducible transcription factor (HIF)-mediated induction of the long noncoding RNA NICI.J Biol Chem. 2020 Mar 27;295(13):4065-4078. doi: 10.1074/jbc.RA119.009827. Epub 2019 Nov 5.
• [475] Association between ZIP10 gene expression and tumor aggressiveness in renal cell carcinoma.Gene. 2014 Nov 15;552(1):195-8. doi: 10.1016/j.gene.2014.09.010. Epub 2014 Sep 6.
• [476] Zinc transporter genes and urological cancers: integrated analysis suggests a role for ZIP11 in bladder cancer.Tumour Biol. 2015 Sep;36(10):7431-7. doi: 10.1007/s13277-015-3459-2. Epub 2015 Apr 23.
• [477] Localization of NBC-1 variants in human kidney and renal cell carcinoma.Biochem Biophys Res Commun. 2003 Oct 31;310(4):1213-8. doi: 10.1016/j.bbrc.2003.09.147.
• [478] Acetyl-CoA synthetase 2 enhances tumorigenesis and is indicative of a poor prognosis for patients with renal cell carcinoma.Urol Oncol. 2018 May;36(5):243.e9-243.e20. doi: 10.1016/j.urolonc.2018.01.013. Epub 2018 Mar 2.
• [479] The alterations in alcohol dehydrogenase and aldehyde dehydrogenase activities in the sera of patients with renal cell carcinoma.Adv Med Sci. 2018 Mar;63(1):1-4. doi: 10.1016/j.advms.2017.05.001. Epub 2017 Jul 28.
• [480] Aldehyde dehydrogenase 1 identifies cells with cancer stem cell-like properties in a human renal cell carcinoma cell line.PLoS One. 2013 Oct 8;8(10):e75463. doi: 10.1371/journal.pone.0075463. eCollection 2013.
• [481] Association between cytochrome P450 1A1 (CYP1A1) gene polymorphisms and the risk of renal cell carcinoma: a meta-analysis.Sci Rep. 2015 Jan 29;5:8108. doi: 10.1038/srep08108.
• [482] Expression of lactate dehydrogenase C correlates with poor prognosis in renal cell carcinoma.Tumour Biol. 2017 Mar;39(3):1010428317695968. doi: 10.1177/1010428317695968.
• [483] Potential biomarkers for the therapeutic efficacy of sorafenib, sunitinib and everolimus.Oncol Rep. 2017 Jan;37(1):227-234. doi: 10.3892/or.2016.5232. Epub 2016 Nov 8.
• [484] Human agmatinase is diminished in the clear cell type of renal cell carcinoma.Int J Cancer. 2004 Jan 20;108(3):342-7. doi: 10.1002/ijc.11459.
• [485] The Preoperative Predictive Factors for Pathological T3a Upstaging of Clinical T1 Renal Cell Carcinoma.Diagnostics (Basel). 2019 Jul 15;9(3):76. doi: 10.3390/diagnostics9030076.
• [486] Protein kinase C-mediated modulation of FIH-1 expression by the homeodomain protein CDP/Cut/Cux.Mol Cell Biol. 2007 Oct;27(20):7345-53. doi: 10.1128/MCB.02201-06. Epub 2007 Aug 6.
• [487] In vivo gene expression profile analysis of metallothionein in renal cell carcinoma.Cancer Lett. 2000 Nov 28;160(2):133-40. doi: 10.1016/s0304-3835(00)00534-6.
• [488] Association of GSTT1 non-null and NAT1 slow/rapid genotypes with von Hippel-Lindau tumour suppressor gene transversions in sporadic renal cell carcinoma.Pharmacogenetics. 2001 Aug;11(6):521-35. doi: 10.1097/00008571-200108000-00007.
• [489] Nicotinamide N-Methyltransferase and Its Precursor Substrate Methionine Directly and Indirectly Control Malignant Metabolism During Progression of Renal Cell Carcinoma.Anticancer Res. 2019 Oct;39(10):5427-5436. doi: 10.21873/anticanres.13736.
• [490] Expression parameters of the metabolic pathway genes pyruvate dehydrogenase kinase-1 (PDK-1) and DJ-1/PARK7 in renal cell carcinoma (RCC).World J Urol. 2013 Oct;31(5):1191-6. doi: 10.1007/s00345-012-0874-5. Epub 2012 Apr 29.
• [491] Imaging of renal cell carcinoma in patients with acquired cystic disease of the kidney: comparison (11)C-choline and FDG PET/CT with dynamic contrast-enhanced CT.Jpn J Radiol. 2019 Feb;37(2):165-177. doi: 10.1007/s11604-018-0789-1. Epub 2018 Oct 30.
• [492] Differential aminoacylase expression in neuroblastoma.Int J Cancer. 2011 Sep 15;129(6):1322-30. doi: 10.1002/ijc.25798. Epub 2011 Apr 1.
• [493] The Adiponectin-AdipoR1 Axis Mediates Tumor Progression and Tyrosine Kinase Inhibitor Resistance in Metastatic Renal Cell Carcinoma.Neoplasia. 2019 Sep;21(9):921-931. doi: 10.1016/j.neo.2019.07.004. Epub 2019 Aug 8.
• [494] Role of APLP2 in the prognosis and clinicopathology of renal cell carcinoma.Oncol Lett. 2019 Jan;17(1):508-513. doi: 10.3892/ol.2018.9577. Epub 2018 Oct 15.
• [495] Analysis of the characteristics of chemotherapy-resistant renal cell carcinomas based on global transcriptional analysis of their tissues and cell lines.PLoS One. 2019 Nov 27;14(11):e0225721. doi: 10.1371/journal.pone.0225721. eCollection 2019.
• [496] Pharmacologic Targeting of Hypoxia-Inducible Factors.Annu Rev Pharmacol Toxicol. 2019 Jan 6;59:379-403. doi: 10.1146/annurev-pharmtox-010818-021637.
• [497] CA8 promotes RCC proliferation and migration though its expression level is lower in tumor compared to adjacent normal tissue.Biomed Pharmacother. 2020 Jan;121:109578. doi: 10.1016/j.biopha.2019.109578. Epub 2019 Nov 10.
• [498] Nephroblastoma overexpressed gene expression and its prognostic implications of clinical outcomes in renal cell carcinoma patients.Cancer Biomark. 2017 Sep 7;20(3):241-246. doi: 10.3233/CBM-170017.
• [499] The metastasis suppressor CD82/KAI1 regulates cell migration and invasion via inhibiting TGF- 1/Smad signaling in renal cell carcinoma.Oncotarget. 2017 May 23;8(31):51559-51568. doi: 10.18632/oncotarget.18086. eCollection 2017 Aug 1.
• [500] VHL loss in renal cell carcinoma leads to up-regulation of CUB domain-containing protein 1 to stimulate PKC{delta}-driven migration.Proc Natl Acad Sci U S A. 2011 Feb 1;108(5):1931-6. doi: 10.1073/pnas.1011777108. Epub 2011 Jan 13.
• [501] Knockdown of CHCHD2 inhibits migration and angiogenesis of human renal cell carcinoma: A potential molecular marker for treatment of RCC.Oncol Lett. 2019 Jan;17(1):765-772. doi: 10.3892/ol.2018.9686. Epub 2018 Nov 12.
• [502] M2 Macrophage Marker Chitinase 3-Like 2 (CHI3L2) Associates With Progression of Conventional Renal Cell Carcinoma.Anticancer Res. 2019 Dec;39(12):6939-6943. doi: 10.21873/anticanres.13915.
• [503] CMTM5 inhibits renal cancer cell growth through inducing cell-cycle arrest and apoptosis.Oncol Lett. 2017 Aug;14(2):1536-1542. doi: 10.3892/ol.2017.6350. Epub 2017 Jun 8.
• [504] Cyclin D1 and p57 expression in relation to clinicopathological characteristics and overall survival in patients with renal cell carcinoma.J BUON. 2019 Jan-Feb;24(1):301-309.
• [505] miR-26 suppresses renal cell cancer via down-regulating coronin-3.Mol Cell Biochem. 2020 Jan;463(1-2):137-146. doi: 10.1007/s11010-019-03636-2. Epub 2019 Oct 8.
• [506] Cullin 5 is a novel candidate tumor suppressor in renal cell carcinoma involved in the maintenance of genome stability.Oncogenesis. 2019 Jan 9;8(1):4. doi: 10.1038/s41389-018-0110-2.
• [507] Tumoural CXCL16 expression is a novel prognostic marker of longer survival times in renal cell cancer patients.Eur J Cancer. 2009 Feb;45(3):478-89. doi: 10.1016/j.ejca.2008.10.023. Epub 2008 Dec 11.
• [508] Human beta-defensin-1, a potential chromosome 8p tumor suppressor: control of transcription and induction of apoptosis in renal cell carcinoma.Cancer Res. 2006 Sep 1;66(17):8542-9. doi: 10.1158/0008-5472.CAN-06-0294.
• [509] Estrogen receptor-binding fragment-associated gene 9 expression and its clinical significance in human testicular cancer.Int J Urol. 2009 Mar;16(3):329-32. doi: 10.1111/j.1442-2042.2008.02233.x. Epub 2009 Jan 20.
• [510] Genetic Underpinnings of Renal Cell Carcinoma With Leiomyomatous Stroma.Am J Surg Pathol. 2019 Aug;43(8):1135-1144. doi: 10.1097/PAS.0000000000001255.
• [511] A novel protein is lower expressed in renal cell carcinoma.Int J Mol Sci. 2014 Apr 29;15(5):7398-408. doi: 10.3390/ijms15057398.
• [512] Methylation-associated silencing of TU3A in human cancers.Int J Oncol. 2008 Oct;33(4):893-9.
• [513] miR-29b and miR-198 overexpression in CD8+ T cells of renal cell carcinoma patients down-modulates JAK3 and MCL-1 leading to immune dysfunction.J Transl Med. 2016 Apr 11;14:84. doi: 10.1186/s12967-016-0841-9.
• [514] MicroRNA-125a suppresses cell migration, invasion, and regulates hyaluronic acid synthase 1 expression by targeting signal transducers and activators of transcription 3 in renal cell carcinoma cells.J Cell Biochem. 2019 Feb;120(2):1894-1902. doi: 10.1002/jcb.27503. Epub 2018 Sep 6.
• [515] Diagnostic role of kidney injury molecule-1 in renal cell carcinoma.Int Urol Nephrol. 2019 Nov;51(11):1893-1902. doi: 10.1007/s11255-019-02231-0. Epub 2019 Aug 5.
• [516] HepaCAM Regulates Warburg Effect of Renal Cell Carcinoma via HIF-1/NF-B Signaling Pathway.Urology. 2019 May;127:61-67. doi: 10.1016/j.urology.2018.11.033. Epub 2018 Dec 4.
• [517] Inhibitor of growth 4 inhibits cell proliferation, migration, and induces apoptosis of renal cell carcinoma cells.J Cell Biochem. 2019 Apr;120(4):6709-6717. doi: 10.1002/jcb.27967. Epub 2018 Nov 2.
• [518] Biochemical and Epigenetic Insights into L-2-Hydroxyglutarate, a Potential Therapeutic Target in Renal Cancer.Clin Cancer Res. 2018 Dec 15;24(24):6433-6446. doi: 10.1158/1078-0432.CCR-18-1727. Epub 2018 Aug 14.
• [519] Germline and somatic DNA methylation and epigenetic regulation of KILLIN in renal cell carcinoma.Genes Chromosomes Cancer. 2011 Aug;50(8):654-61. doi: 10.1002/gcc.20887. Epub 2011 May 16.
• [520] Karyopherin Alpha 2 Is an Adverse Prognostic Factor in Clear-Cell and Papillary Renal-Cell Carcinoma.Clin Genitourin Cancer. 2019 Feb;17(1):e167-e175. doi: 10.1016/j.clgc.2018.10.008. Epub 2018 Oct 23.
• [521] MicroRNA-200b is downregulated and suppresses metastasis by targeting LAMA4 in renal cell carcinoma.EBioMedicine. 2019 Jun;44:439-451. doi: 10.1016/j.ebiom.2019.05.041. Epub 2019 May 23.
• [522] Characterization of the expression of LAT1 as a prognostic indicator and a therapeutic target in renal cell carcinoma.Sci Rep. 2019 Nov 20;9(1):16776. doi: 10.1038/s41598-019-53397-7.
• [523] High expression of MICA in human kidney cancer tissue and renal cell carcinoma lines.Asian Pac J Cancer Prev. 2014;15(4):1715-7. doi: 10.7314/apjcp.2014.15.4.1715.
• [524] HMGB1/RAGE axis mediates the apoptosis, invasion, autophagy, and angiogenesis of the renal cell carcinoma.Onco Targets Ther. 2018 Aug 1;11:4501-4510. doi: 10.2147/OTT.S167197. eCollection 2018.
• [525] Mitochondrial pyruvate carrier 1 functions as a tumor suppressor and predicts the prognosis of human renal cell carcinoma.Lab Invest. 2019 Feb;99(2):191-199. doi: 10.1038/s41374-018-0138-0. Epub 2018 Oct 5.
• [526] DNA methylation of metallothionein genes is associated with the clinical features of renal cell carcinoma.Oncol Rep. 2019 Jun;41(6):3535-3544. doi: 10.3892/or.2019.7109. Epub 2019 Apr 10.
• [527] NDNF inhibits the migration and invasion of human renal cancer cells through epithelial-mesenchymal transition.Oncol Lett. 2019 Mar;17(3):2969-2975. doi: 10.3892/ol.2019.9937. Epub 2019 Jan 15.
• [528] Suppression of GLTSCR2 expression in renal cell carcinomas.Pathol Res Pract. 2016 Feb;212(2):120-4. doi: 10.1016/j.prp.2015.12.005. Epub 2015 Dec 14.
• [529] Suppressed OGT expression inhibits cell proliferation and modulates EGFR expression in renal cell carcinoma.Cancer Manag Res. 2019 Mar 19;11:2215-2223. doi: 10.2147/CMAR.S190642. eCollection 2019.
• [530] Downregulation of PDCD4 by miR-21 suppresses tumor transformation and proliferation in a nude mouse renal cancer model.Oncol Lett. 2017 Sep;14(3):3371-3378. doi: 10.3892/ol.2017.6605. Epub 2017 Jul 18.
• [531] MiR-23a-3p acts as an oncogene and potential prognostic biomarker by targeting PNRC2 in RCC.Biomed Pharmacother. 2019 Feb;110:656-666. doi: 10.1016/j.biopha.2018.11.065. Epub 2018 Dec 12.
• [532] Reference genes for gene expression analysis by real-time reverse transcription polymerase chain reaction of renal cell carcinoma.Diagn Mol Pathol. 2011 Dec;20(4):212-7. doi: 10.1097/PDM.0b013e318212e0a9.
• [533] RBM10-TFE3 renal cell carcinoma characterised by paracentric inversion with consistent closely split signals in break-apart fluorescence in-situ hybridisation: study of 10 cases and a literature review.Histopathology. 2019 Aug;75(2):254-265. doi: 10.1111/his.13866. Epub 2019 Jun 25.
• [534] RIN1 promotes renal cell carcinoma malignancy by activating EGFR signaling through Rab25.Cancer Sci. 2017 Aug;108(8):1620-1627. doi: 10.1111/cas.13297. Epub 2017 Jul 3.
• [535] Inactivation of SAG or ROC1 E3 Ligase Inhibits Growth and Survival of Renal Cell Carcinoma Cells: Effect of BIM.Transl Oncol. 2019 Jun;12(6):810-818. doi: 10.1016/j.tranon.2019.03.002. Epub 2019 Apr 4.
• [536] von Hippel-Lindau mutants in renal cell carcinoma are regulated by increased expression of RSUME.Cell Death Dis. 2019 Mar 19;10(4):266. doi: 10.1038/s41419-019-1507-3.
• [537] LncRNA SCAMP1 regulates ZEB1/JUN and autophagy to promote pediatric renal cell carcinoma under oxidative stress via miR-429.Biomed Pharmacother. 2019 Dec;120:109460. doi: 10.1016/j.biopha.2019.109460. Epub 2019 Sep 21.
• [538] Vimentin Overexpressions Induced by Cell Hypoxia Promote Vasculogenic Mimicry by Renal Cell Carcinoma Cells.Biomed Res Int. 2019 Jul 21;2019:7259691. doi: 10.1155/2019/7259691. eCollection 2019.
• [539] SFRP1 CpG island methylation locus is associated with renal cell cancer susceptibility and disease recurrence.Epigenetics. 2012 May;7(5):447-57. doi: 10.4161/epi.19614. Epub 2012 May 1.
• [540] Secreted frizzled-related protein-5 is epigenetically downregulated and functions as a tumor suppressor in kidney cancer.Int J Cancer. 2011 Feb 1;128(3):541-50. doi: 10.1002/ijc.25357.
• [541] UCA1 promotes cell proliferation and invasion and inhibits apoptosis through regulation of the miR129-SOX4 pathway in renal cell carcinoma.Onco Targets Ther. 2018 May 1;11:2475-2487. doi: 10.2147/OTT.S160192. eCollection 2018.
• [542] LINC00961 restrains cancer progression via modulating epithelial-mesenchymal transition in renal cell carcinoma.J Cell Physiol. 2019 May;234(5):7257-7265. doi: 10.1002/jcp.27483. Epub 2018 Oct 26.
• [543] The Role of Serine Peptidase Inhibitor Kazal Type 13 (SPINK13) as a Clinicopathological and Prognostic Biomarker in Patients with Clear Cell Renal Cell Carcinoma.Med Sci Monit. 2019 Dec 11;25:9458-9470. doi: 10.12659/MSM.917754.
• [544] Dysregulated HAI-2 Plays an Important Role in Renal Cell Carcinoma Bone Metastasis through Ligand-Dependent MET Phosphorylation.Cancers (Basel). 2018 Jun 8;10(6):190. doi: 10.3390/cancers10060190.
• [545] Standardized report template for indeterminate renal masses at CT and MRI: a collaborative product of the SAR Disease-Focused Panel on Renal Cell Carcinoma.Abdom Radiol (NY). 2019 Apr;44(4):1423-1429. doi: 10.1007/s00261-018-1851-2.
• [546] Syntaxin 6: A novel predictive and prognostic biomarker in papillary renal cell carcinoma.Sci Rep. 2019 Feb 28;9(1):3146. doi: 10.1038/s41598-019-39305-z.
• [547] MicroRNA-21 functions as an oncogene and promotes cell proliferation and invasion via TIMP3 in renal cancer.Eur Rev Med Pharmacol Sci. 2017 Oct;21(20):4566-4576.
• [548] TNIP1 Inhibits Proliferation And Promotes Apoptosis In Clear Cell Renal Carcinoma Through Targeting C/Ebp.Onco Targets Ther. 2019 Nov 18;12:9861-9871. doi: 10.2147/OTT.S216138. eCollection 2019.
• [549] TRIB3 Promotes the Proliferation and Invasion of Renal Cell Carcinoma Cells via Activating MAPK Signaling Pathway.Int J Biol Sci. 2019 Jan 1;15(3):587-597. doi: 10.7150/ijbs.29737. eCollection 2019.
• [550] HCaRG/COMMD5 inhibits ErbB receptor-driven renal cell carcinoma.Oncotarget. 2017 May 19;8(41):69559-69576. doi: 10.18632/oncotarget.18012. eCollection 2017 Sep 19.
• [551] Autoantibody against arrestin-1 as a potential biomarker of renal cell carcinoma.Biochimie. 2019 Feb;157:26-37. doi: 10.1016/j.biochi.2018.10.019. Epub 2018 Oct 30.
• [552] Association between ACYP2 polymorphisms and the risk of renal cell cancer.Mol Genet Genomic Med. 2019 Nov;7(11):e966. doi: 10.1002/mgg3.966. Epub 2019 Sep 5.
• [553] High expression of fructose-bisphosphate aldolaseA induces progression of renal cell carcinoma.Oncol Rep. 2018 Jun;39(6):2996-3006. doi: 10.3892/or.2018.6378. Epub 2018 Apr 18.
• [554] Clinical Relevance of Gene Copy Number Variation in Metastatic Clear Cell Renal Cell Carcinoma.Clin Genitourin Cancer. 2018 Aug;16(4):e795-e805. doi: 10.1016/j.clgc.2018.02.013. Epub 2018 Feb 23.
• [555] ARRDC1 and ARRDC3 act as tumor suppressors in renal cell carcinoma by facilitating YAP1 degradation.Am J Cancer Res. 2018 Jan 1;8(1):132-143. eCollection 2018.
• [556] Hypoxia-regulated lncRNA CRPAT4 promotes cell migration via regulating AVL9 in clear cell renal cell carcinomas.Onco Targets Ther. 2018 Aug 3;11:4537-4545. doi: 10.2147/OTT.S169155. eCollection 2018.
• [557] CAV2 promotes the growth of renal cell carcinoma through the EGFR/PI3K/Akt pathway.Onco Targets Ther. 2018 Sep 25;11:6209-6216. doi: 10.2147/OTT.S172803. eCollection 2018.
• [558] Identification of a novel lncRNA induced by the nephrotoxin ochratoxin A and expressed in human renal tumor tissue.Cell Mol Life Sci. 2018 Jun;75(12):2241-2256. doi: 10.1007/s00018-017-2731-6. Epub 2017 Dec 27.
• [559] CD151 promotes cell metastasis via activating TGF-1/Smad signaling in renal cell carcinoma.Oncotarget. 2018 Jan 8;9(17):13313-13323. doi: 10.18632/oncotarget.24028. eCollection 2018 Mar 2.
• [560] Expression of cold-inducible RNA-binding protein (CIRP) in renal cell carcinoma and the effect of CIRP downregulation cell proliferation and chemosensitivity to gemcitabine.Oncol Lett. 2018 May;15(5):7611-7616. doi: 10.3892/ol.2018.8338. Epub 2018 Mar 23.
• [561] CNPY2 promoted the proliferation of renal cell carcinoma cells and increased the expression of TP53.Biochem Biophys Res Commun. 2017 Apr 1;485(2):267-271. doi: 10.1016/j.bbrc.2017.02.095. Epub 2017 Feb 21.
• [562] Novel insights into biomarkers associated with renal cell carcinoma.Oncol Lett. 2018 Jul;16(1):83-90. doi: 10.3892/ol.2018.8665. Epub 2018 May 8.
• [563] RNAa and Vector-Mediated Overexpression of DIRAS1 Suppresses Tumor Growth and Migration in Renal Cell Carcinoma.Mol Ther Nucleic Acids. 2018 Sep 7;12:845-853. doi: 10.1016/j.omtn.2018.07.019. Epub 2018 Aug 8.
• [564] Three vasoactive peptides, endothelin-1, adrenomedullin and urotensin-II, in human tumour cell lines of different origin: expression and effects on proliferation.Clin Sci (Lond). 2002 Aug;103 Suppl 48:35S-38S. doi: 10.1042/CS103S035S.
• [565] High eukaryotic translation elongation factor 1 alpha 1 expression promotes proliferation and predicts poor prognosis in clear cell renal cell carcinoma.Neoplasma. 2020 Jan;67(1):78-84. doi: 10.4149/neo_2019_190224N158. Epub 2019 Nov 26.
• [566] Clinical validation of serum endocan (ESM-1) as a potential biomarker in patients with renal cell carcinoma.Oncotarget. 2017 Dec 10;9(1):662-667. doi: 10.18632/oncotarget.23087. eCollection 2018 Jan 2.
• [567] The Expression Patterns of FAM83H and PANX2 Are Associated With Shorter Survival of Clear Cell Renal Cell Carcinoma Patients.Front Oncol. 2019 Jan 22;9:14. doi: 10.3389/fonc.2019.00014. eCollection 2019.
• [568] SIRT1 downregulated FGB expression to inhibit RCC tumorigenesis by destabilizing STAT3.Exp Cell Res. 2019 Sep 15;382(2):111466. doi: 10.1016/j.yexcr.2019.06.011. Epub 2019 Jun 12.
• [569] The Diagnostic Value of FNDC5/Irisin in Renal Cell Cancer.Int Braz J Urol. 2018 Jul-Aug;44(4):734-739. doi: 10.1590/S1677-5538.IBJU.2017.0404.
• [570] Loss of Fnip1 alters kidney developmental transcriptional program and synergizes with TSC1 loss to promote mTORC1 activation and renal cyst formation.PLoS One. 2018 Jun 13;13(6):e0197973. doi: 10.1371/journal.pone.0197973. eCollection 2018.
• [571] FOXK2 suppresses the malignant phenotype and induces apoptosis through inhibition of EGFR in clear-cell renal cell carcinoma.Int J Cancer. 2018 Jun 15;142(12):2543-2557. doi: 10.1002/ijc.31278. Epub 2018 Feb 14.
• [572] Knockdown of GA-binding protein subunit 1 inhibits cell proliferation via p21 induction in renal cell carcinoma.Int J Oncol. 2018 Aug;53(2):886-894. doi: 10.3892/ijo.2018.4411. Epub 2018 May 17.
• [573] Regulation of ferroptotic cancer cell death by GPX4. Cell. 2014 Jan 16;156(1-2):317-331.
• [574] miR-488 inhibits cell growth and metastasis in renal cell carcinoma by targeting HMGN5.Onco Targets Ther. 2018 Apr 18;11:2205-2216. doi: 10.2147/OTT.S156361. eCollection 2018.
• [575] Novel splicing in IGFN1 intron 15 and role of stable G-quadruplex in the regulation of splicing in renal cell carcinoma.PLoS One. 2018 Oct 18;13(10):e0205660. doi: 10.1371/journal.pone.0205660. eCollection 2018.
• [576] Kinesin Motor Protein KIFC1 Is a Target Protein of miR-338-3p and Is Associated With Poor Prognosis and Progression of Renal Cell Carcinoma.Oncol Res. 2018 Dec 27;27(1):125-137. doi: 10.3727/096504018X15213115046567. Epub 2018 Mar 21.
• [577] A KLF6-driven transcriptional network links lipid homeostasis and tumour growth in renal carcinoma.Nat Commun. 2019 Mar 11;10(1):1152. doi: 10.1038/s41467-019-09116-x.
• [578] Knockdown of LETM1 inhibits proliferation and metastasis of human renal cell carcinoma cells.Oncol Lett. 2018 Nov;16(5):6377-6382. doi: 10.3892/ol.2018.9449. Epub 2018 Sep 18.
• [579] The Lim1 oncogene as a new therapeutic target for metastatic human renal cell carcinoma.Oncogene. 2019 Jan;38(1):60-72. doi: 10.1038/s41388-018-0413-y. Epub 2018 Aug 3.
• [580] MAGI1 mediates tumor metastasis through c-Myb/miR-520h/MAGI1 signaling pathway in renal cell carcinoma.Apoptosis. 2019 Dec;24(11-12):837-848. doi: 10.1007/s10495-019-01562-8.
• [581] -1,2-Mannosidase MAN1C1 Inhibits Proliferation and Invasion of Clear Cell Renal Cell Carcinoma.J Cancer. 2018 Nov 24;9(24):4618-4626. doi: 10.7150/jca.27673. eCollection 2018.
• [582] Ubiquitination of MAP1LC3B by pVHL is associated with autophagy and cell death in renal cell carcinoma.Cell Death Dis. 2019 Mar 22;10(4):279. doi: 10.1038/s41419-019-1520-6.
• [583] Expression of minichromosome maintenance genes in renal cell carcinoma.Cancer Manag Res. 2017 Nov 15;9:637-647. doi: 10.2147/CMAR.S146528. eCollection 2017.
• [584] MCM5 promotes tumour proliferation and correlates with the progression and prognosis of renal cell carcinoma.Int Urol Nephrol. 2019 Sep;51(9):1517-1526. doi: 10.1007/s11255-019-02169-3. Epub 2019 Jun 12.
• [585] MTA2 as a Potential Biomarker and Its Involvement in Metastatic Progression of Human Renal Cancer by miR-133b Targeting MMP-9.Cancers (Basel). 2019 Nov 23;11(12):1851. doi: 10.3390/cancers11121851.
• [586] MUC13 overexpression in renal cell carcinoma plays a central role in tumor progression and drug resistance.Int J Cancer. 2017 May 15;140(10):2351-2363. doi: 10.1002/ijc.30651. Epub 2017 Feb 28.
• [587] Co-expression of Cancer Stem Cell Markers OCT4 and NANOG Predicts Poor Prognosis in Renal Cell Carcinomas.Sci Rep. 2018 Aug 6;8(1):11739. doi: 10.1038/s41598-018-30168-4.
• [588] Major Differences in Hypoxia Tolerance and P38 Regulation Among Different Renal Cells.Cell Physiol Biochem. 2018;46(4):1483-1492. doi: 10.1159/000489188. Epub 2018 Apr 19.
• [589] Knockdown of NSD2 Suppresses Renal Cell Carcinoma Metastasis by Inhibiting Epithelial-Mesenchymal Transition.Int J Med Sci. 2019 Sep 20;16(10):1404-1411. doi: 10.7150/ijms.36128. eCollection 2019.
• [590] A novel function of NUCB2 in promoting the development and invasion of renal cell carcinoma.Oncol Lett. 2018 Feb;15(2):2425-2430. doi: 10.3892/ol.2017.7563. Epub 2017 Dec 8.
• [591] Renal cell carcinoma suspected at time of organ donation 2008-2016: A report of the OPTN ad hoc Disease Transmission Advisory Committee Registry.Clin Transplant. 2019 Jul;33(7):e13597. doi: 10.1111/ctr.13597. Epub 2019 Jun 25.
• [592] NudCD1 affects renal cell carcinoma through regulating LIS1/Dynein signaling pathway.Am J Transl Res. 2018 Feb 15;10(2):519-524. eCollection 2018.
• [593] Modifiable risk factors to reduce renal cell carcinoma incidence: Insight from the PLCO trial.Urol Oncol. 2018 Jul;36(7):340.e1-340.e6. doi: 10.1016/j.urolonc.2018.04.011. Epub 2018 May 17.
• [594] The Clinical Value of PELP1 for Breast Cancer: A Comparison with Multiple Cancers and Analysis in Breast Cancer Subtypes.Cancer Res Treat. 2019 Apr;51(2):706-717. doi: 10.4143/crt.2018.316. Epub 2018 Aug 23.
• [595] Anticancer activity of Schiff base-Poloxamer P85 combination against kidney cancer.Int Urol Nephrol. 2018 Feb;50(2):247-255. doi: 10.1007/s11255-017-1782-9. Epub 2017 Dec 29.
• [596] PLIN3 is up-regulated and correlates with poor prognosis in clear cell renal cell carcinoma.Urol Oncol. 2018 Jul;36(7):343.e9-343.e19. doi: 10.1016/j.urolonc.2018.04.006.
• [597] Exploring the Natural Piericidins as Anti-Renal Cell Carcinoma Agents Targeting Peroxiredoxin 1.J Med Chem. 2019 Aug 8;62(15):7058-7069. doi: 10.1021/acs.jmedchem.9b00598. Epub 2019 Jul 25.
• [598] The clinical significance of PYCR1 expression in renal cell carcinoma.Medicine (Baltimore). 2019 Jul;98(28):e16384. doi: 10.1097/MD.0000000000016384.
• [599] miR-384 suppressed renal cell carcinoma cell proliferation and migration through targeting RAB23.J Cell Biochem. 2019 Feb;120(2):1420-1426. doi: 10.1002/jcb.27180. Epub 2018 Nov 2.
• [600] The expression and function of RASAL2 in renal cell carcinoma angiogenesis.Cell Death Dis. 2018 Aug 29;9(9):881. doi: 10.1038/s41419-018-0898-x.
• [601] RASSF6-mediated inhibition of Mcl-1 through JNK activation improves the anti-tumor effects of sorafenib in renal cell carcinoma.Cancer Lett. 2018 Sep 28;432:75-83. doi: 10.1016/j.canlet.2018.05.048. Epub 2018 Jun 1.
• [602] Prolonged survival of renal cancer patients is concomitant with a higher regucalcin gene expression in tumor tissues: Overexpression of regucalcin suppresses the growth of human renal cell carcinoma cells in vitro.Int J Oncol. 2019 Jan;54(1):188-198. doi: 10.3892/ijo.2018.4611. Epub 2018 Oct 30.
• [603] Combined Treatment with Valproic Acid and 5-Aza-2'-Deoxycytidine Synergistically Inhibits Human Clear Cell Renal Cell Carcinoma Growth and Migration.Med Sci Monit. 2018 Feb 19;24:1034-1043. doi: 10.12659/msm.906020.
• [604] Effect of Switching Systemic Treatment After Stereotactic Radiosurgery for Oligoprogressive, Metastatic Renal Cell Carcinoma.Clin Genitourin Cancer. 2018 Oct;16(5):413-419.e1. doi: 10.1016/j.clgc.2018.07.018. Epub 2018 Aug 17.
• [605] SCUBE1: a promising biomarker in renal cell cancer.Int Braz J Urol. 2017 Jul-Aug;43(4):638-643. doi: 10.1590/S1677-5538.IBJU.2016.0316.
• [606] Cyanidin Curtails Renal Cell Carcinoma Tumorigenesis.Cell Physiol Biochem. 2018;46(6):2517-2531. doi: 10.1159/000489658. Epub 2018 May 5.
• [607] MiR-376a functions as tumor suppressor by targeting SGK3 in renal cell carcinoma.Eur Rev Med Pharmacol Sci. 2019 May;23(9):3726-3732. doi: 10.26355/eurrev_201905_17798.
• [608] Germline Genetic Biomarkers of Sunitinib Efficacy in Advanced Renal Cell Carcinoma: Results From the RENAL EFFECT Trial.Clin Genitourin Cancer. 2017 Oct;15(5):526-533. doi: 10.1016/j.clgc.2017.02.006. Epub 2017 Feb 27.
• [609] Autocrine and paracrine STIP1 signaling promote osteolytic bone metastasis in renal cell carcinoma.Oncotarget. 2017 Mar 7;8(10):17012-17026. doi: 10.18632/oncotarget.15222.
• [610] Chemical shift magnetic resonance imaging for distinguishing minimal-fat renal angiomyolipoma from renal cell carcinoma: a meta-analysis.Eur Radiol. 2018 May;28(5):1854-1861. doi: 10.1007/s00330-017-5141-0. Epub 2017 Nov 24.
• [611] Down-regulation of C12orf59 is associated with a poor prognosis and VHL mutations in renal cell carcinoma.Oncotarget. 2016 Feb 9;7(6):6824-34. doi: 10.18632/oncotarget.6829.
• [612] Vitamin D receptor suppresses proliferation and metastasis in renal cell carcinoma cell lines via regulating the expression of the epithelial Ca2+ channel TRPV5.PLoS One. 2018 Apr 16;13(4):e0195844. doi: 10.1371/journal.pone.0195844. eCollection 2018.
• [613] Expression of resistance factors (P-glycoprotein, glutathione S-transferase-pi, and topoisomerase II) and their interrelationship to proto-oncogene products in renal cell carcinomas.Cancer. 1993 Jun 15;71(12):3981-7. doi: 10.1002/1097-0142(19930615)71:12<3981::aid-cncr2820711231>3.0.co;2-a.
• [614] DNA methyltransferase inhibitor-mediated apoptosis in the Wnt/-catenin signal pathway in a renal cell carcinoma cell line.Exp Biol Med (Maywood). 2013 Sep;238(9):1009-16. doi: 10.1177/1535370213498984. Epub 2013 Aug 23.
• [615] The network of DAB2IP-miR-138 in regulating drug resistance of renal cell carcinoma associated with stem-like phenotypes.Oncotarget. 2017 May 9;8(40):66975-66986. doi: 10.18632/oncotarget.17756. eCollection 2017 Sep 15.
• [616] Expression of two isozymes of acyl-coenzyme A: cholesterol acyltransferase-1 and -2 in clear cell type renal cell carcinoma.Int J Urol. 2008 Feb;15(2):166-70. doi: 10.1111/j.1442-2042.2007.01947.x.
• [617] Predicted versus observed 30-day perioperative outcomes using the ACS NSQIP surgical risk calculator in patients undergoing partial nephrectomy for renal cell carcinoma.Int Urol Nephrol. 2018 Jul;50(7):1249-1256. doi: 10.1007/s11255-018-1898-6. Epub 2018 Jun 4.
• [618] Dual-Tracer PET/CT Differentiates 2 Types of Primary Cancers and Metastases in a Patient With Crossed Fused Renal Ectopia.Clin Nucl Med. 2019 Feb;44(2):157-158. doi: 10.1097/RLU.0000000000002390.
• [619] Effect of ADAM28 on carcinoma cell metastasis by cleavage of von Willebrand factor.J Natl Cancer Inst. 2012 Jun 20;104(12):906-22. doi: 10.1093/jnci/djs232. Epub 2012 May 25.
• [620] H1/pAIM2 nanoparticles exert anti-tumour effects that is associated with the inflammasome activation in renal carcinoma.J Cell Mol Med. 2018 Nov;22(11):5670-5681. doi: 10.1111/jcmm.13842. Epub 2018 Aug 30.
• [621] Pyruvate Kinase M2 Activates mTORC1 by Phosphorylating AKT1S1.Sci Rep. 2016 Feb 15;6:21524. doi: 10.1038/srep21524.
• [622] Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma.Cancer Res. 2005 Jun 1;65(11):4598-606. doi: 10.1158/0008-5472.CAN-04-3371.
• [623] Expression of the angiopoietins and their receptor Tie2 in human renal clear cell carcinomas; regulation by the von Hippel-Lindau gene and hypoxia.J Pathol. 2002 Dec;198(4):502-10. doi: 10.1002/path.1228.
• [624] Ankyrin repeat and single KH domain 1 (ANKHD1) drives renal cancer cell proliferation via binding to and altering a subset of miRNAs.J Biol Chem. 2018 Jun 22;293(25):9570-9579. doi: 10.1074/jbc.RA117.000975. Epub 2018 Apr 25.
• [625] ARPP protein is selectively expressed in renal oncocytoma, but rarely in renal cell carcinomas.Mod Pathol. 2007 Feb;20(2):199-207. doi: 10.1038/modpathol.3800730. Epub 2007 Jan 5.
• [626] Methylation of the APAF-1 and DAPK-1 promoter region correlates with progression of renal cell carcinoma in North Indian population.Tumour Biol. 2012 Apr;33(2):395-402. doi: 10.1007/s13277-011-0235-9. Epub 2011 Sep 16.
• [627] High APOBEC3B expression is a predictor of recurrence in patients with low-risk clear cell renal cell carcinoma.Urol Oncol. 2015 Aug;33(8):340.e1-8. doi: 10.1016/j.urolonc.2015.05.009. Epub 2015 Jun 4.
• [628] Gene expression profiling of chromophobe renal cell carcinomas and renal oncocytomas by Affymetrix GeneChip using pooled and individual tumours.Int J Biol Sci. 2009 Jul 29;5(6):517-27. doi: 10.7150/ijbs.5.517.
• [629] The role of apoptosis repressor with a CARD domain (ARC) in the therapeutic resistance of renal cell carcinoma (RCC): the crucial role of ARC in the inhibition of extrinsic and intrinsic apoptotic signalling.Cell Commun Signal. 2017 May 2;15(1):16. doi: 10.1186/s12964-017-0170-5.
• [630] ARHGAP24 inhibits cell cycle progression, induces apoptosis and suppresses invasion in renal cell carcinoma.Oncotarget. 2016 Aug 9;7(32):51829-51839. doi: 10.18632/oncotarget.10386.
• [631] Rho GDP dissociation inhibitor- in renal cell carcinoma.Oncol Lett. 2017 Dec;14(6):8190-8196. doi: 10.3892/ol.2017.7233. Epub 2017 Oct 20.
• [632] Development of a Novel Antibody-Drug Conjugate for the Potential Treatment of Ovarian, Lung, and Renal Cell Carcinoma Expressing TIM-1.Mol Cancer Ther. 2016 Dec;15(12):2946-2954. doi: 10.1158/1535-7163.MCT-16-0393. Epub 2016 Sep 26.
• [633] Xp11.2 translocation/TFE3 gene fusion renal cell carcinoma with a micropapillary pattern: cases report and literature review.Am J Transl Res. 2019 Jan 15;11(1):327-339. eCollection 2019.
• [634] ATF2 predicts poor prognosis and promotes malignant phenotypes in renal cell carcinoma.J Exp Clin Cancer Res. 2016 Jul 4;35(1):108. doi: 10.1186/s13046-016-0383-2.
• [635] Epigenetic silencing of Na,K-ATPase 1 subunit gene ATP1B1 by methylation in clear cell renal cell carcinoma.Epigenetics. 2014 Apr;9(4):579-86. doi: 10.4161/epi.27795. Epub 2014 Jan 22.
• [636] Genome-wide methylation analysis identifies epigenetically inactivated candidate tumour suppressor genes in renal cell carcinoma.Oncogene. 2011 Mar 24;30(12):1390-401. doi: 10.1038/onc.2010.525. Epub 2010 Dec 6.
• [637] Receptor tyrosine kinase-like orphan receptor 2 (Ror2) expression creates a poised state of Wnt signaling in renal cancer.J Biol Chem. 2013 Sep 6;288(36):26301-26310. doi: 10.1074/jbc.M113.466086. Epub 2013 Jul 26.
• [638] Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells.Cancer Res. 2006 Dec 1;66(23):11447-54. doi: 10.1158/0008-5472.CAN-06-0998.
• [639] New criteria for improved diagnosis of Bardet-Biedl syndrome: results of a population survey.J Med Genet. 1999 Jun;36(6):437-46.
• [640] Functional characterization of the 12p12.1 renal cancer-susceptibility locus implicates BHLHE41.Nat Commun. 2016 Jul 7;7:12098. doi: 10.1038/ncomms12098.
• [641] Identification of candidate tumour suppressor genes frequently methylated in renal cell carcinoma.Oncogene. 2010 Apr 8;29(14):2104-17. doi: 10.1038/onc.2009.493. Epub 2010 Feb 15.
• [642] Expression and epigenetic regulatory mechanism of BNIP3 in clear cell renal cell carcinoma.Int J Oncol. 2019 Jan;54(1):348-360. doi: 10.3892/ijo.2018.4603. Epub 2018 Oct 24.
• [643] BSND is a Novel Immunohistochemical Marker for Oncocytic Salivary Gland Tumors.Pathol Oncol Res. 2018 Apr;24(2):439-444. doi: 10.1007/s12253-017-0248-9. Epub 2017 May 3.
• [644] BTG3 tumor suppressor gene promoter demethylation, histone modification and cell cycle arrest by genistein in renal cancer. Carcinogenesis. 2009 Apr;30(4):662-70. doi: 10.1093/carcin/bgp042. Epub 2009 Feb 12.
• [645] Expression and clinical significance of RCDG1 in renal cell carcinoma: a novel renal cancerassociated gene.Mol Med Rep. 2014 Sep;10(3):1583-9. doi: 10.3892/mmr.2014.2388. Epub 2014 Jul 16.
• [646] Honokiol inhibits c-Met-HO-1 tumor-promoting pathway and its cross-talk with calcineurin inhibitor-mediated renal cancer growth.Sci Rep. 2017 Jul 19;7(1):5900. doi: 10.1038/s41598-017-05455-1.
• [647] Down-regulation of CacyBP is associated with poor prognosis and the effects on COX-2 expression in breast cancer.Int J Oncol. 2010 Nov;37(5):1261-9. doi: 10.3892/ijo_00000777.
• [648] Aberrant methylation and loss of CADM2 tumor suppressor expression is associated with human renal cell carcinoma tumor progression.Biochem Biophys Res Commun. 2013 Jun 14;435(4):526-32. doi: 10.1016/j.bbrc.2013.04.074. Epub 2013 May 3.
• [649] Lead, calcium uptake, and related genetic variants in association with renal cell carcinoma risk in a cohort of male Finnish smokers.Cancer Epidemiol Biomarkers Prev. 2012 Jan;21(1):191-201. doi: 10.1158/1055-9965.EPI-11-0670. Epub 2011 Nov 15.
• [650] Anti-neuroblastoma antibody chCE7 binds to an isoform of L1-CAM present in renal carcinoma cells.Int J Cancer. 1999 Oct 29;83(3):401-8. doi: 10.1002/(sici)1097-0215(19991029)83:3<401::aid-ijc17>3.0.co;2-a.
• [651] New Insights Into the Mechanism of COP9 Signalosome-Cullin-RING Ubiquitin-Ligase Pathway Deregulation in Urological Cancers.Int Rev Cell Mol Biol. 2016;323:181-229. doi: 10.1016/bs.ircmb.2015.12.007. Epub 2016 Feb 16.
• [652] Evaluating the expression of CARMA3 as a prognostic tumor marker in renal cell carcinoma.Tumour Biol. 2013 Dec;34(6):3431-5. doi: 10.1007/s13277-013-0917-6. Epub 2013 Jun 15.
• [653] Downregulation of lncRNA SDPR-AS is associated with poor prognosis in renal cell carcinoma.Onco Targets Ther. 2017 Jun 19;10:3039-3047. doi: 10.2147/OTT.S137641. eCollection 2017.
• [654] Von Hippel-Lindau gene product directs cytokinesis: a new tumor suppressor function.J Cell Sci. 2011 Jul 1;124(Pt 13):2132-42. doi: 10.1242/jcs.087122. Epub 2011 Jun 7.
• [655] Molecular analysis of germline t(3;6) and t(3;12) associated with conventional renal cell carcinomas indicates their rate-limiting role and supports the three-hit model of carcinogenesis.Cancer Genet Cytogenet. 2010 Aug;201(1):15-23. doi: 10.1016/j.cancergencyto.2010.04.018.
• [656] The suppressing role of miR-622 in renal cell carcinoma progression by down-regulation of CCL18/MAPK signal pathway.Cell Biosci. 2018 Mar 2;8:17. doi: 10.1186/s13578-018-0212-8. eCollection 2018.
• [657] Let-7d suppresses growth, metastasis, and tumor macrophage infiltration in renal cell carcinoma by targeting COL3A1 and CCL7.Mol Cancer. 2014 Sep 6;13:206. doi: 10.1186/1476-4598-13-206.
• [658] Change in expression of cyclin G2 in kidney cancer cell and its significance.Tumour Biol. 2014 Apr;35(4):3177-83. doi: 10.1007/s13277-013-1415-6. Epub 2013 Nov 23.
• [659] CD1d expression in renal cell carcinoma is associated with higher relapse rates, poorer cancer-specific and overall survival.J Clin Pathol. 2015 Mar;68(3):200-5. doi: 10.1136/jclinpath-2014-202735. Epub 2014 Dec 4.
• [660] t(6;11) renal cell carcinoma: a study of seven cases including two with aggressive behavior, and utility of CD68 (PG-M1) in the differential diagnosis with pure epithelioid PEComa/epithelioid angiomyolipoma.Mod Pathol. 2018 Mar;31(3):474-487. doi: 10.1038/modpathol.2017.144. Epub 2017 Oct 20.
• [661] Expression of cadherin-8 in renal cell carcinoma and fetal kidney.Int J Cancer. 2002 Oct 1;101(4):327-34. doi: 10.1002/ijc.10623.
• [662] Cadherin-9 is a novel cell surface marker for the heterogeneous pool of renal fibroblasts.PLoS One. 2007 Aug 1;2(7):e657. doi: 10.1371/journal.pone.0000657.
• [663] Loss of cadherin related family member 5 (CDHR5) expression in clear cell renal cell carcinoma is a prognostic marker of disease progression.Oncotarget. 2017 Aug 24;8(43):75076-75086. doi: 10.18632/oncotarget.20507. eCollection 2017 Sep 26.
• [664] Cyclin-dependent kinase-associated protein phosphatase is overexpressed in alcohol-related hepatocellular carcinoma and influences xenograft tumor growth.Oncol Rep. 2013 Mar;29(3):903-10. doi: 10.3892/or.2012.2208. Epub 2012 Dec 24.
• [665] Upregulation of the KIAA1199 gene is associated with cellular mortality.Cancer Lett. 2006 Jul 28;239(1):71-7. doi: 10.1016/j.canlet.2005.07.028. Epub 2005 Sep 12.
• [666] Upregulation of centromere protein H is associated with progression of renal cell carcinoma.J Mol Histol. 2015 Oct;46(4-5):377-85. doi: 10.1007/s10735-015-9635-2. Epub 2015 Aug 7.
• [667] CEP55 promotes epithelial-mesenchymal transition in renal cell carcinoma through PI3K/AKT/mTOR pathway.Clin Transl Oncol. 2019 Jul;21(7):939-949. doi: 10.1007/s12094-018-02012-8. Epub 2019 Jan 3.
• [668] Induced transcriptional expression of calcium-binding protein S100A1 and S100A10 genes in human renal cell carcinoma.Cancer Lett. 2002 Jan 10;175(1):71-7. doi: 10.1016/s0304-3835(01)00724-8.
• [669] Clinical significance and prognostic value of chromatin assembly factor-1 overexpression in human solid tumours.Histopathology. 2010 Nov;57(5):716-24. doi: 10.1111/j.1365-2559.2010.03681.x.
• [670] The epigenetic modifier CHD5 functions as a novel tumor suppressor for renal cell carcinoma and is predominantly inactivated by promoter CpG methylation.Oncotarget. 2016 Apr 19;7(16):21618-30. doi: 10.18632/oncotarget.7822.
• [671] Chmp1A acts as a tumor suppressor gene that inhibits proliferation of renal cell carcinoma.Cancer Lett. 2012 Jun 28;319(2):190-196. doi: 10.1016/j.canlet.2012.01.010. Epub 2012 Jan 17.
• [672] DNA sequences proximal to human mitochondrial DNA deletion breakpoints prevalent in human disease form G-quadruplexes, a class of DNA structures inefficiently unwound by the mitochondrial replicative Twinkle helicase.J Biol Chem. 2014 Oct 24;289(43):29975-93. doi: 10.1074/jbc.M114.567073. Epub 2014 Sep 5.
• [673] Impact of Perioperative Infection on Cancer Specific Survival after Nephrectomy for Renal Cell Carcinoma.J Urol. 2017 Nov;198(5):1027-1032. doi: 10.1016/j.juro.2017.05.070. Epub 2017 May 25.
• [674] CIP2A Promotes Proliferation, Invasion and Chemoresistance to Cisplatin in Renal Cell Carcinoma.J Cancer. 2018 Oct 17;9(21):4029-4038. doi: 10.7150/jca.25005. eCollection 2018.
• [675] Genetic clustering of clear cell renal cell carcinoma based on array-comparative genomic hybridization: its association with DNA methylation alteration and patient outcome.Clin Cancer Res. 2008 Sep 1;14(17):5531-9. doi: 10.1158/1078-0432.CCR-08-0443.
• [676] Prognostic implication of p27Kip1, Skp2 and Cks1 expression in renal cell carcinoma: a tissue microarray study.J Exp Clin Cancer Res. 2008 Oct 15;27(1):51. doi: 10.1186/1756-9966-27-51.
• [677] Claudin-7 and claudin-8: immunohistochemical markers for the differential diagnosis of chromophobe renal cell carcinoma and renal oncocytoma.Hum Pathol. 2009 Feb;40(2):206-10. doi: 10.1016/j.humpath.2008.07.002. Epub 2008 Sep 16.
• [678] Immunohistochemical diagnosis of renal neoplasms.Arch Pathol Lab Med. 2011 Jan;135(1):92-109. doi: 10.5858/2010-0478-RAR.1.
• [679] FOXC2 and CLIP4 : a potential biomarker for synchronous metastasis of ?-cm clear cell renal cell carcinomas.Oncotarget. 2016 Aug 9;7(32):51423-51434. doi: 10.18632/oncotarget.9842.
• [680] A novel CLTC-TFE3 gene fusion in pediatric renal adenocarcinoma with t(X;17)(p11.2;q23).Oncogene. 2003 Aug 14;22(34):5374-8. doi: 10.1038/sj.onc.1206686.
• [681] Prognostic and clinicopathological role of high Ki-67 expression in patients with renal cell carcinoma: a systematic review and meta-analysis.Sci Rep. 2017 Mar 13;7:44281. doi: 10.1038/srep44281.
• [682] The expression of tumstatin is down-regulated in renal carcinoma.Mol Biol Rep. 2010 Jun;37(5):2273-7. doi: 10.1007/s11033-009-9718-9. Epub 2009 Aug 18.
• [683] COP1 is downregulated in renal cell carcinoma (RCC) and inhibits the migration of RCC ACHN cells invitro.Mol Med Rep. 2016 Aug;14(2):1371-8. doi: 10.3892/mmr.2016.5373. Epub 2016 Jun 7.
• [684] Cellular retinoic acid binding protein I: expression and functional influence in renal cell carcinoma. Tumour Biol. 2005 Nov-Dec;26(6):313-23. doi: 10.1159/000089262. Epub 2005 Oct 25.
• [685] Expression and functional influence of cellular retinoic acid-binding protein II in renal cell carcinoma.Urol Int. 2005;75(3):269-76. doi: 10.1159/000087807.
• [686] Paraganglioma, neuroblastoma, and a SDHB mutation: Resolution of a 30-year-old mystery.Am J Med Genet A. 2010 Jun;152A(6):1531-5. doi: 10.1002/ajmg.a.33384.
• [687] Knockdown of Collagen Triple Helix Repeat Containing-1 Inhibits the Proliferation and Epithelial-to-Mesenchymal Transition in Renal Cell Carcinoma Cells.Oncol Res. 2016 Oct 27;24(6):477-485. doi: 10.3727/096504016X14685034103716.
• [688] The expression of Cullin1 is increased in renal cell carcinoma and promotes cancer cell proliferation, migration, and invasion.Tumour Biol. 2016 Sep;37(9):12823-12831. doi: 10.1007/s13277-016-5151-6. Epub 2016 Jul 23.
• [689] Androgen receptor (AR) signaling promotes RCC progression via increased endothelial cell proliferation and recruitment by modulating AKTNF-BCXCL5 signaling.Sci Rep. 2016 Nov 16;6:37085. doi: 10.1038/srep37085.
• [690] Downregulation of Human DAB2IP Gene Expression in Renal Cell Carcinoma Results in Resistance to Ionizing Radiation.Clin Cancer Res. 2019 Jul 15;25(14):4542-4551. doi: 10.1158/1078-0432.CCR-18-3004. Epub 2019 Apr 18.
• [691] The long noncoding RNA KCNQ1DN suppresses the survival of renal cell carcinoma cells through downregulating c-Myc.J Cancer. 2019 Aug 19;10(19):4662-4670. doi: 10.7150/jca.29280. eCollection 2019.
• [692] Dysregulated D-dopachrome tautomerase, a hypoxia-inducible factor-dependent gene, cooperates with macrophage migration inhibitory factor in renal tumorigenesis.J Biol Chem. 2014 Feb 7;289(6):3713-23. doi: 10.1074/jbc.M113.500694. Epub 2013 Dec 19.
• [693] DDX31 regulates the p53-HDM2 pathway and rRNA gene transcription through its interaction with NPM1 in renal cell carcinomas.Cancer Res. 2012 Nov 15;72(22):5867-77. doi: 10.1158/0008-5472.CAN-12-1645. Epub 2012 Sep 27.
• [694] Identification of novel targets for antiangiogenic therapy by comparing the gene expressions of tumor and normal endothelial cells.Cancer Sci. 2014 May;105(5):560-7. doi: 10.1111/cas.12394. Epub 2014 Apr 19.
• [695] Human alpha-defensins HNPs-1, -2, and -3 in renal cell carcinoma: influences on tumor cell proliferation.Am J Pathol. 2002 Apr;160(4):1311-24. doi: 10.1016/s0002-9440(10)62558-8.
• [696] Involvement of erbB4 and tumor marker genes in renal carcinoma regulatory network.Saudi J Biol Sci. 2017 Dec;24(8):1787-1791. doi: 10.1016/j.sjbs.2017.11.013. Epub 2017 Nov 10.
• [697] Increased DKC1 expression in glioma and its significance in tumor cell proliferation, migration and invasion.Invest New Drugs. 2019 Dec;37(6):1177-1186. doi: 10.1007/s10637-019-00748-w. Epub 2019 Mar 7.
• [698] Aberrant promoter methylation of DLEC1, a critical 3p22 tumor suppressor for renal cell carcinoma, is associated with more advanced tumor stage.J Urol. 2010 Aug;184(2):731-7. doi: 10.1016/j.juro.2010.03.108. Epub 2010 Jun 19.
• [699] Metastatic renal clear cell carcinoma in the parotid gland: a study of immunohistochemical profile and cell adhesion molecules (CAMs) expression in two cases.Pathol Oncol Res. 2007;13(2):161-5. doi: 10.1007/BF02893494. Epub 2007 Jul 3.
• [700] TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers.Am J Surg Pathol. 2016 Jun;40(6):723-37. doi: 10.1097/PAS.0000000000000631.
• [701] Overexpression of DLC-1 induces cell apoptosis and proliferation inhibition in the renal cell carcinoma.Cancer Lett. 2009 Sep 28;283(1):59-67. doi: 10.1016/j.canlet.2009.03.025. Epub 2009 Apr 19.
• [702] Upregulated expression of eIF3C is associated with malignant behavior in renal cell carcinoma.Int J Oncol. 2019 Dec;55(6):1385-1395. doi: 10.3892/ijo.2019.4903. Epub 2019 Oct 21.
• [703] EIF3D promotes sunitinib resistance of renal cell carcinoma by interacting with GRP78 and inhibiting its degradation.EBioMedicine. 2019 Nov;49:189-201. doi: 10.1016/j.ebiom.2019.10.030. Epub 2019 Oct 26.
• [704] Hypoxic 3D in vitro culture models reveal distinct resistance processes to TKIs in renal cancer cells.Cell Biosci. 2017 Dec 16;7:71. doi: 10.1186/s13578-017-0197-8. eCollection 2017.
• [705] The Ets transcription factor ELF5 functions as a tumor suppressor in the kidney.Twin Res Hum Genet. 2011 Aug;14(4):316-22. doi: 10.1375/twin.14.4.316.
• [706] Refined mapping of the human Ets-related gene Elk-1 to Xp11.2-p11.4, distal to the OATL1 region.Hum Genet. 1994 Oct;94(4):442-4. doi: 10.1007/BF00201610.
• [707] Genomic profiling identifies alterations in TGFbeta signaling through loss of TGFbeta receptor expression in human renal cell carcinogenesis and progression.Oncogene. 2003 Sep 11;22(39):8053-62. doi: 10.1038/sj.onc.1206835.
• [708] Senescence-associated protein p400 is a prognostic marker in renal cell carcinoma.Oncol Rep. 2013 Nov;30(5):2245-53. doi: 10.3892/or.2013.2698. Epub 2013 Aug 26.
• [709] Higher expression of XPF is a critical factor in intrinsic chemotherapy resistance of human renal cell carcinoma.Int J Cancer. 2016 Dec 15;139(12):2827-2837. doi: 10.1002/ijc.30396. Epub 2016 Sep 16.
• [710] ERCC6L that is up-regulated in high grade of renal cell carcinoma enhances cell viability in vitro and promotes tumor growth in vivo potentially through modulating MAPK signalling pathway.Cancer Gene Ther. 2019 Sep;26(9-10):323-333. doi: 10.1038/s41417-018-0064-8. Epub 2018 Nov 21.
• [711] Functional analysis of fatty acid binding protein 7 and its effect on fatty acid of renal cell carcinoma cell lines.BMC Cancer. 2017 Mar 14;17(1):192. doi: 10.1186/s12885-017-3184-x.
• [712] Ectopic expression of the TERE1 (UBIAD1) protein inhibits growth of renal clear cell carcinoma cells: altered metabolic phenotype associated with reactive oxygen species, nitric oxide and SXR target genes involved in cholesterol and lipid metabolism.Int J Oncol. 2013 Aug;43(2):638-52. doi: 10.3892/ijo.2013.1985. Epub 2013 Jun 12.
• [713] Fibulin-1 is down-regulated through promoter hypermethylation and suppresses renal cell carcinoma progression.J Urol. 2013 Jul;190(1):291-301. doi: 10.1016/j.juro.2013.01.098. Epub 2013 Feb 4.
• [714] FBXO22 Suppresses Metastasis in Human Renal Cell Carcinoma via Inhibiting MMP-9-Mediated Migration and Invasion and VEGF-Mediated Angiogenesis.Int J Biol Sci. 2019 Jan 24;15(3):647-656. doi: 10.7150/ijbs.31293. eCollection 2019.
• [715] Cytotoxic markers and frequency predict functional capacity of natural killer cells infiltrating renal cell carcinoma.Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):718-25. doi: 10.1158/1078-0432.CCR-05-0857.
• [716] Kindlin? promotes clear cell renal cell carcinoma progression through the Wnt signaling pathway.Oncol Rep. 2017 Sep;38(3):1551-1560. doi: 10.3892/or.2017.5789. Epub 2017 Jul 4.
• [717] Identification of fibroblast growth factor-5 as an overexpressed antigen in multiple human adenocarcinomas.Cancer Res. 2001 Jul 15;61(14):5511-6.
• [718] Smad4 suppresses the progression of renal cell carcinoma via the activation of forkhead box protein H1.Mol Med Rep. 2015 Apr;11(4):2717-22. doi: 10.3892/mmr.2014.3061. Epub 2014 Dec 8.
• [719] Cell-Type-Specific Gene Programs of the Normal Human Nephron Define Kidney Cancer Subtypes.Cell Rep. 2017 Aug 8;20(6):1476-1489. doi: 10.1016/j.celrep.2017.07.043.
• [720] CircRNA ZNF609 functions as a competitive endogenous RNA to regulate FOXP4 expression by sponging miR-138-5p in renal carcinoma.J Cell Physiol. 2019 Jul;234(7):10646-10654. doi: 10.1002/jcp.27744. Epub 2018 Nov 27.
• [721] Role of secreted frizzled-related protein 3 in human renal cell carcinoma.Cancer Res. 2010 Mar 1;70(5):1896-905. doi: 10.1158/0008-5472.CAN-09-3549. Epub 2010 Feb 16.
• [722] miR-124 represses FZD5 to attenuate P-glycoprotein-mediated chemo-resistance in renal cell carcinoma.Tumour Biol. 2015 Sep;36(9):7017-26. doi: 10.1007/s13277-015-3369-3. Epub 2015 Apr 12.
• [723] Frizzled 8 promotes the cell proliferation and metastasis of renal cell carcinoma.Oncotarget. 2017 Sep 8;8(45):78989-79002. doi: 10.18632/oncotarget.20742. eCollection 2017 Oct 3.
• [724] Cancer-associated expression of glycolipid sulfotransferase gene in human renal cell carcinoma cells.Cancer Res. 1998 Sep 1;58(17):3800-5.
• [725] Roles of GalNAc-disialyl Lactotetraosyl Antigens in Renal Cancer Cells.Sci Rep. 2018 May 4;8(1):7017. doi: 10.1038/s41598-018-25521-6.
• [726] Polypeptide N-acetylgalactosaminyl transferase 3 independently predicts high-grade tumours and poor prognosis in patients with renal cell carcinomas.Br J Cancer. 2013 Jul 23;109(2):472-81. doi: 10.1038/bjc.2013.331. Epub 2013 Jun 25.
• [727] GATA5 CpG island hypermethylation is an independent predictor for poor clinical outcome in renal cell carcinoma.Oncol Rep. 2014 Apr;31(4):1523-30. doi: 10.3892/or.2014.3030. Epub 2014 Feb 18.
• [728] Vitamin D binding protein and risk of renal cell carcinoma in the prostate, lung, colorectal and ovarian cancer screening trial.Int J Cancer. 2020 Aug 1;147(3):669-674. doi: 10.1002/ijc.32758. Epub 2019 Nov 19.
• [729] Single nucleotide polymorphisms of microRNA machinery genes modify the risk of renal cell carcinoma.Clin Cancer Res. 2008 Dec 1;14(23):7956-62. doi: 10.1158/1078-0432.CCR-08-1199.
• [730] Identifying CD82 (KAI1) as a marker for human chromophobe renal cell carcinoma.Histopathology. 2009 Dec;55(6):687-95. doi: 10.1111/j.1365-2559.2009.03449.x.
• [731] MiR-30b-5p functions as a tumor suppressor in cell proliferation, metastasis and epithelial-to-mesenchymal transition by targeting G-protein subunit -13 in renal cell carcinoma.Gene. 2017 Aug 30;626:275-281. doi: 10.1016/j.gene.2017.05.040. Epub 2017 May 20.
• [732] Identification of novel VHL target genes and relationship to hypoxic response pathways.Oncogene. 2005 Jun 30;24(28):4549-58. doi: 10.1038/sj.onc.1208649.
• [733] Golgi Phosphoprotein 3 Promotes Malignant Phenotypes via FAK/Raf/MEK and Wnt/-Catenin Signaling Pathways in Human Renal Cell Carcinoma.J Biomed Nanotechnol. 2019 Aug 1;15(8):1812-1823. doi: 10.1166/jbn.2019.2804.
• [734] Detection of transcript for brain-type fatty Acid-binding protein in tumor and urine of patients with renal cell carcinoma.Urology. 2007 Feb;69(2):236-40. doi: 10.1016/j.urology.2006.09.060.
• [735] Association of glutathione S-transferase M1, T1, and P1 polymorphisms with renal cell carcinoma: evidence from 11 studies.Tumour Biol. 2014 Apr;35(4):3867-73. doi: 10.1007/s13277-013-1513-5. Epub 2013 Dec 15.
• [736] Global histone acetylation levels: prognostic relevance in patients with renal cell carcinoma.Cancer Sci. 2010 Dec;101(12):2664-9. doi: 10.1111/j.1349-7006.2010.01717.x. Epub 2010 Sep 1.
• [737] Differential expression of TIM-3 between primary and metastatic sites in renal cell carcinoma.BMC Cancer. 2019 Jan 10;19(1):49. doi: 10.1186/s12885-019-5273-5.
• [738] Prognostic and diagnostic relevance of hypermethylated in cancer 1 (HIC1) CpG island methylation in renal cell carcinoma.Int J Oncol. 2012 May;40(5):1650-8. doi: 10.3892/ijo.2012.1367. Epub 2012 Feb 10.
• [739] Dominant-negative HIF-3 alpha 4 suppresses VHL-null renal cell carcinoma progression.Cell Cycle. 2007 Nov 15;6(22):2810-6. doi: 10.4161/cc.6.22.4947. Epub 2007 Aug 29.
• [740] Inactivation of RASSF1C during in vivo tumor growth identifies it as a tumor suppressor gene.Oncogene. 2004 Aug 5;23(35):5941-9. doi: 10.1038/sj.onc.1207789.
• [741] HLA-G and HLA-E specific mRNAs connote opposite prognostic significance in renal cell carcinoma.Diagn Pathol. 2012 May 29;7:58. doi: 10.1186/1746-1596-7-58.
• [742] Molecular characterization of kidney cancer: association of hyaluronic acid family with histological subtypes and metastasis.Cancer. 2012 May 1;118(9):2394-402. doi: 10.1002/cncr.26520. Epub 2011 Sep 1.
• [743] Cytoplasmic Accumulation of Heterogeneous Nuclear Ribonucleoprotein K Strongly Promotes Tumor Invasion in Renal Cell Carcinoma Cells.PLoS One. 2015 Dec 29;10(12):e0145769. doi: 10.1371/journal.pone.0145769. eCollection 2015.
• [744] Heterogeneous nuclear ribonucleoprotein U-like 1 and Poly (ADP-ribose) polymerase 1 are downregulated in renal cell carcinoma and connected with the prognosis.Cancer Biomark. 2013 Jan 1;13(6):411-5. doi: 10.3233/CBM-140390.
• [745] HOX gene expression in normal and neoplastic human kidney.Int J Cancer. 1992 Jul 30;51(6):892-7. doi: 10.1002/ijc.2910510610.
• [746] Overexpression of HOXC11 homeobox gene in clear cell renal cell carcinoma induces cellular proliferation and is associated with poor prognosis.Tumour Biol. 2015 Apr;36(4):2821-9. doi: 10.1007/s13277-014-2909-6. Epub 2014 Dec 5.
• [747] Targeting the testis-specific heat-shock protein 70-2 (HSP70-2) reduces cellular growth, migration, and invasion in renal cell carcinoma cells.Tumour Biol. 2014 Dec;35(12):12695-706. doi: 10.1007/s13277-014-2594-5. Epub 2014 Sep 12.
• [748] Downregulation of the tumor suppressor HSPB7, involved in the p53 pathway, in renal cell carcinoma by hypermethylation.Int J Oncol. 2014 May;44(5):1490-8. doi: 10.3892/ijo.2014.2314. Epub 2014 Feb 27.
• [749] Evaluation of renal cell carcinoma vaccines targeting carbonic anhydrase IX using heat shock protein 110.Cancer Immunol Immunother. 2007 Jul;56(7):1097-105. doi: 10.1007/s00262-006-0258-z. Epub 2006 Dec 5.
• [750] HtrA3 is regulated by 15-deoxy-Delta12,14-prostaglandin J2 independently of PPARgamma in clear cell renal cell carcinomas.Biochem Biophys Res Commun. 2010 Apr 9;394(3):453-8. doi: 10.1016/j.bbrc.2009.11.163. Epub 2009 Nov 29.
• [751] Nivolumab in the treatment of advanced renal cell carcinoma.Future Oncol. 2018 Jul;14(17):1679-1689. doi: 10.2217/fon-2017-0533. Epub 2018 Feb 20.
• [752] Sensitization of renal carcinoma to radiation using alpha interferon (IFNA) gene transfection.Radiat Res. 1997 Nov;148(5):443-8.
• [753] miR-372 suppresses tumour proliferation and invasion by targeting IGF2BP1 in renal cell carcinoma.Cell Prolif. 2015 Oct;48(5):593-9. doi: 10.1111/cpr.12207.
• [754] External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma.Cancer. 2008 Apr 1;112(7):1471-9. doi: 10.1002/cncr.23296.
• [755] Insulin like growth factor binding protein 4 promotes GBM progression and regulates key factors involved in EMT and invasion.J Neurooncol. 2014 Feb;116(3):455-64. doi: 10.1007/s11060-013-1324-y. Epub 2014 Jan 7.
• [756] Significant association of interleukin 10 receptor mRNA levels with renal cell carcinoma metastasis.Biomed Res. 2008 Feb;29(1):19-25. doi: 10.2220/biomedres.29.19.
• [757] Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum(II) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody. Cancer Res. 1995 Feb 1;55(3):590-6.
• [758] Immunoreactivity of CD10 and inhibin alpha in differentiating hemangioblastoma of central nervous system from metastatic clear cell renal cell carcinoma.Mod Pathol. 2005 Jun;18(6):788-94. doi: 10.1038/modpathol.3800351.
• [759] SubID, a non-median dichotomization tool for heterogeneous populations, reveals the pan-cancer significance of INPP4B and its regulation by EVI1 in AML.PLoS One. 2018 Feb 7;13(2):e0191510. doi: 10.1371/journal.pone.0191510. eCollection 2018.
• [760] Hyper-interleukin-11 novel designer molecular adjuvant targeting gp130 for whole cell cancer vaccines.Expert Opin Biol Ther. 2011 Dec;11(12):1555-67. doi: 10.1517/14712598.2011.627852. Epub 2011 Oct 14.
• [761] Diverse CD8+ T-cell responses to renal cell carcinoma antigens in patients treated with an autologous granulocyte-macrophage colony-stimulating factor gene-transduced renal tumor cell vaccine.Cancer Res. 2005 Feb 1;65(3):1079-88.
• [762] Multiple tumor suppressors regulate a HIF-dependent negative feedback loop via ISGF3 in human clear cell renal cancer.Elife. 2018 Oct 25;7:e37925. doi: 10.7554/eLife.37925.
• [763] Genetic variation in platelet integrin alphabeta (GPIIb/IIIa) and the metastatic potential of renal cell carcinoma.BJU Int. 2006 Jul;98(1):201-4. doi: 10.1111/j.1464-410X.2006.06196.x.
• [764] Acquired resistance to temsirolimus is associated with integrin 7 driven chemotactic activity of renal cell carcinoma in vitro.Oncotarget. 2018 Apr 10;9(27):18747-18759. doi: 10.18632/oncotarget.24650. eCollection 2018 Apr 10.
• [765] Antitumor effect and biological pathways of a recombinant adeno-associated virus as a human renal cell carcinoma suppressor.Tumour Biol. 2014 Nov;35(11):10993-1003. doi: 10.1007/s13277-014-2393-z. Epub 2014 Aug 5.
• [766] Jam3 promotes migration and suppresses apoptosis of renal carcinoma cell lines.Int J Mol Med. 2018 Nov;42(5):2923-2929. doi: 10.3892/ijmm.2018.3854. Epub 2018 Sep 4.
• [767] Kank1 reexpression induced by 5-Aza-2'-deoxycytidine suppresses nasopharyngeal carcinoma cell proliferation and promotes apoptosis.Int J Clin Exp Pathol. 2015 Feb 1;8(2):1658-65. eCollection 2015.
• [768] Overexpressed CacyBP/SIP leads to the suppression of growth in renal cell carcinoma.Biochem Biophys Res Commun. 2007 May 18;356(4):864-71. doi: 10.1016/j.bbrc.2007.03.080. Epub 2007 Mar 26.
• [769] Correlation of low expression of hMOF with clinicopathological features of colorectal carcinoma, gastric cancer and renal cell carcinoma.Int J Oncol. 2014 Apr;44(4):1207-14. doi: 10.3892/ijo.2014.2266. Epub 2014 Jan 21.
• [770] Mapping of constitutional translocation breakpoints in renal cell cancer patients: identification of KCNIP4 as a candidate gene.Cancer Genet Cytogenet. 2007 Nov;179(1):11-8. doi: 10.1016/j.cancergencyto.2007.07.005.
• [771] A polymorphism in the splice donor site of ZNF419 results in the novel renal cell carcinoma-associated minor histocompatibility antigen ZAPHIR.PLoS One. 2011;6(6):e21699. doi: 10.1371/journal.pone.0021699. Epub 2011 Jun 28.
• [772] Expression and functional role of miR-29b in renal cell carcinoma.Int J Clin Exp Pathol. 2015 Nov 1;8(11):14161-70. eCollection 2015.
• [773] A novel HDAC inhibitor OBP-801 and a PI3K inhibitor LY294002 synergistically induce apoptosis via the suppression of survivin and XIAP in renal cell carcinoma.Int J Oncol. 2013 Oct;43(4):1080-6. doi: 10.3892/ijo.2013.2042. Epub 2013 Jul 30.
• [774] Krppel-like factor 8 (KLF8) is expressed in gliomas of different WHO grades and is essential for tumor cell proliferation.PLoS One. 2012;7(1):e30429. doi: 10.1371/journal.pone.0030429. Epub 2012 Jan 19.
• [775] Prognostic implications of the immunohistochemical expression of human kallikreins 5, 6, 10 and 11 in renal cell carcinoma.Tumour Biol. 2006;27(1):1-7. doi: 10.1159/000090150. Epub 2005 Dec 8.
• [776] Re-evaluation of 33 'unclassified' eosinophilic renal cell carcinomas in young patients.Histopathology. 2018 Mar;72(4):588-600. doi: 10.1111/his.13395. Epub 2017 Dec 4.
• [777] KRT6 interacting with notch1 contributes to progression of renal cell carcinoma, and aliskiren inhibits renal carcinoma cell lines proliferation in vitro.Int J Clin Exp Pathol. 2015 Aug 1;8(8):9182-8. eCollection 2015.
• [778] Methylationassociated inactivation of LATS1 and its effect on demethylation or overexpression on YAP and cell biological function in human renal cell carcinoma.Int J Oncol. 2014 Dec;45(6):2511-21. doi: 10.3892/ijo.2014.2687. Epub 2014 Sep 30.
• [779] Four new human renal cell carcinoma cell lines expressing globo-series gangliosides.Tohoku J Exp Med. 1999 Oct;189(2):95-105. doi: 10.1620/tjem.189.95.
• [780] Profilin 1 overexpression in renal cell carcinoma.Int J Urol. 2011 Jan;18(1):63-71. doi: 10.1111/j.1442-2042.2010.02670.x. Epub 2010 Nov 22.
• [781] LRIG1 and epidermal growth factor receptor in renal cell carcinoma: a quantitative RT--PCR and immunohistochemical analysis.Br J Cancer. 2003 Oct 6;89(7):1285-9. doi: 10.1038/sj.bjc.6601208.
• [782] Over expression of HIF1 is associated with inactivation of both LimD1 and VHL in renal cell carcinoma: Clinical importance.Pathol Res Pract. 2017 Dec;213(12):1477-1481. doi: 10.1016/j.prp.2017.10.009. Epub 2017 Oct 10.
• [783] Increased glyceraldehyde-3-phosphate dehydrogenase expression in renal cell carcinoma identified by RNA-based, arbitrarily primed polymerase chain reaction.Cancer. 2000 Jul 1;89(1):152-64.
• [784] Methylation pattern of the putative tumor-suppressor gene LRRC3B promoter in clear cell renal cell carcinomas.Mol Med Rep. 2012 Feb;5(2):509-12. doi: 10.3892/mmr.2011.681. Epub 2011 Nov 16.
• [785] The t(1;3) breakpoint-spanning genes LSAMP and NORE1 are involved in clear cell renal cell carcinomas.Cancer Cell. 2003 Nov;4(5):405-13. doi: 10.1016/s1535-6108(03)00269-1.
• [786] Identification of TGF--activated kinase 1 as a possible novel target for renal cell carcinoma intervention.Biochem Biophys Res Commun. 2014 Oct 10;453(1):106-11. doi: 10.1016/j.bbrc.2014.09.070. Epub 2014 Sep 26.
• [787] Generation of RAGE-1 and MAGE-9 peptide-specific cytotoxic T-lymphocyte lines for transfer in patients with renal cell carcinoma.Int J Cancer. 2005 Nov 1;117(2):256-64. doi: 10.1002/ijc.21200.
• [788] MAGED4-expression in renal cell carcinoma and identification of an HLA-A*25-restricted MHC class I ligand from solid tumor tissue.Cancer Biol Ther. 2005 Sep;4(9):943-8. doi: 10.4161/cbt.4.9.1907. Epub 2005 Sep 8.
• [789] Role of the RNA-binding protein HuR in human renal cell carcinoma.Carcinogenesis. 2010 Jun;31(6):1018-26. doi: 10.1093/carcin/bgq052. Epub 2010 Mar 10.
• [790] MAML1 acts cooperatively with EGR1 to activate EGR1-regulated promoters: implications for nephrogenesis and the development of renal cancer.PLoS One. 2012;7(9):e46001. doi: 10.1371/journal.pone.0046001. Epub 2012 Sep 27.
• [791] Defects in MAP1S-mediated autophagy turnover of fibronectin cause renal fibrosis.Aging (Albany NY). 2016 May;8(5):977-85. doi: 10.18632/aging.100957.
• [792] Linkage of microRNA and proteome-based profiling data sets: a perspective for the priorization of candidate biomarkers in renal cell carcinoma?.J Proteome Res. 2011 Jan 7;10(1):191-9. doi: 10.1021/pr1011137.
• [793] Development of novel reversal agents, imidazothiazole derivatives, targeting MDR1- and MRP-mediated multidrug resistance.Oncol Res. 1998;10(3):123-32.
• [794] Clinical and Molecular Features of Renal and Pheochromocytoma/Paraganglioma Tumor Association Syndrome (RAPTAS): Case Series and Literature Review.J Clin Endocrinol Metab. 2017 Nov 1;102(11):4013-4022. doi: 10.1210/jc.2017-00562.
• [795] Myoglobin expression in renal cell carcinoma is regulated by hypoxia.Exp Mol Pathol. 2013 Dec;95(3):307-12. doi: 10.1016/j.yexmp.2013.09.003. Epub 2013 Sep 25.
• [796] Genetic susceptibility to renal cell carcinoma: the role of DNA double-strand break repair pathway.Cancer Epidemiol Biomarkers Prev. 2008 Sep;17(9):2366-73. doi: 10.1158/1055-9965.EPI-08-0259.
• [797] Primary microcephaly gene MCPH1 shows a novel molecular biomarker of human renal carcinoma and is regulated by miR-27a.Int J Clin Exp Pathol. 2014 Jul 15;7(8):4895-903. eCollection 2014.
• [798] Knockdown of MSP58 inhibits the proliferation and metastasis in human renal cell carcinoma cells.Biomed Pharmacother. 2017 Jul;91:54-59. doi: 10.1016/j.biopha.2017.04.036. Epub 2017 May 23.
• [799] Comprehensive analysis of the transcriptional profile of the Mediator complex across human cancer types.Oncotarget. 2016 Apr 26;7(17):23043-23055. doi: 10.18632/oncotarget.8469.
• [800] A Rare Partner of TFE3 in the Xp11 Translocation Renal Cell Carcinoma: Clinicopathological Analyses and Detection of MED15-TFE3 Fusion.Biomed Res Int. 2019 Nov 11;2019:5974089. doi: 10.1155/2019/5974089. eCollection 2019.
• [801] The M6A methyltransferase METTL3: acting as a tumor suppressor in renal cell carcinoma.Oncotarget. 2017 Oct 10;8(56):96103-96116. doi: 10.18632/oncotarget.21726. eCollection 2017 Nov 10.
• [802] Expression of the matrix Gla protein in urogenital malignancies.Int J Cancer. 1992 Oct 21;52(4):534-7. doi: 10.1002/ijc.2910520406.
• [803] Loss of PIG3 increases HIF-1 level by promoting protein synthesis via mTOR pathway in renal cell carcinoma cells.Oncotarget. 2016 May 10;7(19):27176-84. doi: 10.18632/oncotarget.8401.
• [804] Induction of cell cycle arrest by increasing GTPRhoA levels via Taxolinduced microtubule polymerization in renal cell carcinoma.Mol Med Rep. 2017 Jun;15(6):4273-4279. doi: 10.3892/mmr.2017.6543. Epub 2017 May 3.
• [805] MTHFD2 links RNA methylation to metabolic reprogramming in renal cell carcinoma.Oncogene. 2019 Aug;38(34):6211-6225. doi: 10.1038/s41388-019-0869-4. Epub 2019 Jul 9.
• [806] Mitochondrial E3 ubiquitin ligase 1 promotes autophagy flux to suppress the development of clear cell renal cell carcinomas.Cancer Sci. 2019 Nov;110(11):3533-3542. doi: 10.1111/cas.14192. Epub 2019 Sep 28.
• [807] MXRA5 is a TGF-1-regulated human protein with anti-inflammatory and anti-fibrotic properties.J Cell Mol Med. 2017 Jan;21(1):154-164. doi: 10.1111/jcmm.12953. Epub 2016 Sep 6.
• [808] NMMHC-IIA-dependent nuclear location of CXCR4 promotes migration and invasion in renal cell carcinoma.Oncol Rep. 2016 Nov;36(5):2681-2688. doi: 10.3892/or.2016.5082. Epub 2016 Sep 12.
• [809] Aberrant expression of napsin A in a subset of malignant lymphomas.Histol Histopathol. 2016 Feb;31(2):213-21. doi: 10.14670/HH-11-669. Epub 2015 Sep 24.
• [810] DNA repair system and renal cell carcinoma prognosis: under the influence of NBS1.Med Oncol. 2015 Nov;32(11):255. doi: 10.1007/s12032-015-0701-0. Epub 2015 Oct 22.
• [811] The genetic locus NRC-1 within chromosome 3p12 mediates tumor suppression in renal cell carcinoma independently of histological type, tumor microenvironment, and VHL mutation.Cancer Res. 1999 May 1;59(9):2182-9.
• [812] Detection of mitochondrial genome depletion by a novel cDNA in renal cell carcinoma.Lab Invest. 1996 Mar;74(3):592-9.
• [813] Neurofilament Heavy polypeptide CpG island methylation associates with prognosis of renal cell carcinoma and prediction of antivascular endothelial growth factor therapy response.Cancer Med. 2014 Apr;3(2):300-9. doi: 10.1002/cam4.181. Epub 2014 Jan 27.
• [814] Expression and regulatory effects on cancer cell behavior of NELL1 and NELL2 in human renal cell carcinoma.Cancer Sci. 2015 May;106(5):656-64. doi: 10.1111/cas.12649. Epub 2015 Mar 26.
• [815] Inverse relationship of epidermal growth factor receptor and HER2/neu gene expression in human renal cell carcinoma.Cancer Res. 1990 Aug 1;50(15):4504-9.
• [816] The plasma membrane sialidase NEU3 regulates the malignancy of renal carcinoma cells by controlling 1 integrin internalization and recycling.J Biol Chem. 2012 Dec 14;287(51):42835-45. doi: 10.1074/jbc.M112.407718. Epub 2012 Nov 8.
• [817] Analysis of the regulation of fatty acid binding protein 7 expression in human renal carcinoma cell lines.BMC Mol Biol. 2011 Jul 19;12:31. doi: 10.1186/1471-2199-12-31.
• [818] MDM2 interacts with NME2 (non-metastatic cells 2, protein) and suppresses the ability of NME2 to negatively regulate cell motility.Carcinogenesis. 2011 Aug;32(8):1133-42. doi: 10.1093/carcin/bgr070. Epub 2011 Apr 18.
• [819] Expression of apoptotic tumour necrosis factor receptor-associated factor, caspase recruitment domain and cell death-inducing DFF-45 effector genes in therapy-treated renal cell carcinoma.Nephrology (Carlton). 2009 Apr;14(2):205-12. doi: 10.1111/j.1440-1797.2008.01027.x.
• [820] Xp11.2 translocation renal neoplasm with features of TFE3 rearrangement associated renal cell carcinoma and Xp11 translocation renal mesenchymal tumor with melanocytic differentiation harboring NONO-TFE3 fusion gene.Pathol Res Pract. 2019 Sep;215(9):152521. doi: 10.1016/j.prp.2019.152521. Epub 2019 Jun 27.
• [821] Characterization of Niemann-Pick Type C2 protein expression in multiple cancers using a novel NPC2 monoclonal antibody.PLoS One. 2013 Oct 17;8(10):e77586. doi: 10.1371/journal.pone.0077586. eCollection 2013.
• [822] Double stranded-RNA-mediated activation of P21 gene induced apoptosis and cell cycle arrest in renal cell carcinoma.Int J Cancer. 2009 Jul 15;125(2):446-52. doi: 10.1002/ijc.24370.
• [823] NUB1, an interferon-inducible protein, mediates anti-proliferative actions and apoptosis in renal cell carcinoma cells through cell-cycle regulation.Br J Cancer. 2010 Mar 2;102(5):873-82. doi: 10.1038/sj.bjc.6605574. Epub 2010 Feb 16.
• [824] Downregulation of nucleolar and spindle-associated protein1 expression suppresses cell migration, proliferation and invasion in renal cell carcinoma.Oncol Rep. 2016 Sep;36(3):1506-16. doi: 10.3892/or.2016.4955. Epub 2016 Jul 20.
• [825] Odd-skipped related transcription factor 1 (OSR1) suppresses tongue squamous cell carcinoma migration and invasion through inhibiting NF-B pathway.Eur J Pharmacol. 2018 Nov 15;839:33-39. doi: 10.1016/j.ejphar.2018.09.020. Epub 2018 Sep 19.
• [826] P3H4 affects renal carcinoma through up-regulating miR-1/133a.Eur Rev Med Pharmacol Sci. 2018 Aug;22(16):5180-5186. doi: 10.26355/eurrev_201808_15714.
• [827] High-resolution analysis of DNA copy number alterations and gene expression in renal clear cell carcinoma.J Pathol. 2007 Dec;213(4):392-401. doi: 10.1002/path.2239.
• [828] Immunohistochemical profiles in primary lung cancers and epithelial pulmonary metastases.Hum Pathol. 2019 Feb;84:221-230. doi: 10.1016/j.humpath.2018.10.009. Epub 2018 Oct 31.
• [829] Aberrant Promoter Methylation of PCDH17 (Protocadherin 17) in Serum and its Clinical Significance in Renal Cell Carcinoma.Med Sci Monit. 2017 Jul 8;23:3318-3323. doi: 10.12659/msm.902077.
• [830] Association between protocadherin 8 promoter hypermethylation and the pathological status of prostate cancer.Oncol Lett. 2017 Aug;14(2):1657-1664. doi: 10.3892/ol.2017.6282. Epub 2017 May 31.
• [831] KIAA0101 is associated with human renal cell carcinoma proliferation and migration induced by erythropoietin.Oncotarget. 2016 Mar 22;7(12):13520-37. doi: 10.18632/oncotarget.5876.
• [832] Mutation analysis of HIF prolyl hydroxylases (PHD/EGLN) in individuals with features of phaeochromocytoma and renal cell carcinoma susceptibility.Endocr Relat Cancer. 2010 Dec 21;18(1):73-83. doi: 10.1677/ERC-10-0113. Print 2011 Feb.
• [833] Common variation at 2q22.3 (ZEB2) influences the risk of renal cancer.Hum Mol Genet. 2013 Feb 15;22(4):825-31. doi: 10.1093/hmg/dds489. Epub 2012 Nov 25.
• [834] Caspase-8 and its inhibitors in RCCs in vivo: the prominent role of ARC.Apoptosis. 2008 Jul;13(7):938-49. doi: 10.1007/s10495-008-0225-6.
• [835] Profilin-1 expression is associated with high grade and stage and decreased disease-free survival in renal cell carcinoma.Hum Pathol. 2015 May;46(5):673-80. doi: 10.1016/j.humpath.2014.11.007. Epub 2014 Nov 26.
• [836] MicroRNA-34a suppresses malignant transformation by targeting c-Myc transcriptional complexes in human renal cell carcinoma.Carcinogenesis. 2012 Feb;33(2):294-300. doi: 10.1093/carcin/bgr286. Epub 2011 Dec 9.
• [837] Inhibition of MMP-9 using a pyrrole-imidazole polyamide reduces cell invasion in renal cell carcinoma.Int J Oncol. 2013 Nov;43(5):1441-6. doi: 10.3892/ijo.2013.2073. Epub 2013 Aug 21.
• [838] Integrin 5 triggers the metastatic potential in renal cell carcinoma.Oncotarget. 2017 Nov 18;8(64):107530-107542. doi: 10.18632/oncotarget.22501. eCollection 2017 Dec 8.
• [839] Nuclear factor-B signaling pathway is involved in phospholipase C-regulated proliferation in human renal cell carcinoma cells.Mol Cell Biochem. 2014 Apr;389(1-2):265-75. doi: 10.1007/s11010-013-1948-4. Epub 2014 Feb 8.
• [840] Bioplasmonic paper-based assay for perilipin-2 non-invasively detects renal cancer.Kidney Int. 2019 Dec;96(6):1417-1421. doi: 10.1016/j.kint.2019.08.020. Epub 2019 Sep 3.
• [841] Targeting neddylation pathway with MLN4924 (Pevonedistat) induces NOXA-dependent apoptosis in renal cell carcinoma.Biochem Biophys Res Commun. 2017 Sep 2;490(4):1183-1188. doi: 10.1016/j.bbrc.2017.06.179. Epub 2017 Jun 29.
• [842] Expression level of CXCL7 in peripheral blood cells is a potential biomarker for the diagnosis of renal cell carcinoma.Cancer Sci. 2017 Dec;108(12):2495-2502. doi: 10.1111/cas.13414. Epub 2017 Oct 25.
• [843] Liprin-4 is a new hypoxia-inducible target gene required for maintenance of cell-cell contacts.Exp Cell Res. 2010 Oct 15;316(17):2883-92. doi: 10.1016/j.yexcr.2010.06.022. Epub 2010 Jul 1.
• [844] Aberrant Methylation of the 1p36 Tumor Suppressor Gene RIZ1 in Renal Cell Carcinoma.Asian Pac J Cancer Prev. 2015;16(9):4071-5. doi: 10.7314/apjcp.2015.16.9.4071.
• [845] PRKX, TTBK2 and RSK4 expression causes Sunitinib resistance in kidney carcinoma- and melanoma-cell lines.Int J Cancer. 2012 Jul 15;131(2):E45-55. doi: 10.1002/ijc.26486. Epub 2012 Feb 28.
• [846] Tumor signatures of PTHLH overexpression, high serum calcium, and poor prognosis were observed exclusively in clear cell but not non clear cell renal carcinomas.Cancer Med. 2014 Aug;3(4):845-54. doi: 10.1002/cam4.270. Epub 2014 May 26.
• [847] A homozygous deletion within the carbonic anhydrase-like domain of the Ptprg gene in murine L-cells.Cancer Res. 1993 Apr 1;53(7):1498-502.
• [848] Diagnostic value of cytokeratin 7 and parvalbumin in differentiating chromophobe renal cell carcinoma from renal oncocytoma.Anal Quant Cytol Histol. 2006 Aug;28(4):228-36.
• [849] Paxillin: application of immunohistochemistry to the diagnosis of chromophobe renal cell carcinoma and oncocytoma.Appl Immunohistochem Mol Morphol. 2001 Dec;9(4):315-8. doi: 10.1097/00129039-200112000-00005.
• [850] YueF overexpression inhibits cell proliferation partly through p21 upregulation in renal cell carcinoma.Int J Mol Sci. 2011;12(4):2477-87. doi: 10.3390/ijms12042477. Epub 2011 Apr 11.
• [851] Involvement of TMEM22 overexpression in the growth of renal cell carcinoma cells.Oncol Rep. 2009 Feb;21(2):305-12.
• [852] The tumor susceptibility gene TMEM127 is mutated in renal cell carcinomas and modulates endolysosomal function.Hum Mol Genet. 2014 May 1;23(9):2428-39. doi: 10.1093/hmg/ddt638. Epub 2013 Dec 13.
• [853] Tissue slice grafts of human renal cell carcinoma: an authentic preclinical model with high engraftment rate and metastatic potential.Urol Oncol. 2014 Jan;32(1):43.e23-30. doi: 10.1016/j.urolonc.2013.05.008. Epub 2013 Aug 2.
• [854] RALY RNA binding protein-like reduced expression is associated with poor prognosis in clear cell renal cell carcinoma.Asian Pac J Cancer Prev. 2012;13(7):3403-8. doi: 10.7314/apjcp.2012.13.7.3403.
• [855] High expression of Ran GTPase is associated with local invasion and metastasis of human clear cell renal cell carcinoma.Int J Cancer. 2008 May 15;122(10):2391-7. doi: 10.1002/ijc.23400.
• [856] miR-28-5p acts as a tumor suppressor in renal cell carcinoma for multiple antitumor effects by targeting RAP1B.Oncotarget. 2016 Nov 8;7(45):73888-73902. doi: 10.18632/oncotarget.12516.
• [857] Rap1GAP regulates renal cell carcinoma invasion.Cancer Lett. 2012 Jul 1;320(1):65-71. doi: 10.1016/j.canlet.2012.01.022. Epub 2012 Jan 20.
• [858] Rap2B promotes angiogenesis via PI3K/AKT/VEGF signaling pathway in human renal cell carcinoma.Tumour Biol. 2017 Jul;39(7):1010428317701653. doi: 10.1177/1010428317701653.
• [859] Preoperative serum cystatin-C as a potential biomarker for prognosis of renal cell carcinoma.PLoS One. 2017 Jun 6;12(6):e0178823. doi: 10.1371/journal.pone.0178823. eCollection 2017.
• [860] Expression and clinicopathological correlations of retinoid acid receptor responder protein 1 in renal cell carcinomas.Biomark Med. 2016 Jul;10(7):721-32. doi: 10.2217/bmm.16.12. Epub 2016 Jun 24.
• [861] Dual roles for coactivator activator and its counterbalancing isoform coactivator modulator in human kidney cell tumorigenesis.Cancer Res. 2008 Oct 1;68(19):7887-96. doi: 10.1158/0008-5472.CAN-08-1734.
• [862] The expression of RNA-binding protein RBM38 decreased in renal cell carcinoma and represses renal cancer cell proliferation, migration, and invasion.Tumour Biol. 2017 May;39(5):1010428317701635. doi: 10.1177/1010428317701635.
• [863] Expression of Ring Box-1 protein and its relationship with Fuhrman grade and other clinical-pathological parameters in renal cell cancer.Urol Oncol. 2020 Jan;38(1):6.e17-6.e22. doi: 10.1016/j.urolonc.2019.09.019. Epub 2019 Oct 23.
• [864] Estrogen inhibits renal cell carcinoma cell progression through estrogen receptor- activation.PLoS One. 2013;8(2):e56667. doi: 10.1371/journal.pone.0056667. Epub 2013 Feb 27.
• [865] Prognostic biomarkers in renal cell carcinoma: is there a relationship with obesity?.Transl Androl Urol. 2019 May;8(Suppl 2):S138-S146. doi: 10.21037/tau.2018.11.10.
• [866] Expression of regulator of G protein signalling protein 5 (RGS5) in the tumour vasculature of human renal cell carcinoma.J Pathol. 2004 May;203(1):551-8. doi: 10.1002/path.1543.
• [867] Variability in the expression of polycomb proteins in different normal and tumoral tissues. A pilot study using tissue microarrays.Mod Pathol. 2006 May;19(5):684-94. doi: 10.1038/modpathol.3800577.
• [868] SETDB2 and RIOX2 are differentially expressed among renal cell tumor subtypes, associating with prognosis and metastization.Epigenetics. 2017;12(12):1057-1064. doi: 10.1080/15592294.2017.1385685. Epub 2018 Jan 22.
• [869] Parathyroid hormone-related protein. Evidence for secretion of a novel mid-region fragment by three different cell types.J Biol Chem. 1992 Sep 5;267(25):18236-43.
• [870] Differentiation between papillary and nonpapillary renal cell carcinomas by DNA analysis.J Natl Cancer Inst. 1989 Apr 5;81(7):527-30. doi: 10.1093/jnci/81.7.527.
• [871] Prognostic Value of RNASEH2A-, CDK1-, and CD151-Related Pathway Gene Profiling for Kidney Cancers.Int J Mol Sci. 2018 May 28;19(6):1586. doi: 10.3390/ijms19061586.
• [872] Really interesting new gene finger protein 121 is a tumor suppressor of renal cell carcinoma.Gene. 2018 Nov 15;676:322-328. doi: 10.1016/j.gene.2018.08.067. Epub 2018 Aug 25.
• [873] Network spatio-temporal analysis predicts disease stage-related genes and pathways in renal cell carcinoma.Genet Mol Res. 2016 May 6;15(2). doi: 10.4238/gmr.15028061.
• [874] Growth suppression induced by the TRC8 hereditary kidney cancer gene is dependent upon JAB1/CSN5.Oncogene. 2005 May 12;24(21):3503-11. doi: 10.1038/sj.onc.1208509.
• [875] Programmed death-1 (PD-1) receptor/PD-1 ligand (PD-L1) expression in fumarate hydratase-deficient renal cell carcinoma.Ann Diagn Pathol. 2017 Aug;29:17-22. doi: 10.1016/j.anndiagpath.2017.04.007. Epub 2017 Apr 24.
• [876] Knockdown of ribosomal protein S15A inhibits human kidney cancer cell growth invitro and invivo.Mol Med Rep. 2019 Feb;19(2):1117-1127. doi: 10.3892/mmr.2018.9751. Epub 2018 Dec 12.
• [877] The ribosomal protein S6 in renal cell carcinoma: functional relevance and potential as biomarker.Oncotarget. 2016 Jan 5;7(1):418-32. doi: 10.18632/oncotarget.6225.
• [878] Loss of the tissue-specific proapoptotic BH3-only protein Nbk/Bik is a unifying feature of renal cell carcinoma.Cell Death Differ. 2006 Apr;13(4):619-27. doi: 10.1038/sj.cdd.4401782.
• [879] Immunohistochemical characterization of renal tumors in patients with Birt-Hogg-Dub syndrome.Pathol Int. 2015 Mar;65(3):126-32. doi: 10.1111/pin.12254. Epub 2015 Jan 19.
• [880] S100A11 regulates renal carcinoma cell proliferation, invasion, and migration via the EGFR/Akt signaling pathway and E-cadherin.Tumour Biol. 2017 May;39(5):1010428317705337. doi: 10.1177/1010428317705337.
• [881] Restricted expression of calcium-binding protein S100A5 in human kidney.Biochem Biophys Res Commun. 2002 Mar 1;291(3):623-7. doi: 10.1006/bbrc.2002.6494.
• [882] Despite differential gene expression profiles pediatric MDS derived mesenchymal stromal cells display functionality in vitro.Stem Cell Res. 2015 Mar;14(2):198-210. doi: 10.1016/j.scr.2015.01.006. Epub 2015 Jan 28.
• [883] The long noncoding RNA HOTAIR activates the Hippo pathway by directly binding to SAV1 in renal cell carcinoma.Oncotarget. 2017 Apr 25;8(35):58654-58667. doi: 10.18632/oncotarget.17414. eCollection 2017 Aug 29.
• [884] Flow cytometric quantitation of the proliferation-associated nuclear antigen p105 and DNA content in patients with renal cell carcinoma.Cancer. 1996 Aug 15;78(4):819-26. doi: 10.1002/(SICI)1097-0142(19960815)78:4<819::AID-CNCR19>3.0.CO;2-Y.
• [885] Regulation of antitumor miR-144-5p targets oncogenes: Direct regulation of syndecan-3 and its clinical significance.Cancer Sci. 2018 Sep;109(9):2919-2936. doi: 10.1111/cas.13722. Epub 2018 Jul 28.
• [886] Selenoprotein M stimulates the proliferative and metastatic capacities of renal cell carcinoma through activating the PI3K/AKT/mTOR pathway.Cancer Med. 2019 Aug;8(10):4836-4844. doi: 10.1002/cam4.2403. Epub 2019 Jul 5.
• [887] Seminal plasma protein in renal cell carcinoma: expression of semenogelin I is a predictor for cancer progression and prognosis.Tumour Biol. 2014 Sep;35(9):9095-100. doi: 10.1007/s13277-014-2184-6. Epub 2014 Jun 11.
• [888] Regulation of carcinoma cell invasion by protein C inhibitor whose expression is decreased in renal cell carcinoma.Int J Cancer. 2004 Feb 10;108(4):516-23. doi: 10.1002/ijc.11594.
• [889] Increased expression of SET domain-containing proteins and decreased expression of Rad51in different classes of renal cell carcinoma.Biosci Rep. 2016 Jun 30;36(3):e00349. doi: 10.1042/BSR20160122. Print 2016 Jul.
• [890] MicroRNA expression profiling of Xp11 renal cell carcinoma.Hum Pathol. 2017 Sep;67:18-29. doi: 10.1016/j.humpath.2017.03.011. Epub 2017 Apr 12.
• [891] Cell-Free SHOX2 DNA Methylation in Blood as a Molecular Staging Parameter for Risk Stratification in Renal Cell Carcinoma Patients: A Prospective Observational Cohort Study.Clin Chem. 2019 Apr;65(4):559-568. doi: 10.1373/clinchem.2018.297549. Epub 2019 Jan 9.
• [892] Transcription factor Six2 induces a stem cell-like phenotype in renal cell carcinoma cells.FEBS Open Bio. 2019 Oct;9(10):1808-1816. doi: 10.1002/2211-5463.12721. Epub 2019 Sep 19.
• [893] Regulation of spindle and kinetochore-associated protein 1 by antitumor miR-10a-5p in renal cell carcinoma.Cancer Sci. 2017 Oct;108(10):2088-2101. doi: 10.1111/cas.13331. Epub 2017 Aug 19.
• [894] Targeted p21(WAF1/CIP1) activation by miR-1236 inhibits cell proliferation and correlates with favorable survival in renal cell carcinoma.Urol Oncol. 2016 Feb;34(2):59.e23-34. doi: 10.1016/j.urolonc.2015.08.014. Epub 2015 Sep 28.
• [895] Promoter CpG island methylation in ion transport mechanisms and associated dietary intakes jointly influence the risk of clear-cell renal cell cancer.Int J Epidemiol. 2017 Apr 1;46(2):622-631. doi: 10.1093/ije/dyw266.
• [896] Human Schlafen 5 (SLFN5) Is a Regulator of Motility and Invasiveness of Renal Cell Carcinoma Cells.Mol Cell Biol. 2015 Aug;35(15):2684-98. doi: 10.1128/MCB.00019-15. Epub 2015 May 26.
• [897] Calcitriol inhibits migration and invasion of renal cell carcinoma cells by suppressing Smad2/3-, STAT3- and -catenin-mediated epithelial-mesenchymal transition.Cancer Sci. 2020 Jan;111(1):59-71. doi: 10.1111/cas.14237.
• [898] SWI/SNF protein expression status in fumarate hydratase-deficient renal cell carcinoma: immunohistochemical analysis of 32 tumors from 28 patients.Hum Pathol. 2018 Jul;77:139-146. doi: 10.1016/j.humpath.2018.04.004. Epub 2018 Apr 22.
• [899] Imaging Review of New and Emerging Sinonasal Tumors and Tumor-Like Entities from the Fourth Edition of the World Health Organization Classification of Head and Neck Tumors.AJNR Am J Neuroradiol. 2019 Apr;40(4):584-590. doi: 10.3174/ajnr.A5978. Epub 2019 Feb 14.
• [900] Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome-Associated Renal Cell Carcinoma Showing High FDG Uptake.Clin Nucl Med. 2019 May;44(5):420-423. doi: 10.1097/RLU.0000000000002495.
• [901] Reduction of transforming growth factor-beta type II receptor is caused by the enhanced ubiquitin-dependent degradation in human renal cell carcinoma.Int J Cancer. 2010 Oct 1;127(7):1517-25. doi: 10.1002/ijc.25164.
• [902] LncRNA NONHSAT113026 represses renal cell carcinoma tumorigenesis through interacting with NF-B/p50 and SLUG.Biomed Pharmacother. 2019 Oct;118:109382. doi: 10.1016/j.biopha.2019.109382. Epub 2019 Aug 28.
• [903] Classic SRY-box protein SOX7 functions as a tumor suppressor regulating WNT signaling and is methylated in renal cell carcinoma.FASEB J. 2019 Jan;33(1):254-263. doi: 10.1096/fj.201701453RR. Epub 2018 Jun 29.
• [904] Sperm-associated antigen 4, a novel hypoxia-inducible factor 1 target, regulates cytokinesis, and its expression correlates with the prognosis of renal cell carcinoma.Am J Pathol. 2013 Jun;182(6):2191-203. doi: 10.1016/j.ajpath.2013.02.024. Epub 2013 Apr 17.
• [905] MicroRNA-200a-3p suppresses tumor proliferation and induces apoptosis by targeting SPAG9 in renal cell carcinoma.Biochem Biophys Res Commun. 2016 Feb 12;470(3):620-626. doi: 10.1016/j.bbrc.2016.01.095. Epub 2016 Jan 23.
• [906] SPARCL1 suppresses cell migration and invasion in renal cell carcinoma.Mol Med Rep. 2017 Nov;16(5):7784-7790. doi: 10.3892/mmr.2017.7535. Epub 2017 Sep 20.
• [907] Tumor-associated trypsin inhibitor in normal and malignant renal tissue and in serum of renal-cell carcinoma patients.Int J Cancer. 1999 Nov 12;83(4):486-90. doi: 10.1002/(sici)1097-0215(19991112)83:4<486::aid-ijc9>3.0.co;2-o.
• [908] Speckle-type POZ protein as a diagnostic biomarker in renal cell carcinoma.J Cancer Res Ther. 2018 Jul-Sep;14(5):977-982. doi: 10.4103/jcrt.JCRT_942_15.
• [909] Sprouty2 is associated with prognosis and suppresses cell proliferation and invasion in renal cell carcinoma.Urology. 2013 Jul;82(1):253.e1-7. doi: 10.1016/j.urology.2013.02.051. Epub 2013 May 17.
• [910] SPTLC1 inhibits cell growth via modulating Akt/FOXO1 pathway in renal cell carcinoma cells.Biochem Biophys Res Commun. 2019 Nov 26;520(1):1-7. doi: 10.1016/j.bbrc.2019.09.073. Epub 2019 Sep 22.
• [911] Identification and characterization of human leukocyte antigen class I ligands in renal cell carcinoma cells.Proteomics. 2011 Jun;11(12):2528-41. doi: 10.1002/pmic.201000486. Epub 2011 May 18.
• [912] Knockdown of Slingshot 2 (SSH2) serine phosphatase induces Caspase3 activation in human carcinoma cell lines with the loss of the Birt-Hogg-Dub tumour suppressor gene (FLCN).Oncogene. 2014 Feb 20;33(8):956-65. doi: 10.1038/onc.2013.27. Epub 2013 Feb 18.
• [913] Human alpha2,3-sialyltransferase (ST3Gal II) is a stage-specific embryonic antigen-4 synthase.J Biol Chem. 2003 Jul 18;278(29):26474-9. doi: 10.1074/jbc.M213223200. Epub 2003 Apr 25.
• [914] MiR-193a-3p and miR-224 mediate renal cell carcinoma progression by targeting alpha-2,3-sialyltransferase IV and the phosphatidylinositol 3 kinase/Akt pathway.Mol Carcinog. 2018 Aug;57(8):1067-1077. doi: 10.1002/mc.22826. Epub 2018 May 2.
• [915] Characterization of a novel gene, STAG1/PMEPA1, upregulated in renal cell carcinoma and other solid tumors.Mol Carcinog. 2001 Sep;32(1):44-53. doi: 10.1002/mc.1063.
• [916] Cepharanthine Enhances TRAIL-Mediated Apoptosis Through STAMBPL1-Mediated Downregulation of Survivin Expression in Renal Carcinoma Cells.Int J Mol Sci. 2018 Oct 22;19(10):3280. doi: 10.3390/ijms19103280.
• [917] AIF downregulation and its interaction with STK3 in renal cell carcinoma.PLoS One. 2014 Jul 3;9(7):e100824. doi: 10.1371/journal.pone.0100824. eCollection 2014.
• [918] SUSD2 is frequently downregulated and functions as a tumor suppressor in RCC and lung cancer.Tumour Biol. 2016 Jul;37(7):9919-30. doi: 10.1007/s13277-015-4734-y. Epub 2016 Jan 27.
• [919] Analysis of the structural integrity of the TAP2 gene in renal cell carcinoma.Int J Oncol. 2003 Oct;23(4):991-9.
• [920] Adenoviral gene therapy for renal cancer requires retargeting to alternative cellular receptors.Cancer Res. 2002 Aug 1;62(15):4273-81.
• [921] Expression level of TBX3 gene in renal carcinoma and its clinical significance.Oncol Lett. 2018 Apr;15(4):4235-4240. doi: 10.3892/ol.2018.7841. Epub 2018 Jan 22.
• [922] Role of VHL gene mutation in human cancer.J Clin Oncol. 2004 Dec 15;22(24):4991-5004. doi: 10.1200/JCO.2004.05.061.
• [923] Restored expression levels of TET1 decrease the proliferation and migration of renal carcinoma cells.Mol Med Rep. 2015 Oct;12(4):4837-42. doi: 10.3892/mmr.2015.4058. Epub 2015 Jul 8.
• [924] TOP2A, HELLS, ATAD2, and TET3 Are Novel Prognostic Markers in Renal Cell Carcinoma.Urology. 2017 Apr;102:265.e1-265.e7. doi: 10.1016/j.urology.2016.12.050. Epub 2017 Jan 6.
• [925] Differential expression of activator protein-2 isoforms in renal cell carcinoma.Urology. 2004 Jul;64(1):162-7. doi: 10.1016/j.urology.2004.02.022.
• [926] New miRNA profiles accurately distinguish renal cell carcinomas and upper tract urothelial carcinomas from the normal kidney.PLoS One. 2014 Mar 12;9(3):e91646. doi: 10.1371/journal.pone.0091646. eCollection 2014.
• [927] Clinicopathologic and Molecular Analysis of the TFEB Fusion Variant Reveals New Members of TFEB Translocation Renal Cell Carcinomas (RCCs): Expanding the Genomic Spectrum.Am J Surg Pathol. 2020 Apr;44(4):477-489. doi: 10.1097/PAS.0000000000001408.
• [928] VHL-TGFBI signaling is involved in the synergy between 5-aza-2'-deoxycytidine and paclitaxel against human renal cell carcinoma.J BUON. 2017 Jul-Aug;22(4):1038-1045.
• [929] mRNA expression of matrix metalloproteases and their inhibitors differs in subtypes of renal cell carcinomas.Eur J Cancer. 2001 Oct;37(15):1839-46. doi: 10.1016/s0959-8049(01)00215-5.
• [930] Unique angiogenic and vasculogenic properties of renal cell carcinoma in a xenograft model of bone metastasis are associated with high levels of vegf-a and decreased ang-1 expression.J Orthop Res. 2012 Feb;30(2):325-33. doi: 10.1002/jor.21500. Epub 2011 Aug 1.
• [931] The effect of TMEFF2 methylation on the tumor stage and survival outcome of clear cell renal cell carcinoma.Cancer Biomark. 2017;19(2):207-212. doi: 10.3233/CBM-161656.
• [932] Characterization of the role of TMEM45A in cancer cell sensitivity to cisplatin.Cell Death Dis. 2019 Dec 4;10(12):919. doi: 10.1038/s41419-019-2088-x.
• [933] Amplification-independent overexpression of thymosin beta-10 mRNA in human renal cell carcinoma.Ren Fail. 1994;16(2):243-54. doi: 10.3109/08860229409044864.
• [934] The soluble Decoy Receptor 3 is regulated by a PI3K-dependent mechanism and promotes migration and invasion in renal cell carcinoma.Mol Cancer. 2013 Oct 10;12(1):120. doi: 10.1186/1476-4598-12-120.
• [935] CpG dinucleotide-specific hypermethylation of the TNS3 gene promoter in human renal cell carcinoma.Epigenetics. 2013 Jul;8(7):739-47. doi: 10.4161/epi.25075. Epub 2013 May 24.
• [936] Analysis of p73 expression pattern in acute myeloid leukemias: lack of DeltaN-p73 expression is a frequent feature of acute promyelocytic leukemia.Leukemia. 2004 Nov;18(11):1804-9. doi: 10.1038/sj.leu.2403483.
• [937] Tumor Protein D52 (TPD52) Inhibits Growth and Metastasis in Renal Cell Carcinoma Cells Through the PI3K/Akt Signaling Pathway.Oncol Res. 2017 May 24;25(5):773-779. doi: 10.3727/096504016X14774889687280. Epub 2016 Nov 8.
• [938] Tropomyosin-1 Functions as a Tumor Suppressor with Respect to Cell Proliferation, Angiogenesis and Metastasis in Renal Cell Carcinoma.J Cancer. 2019 May 21;10(10):2220-2228. doi: 10.7150/jca.28261. eCollection 2019.
• [939] ALK-TPM3 rearrangement in adult renal cell carcinoma: a case report and literature review.Diagn Pathol. 2019 Oct 18;14(1):112. doi: 10.1186/s13000-019-0879-0.
• [940] Patient samples of renal cell carcinoma show reduced expression of TRAF1 compared with normal kidney and functional studies in vitro indicate TRAF1 promotes apoptosis: potential for targeted therapy.Pathology. 2012 Aug;44(5):453-9. doi: 10.1097/PAT.0b013e3283557748.
• [941] Identification and validation of novel prognostic markers in Renal Cell Carcinoma.Dan Med J. 2017 Oct;64(10):B5339.
• [942] Valproic acid inhibits epithelialmesenchymal transition in renal cell carcinoma by decreasing SMAD4 expression.Mol Med Rep. 2017 Nov;16(5):6190-6199. doi: 10.3892/mmr.2017.7394. Epub 2017 Aug 29.
• [943] HNF4alpha reduces proliferation of kidney cells and affects genes deregulated in renal cell carcinoma.Oncogene. 2005 Sep 22;24(42):6418-31. doi: 10.1038/sj.onc.1208794.
• [944] Nutrient-induced FNIP degradation by SCF-TRCP regulates FLCN complex localization and promotes renal cancer progression.Oncotarget. 2017 Feb 7;8(6):9947-9960. doi: 10.18632/oncotarget.14221.
• [945] Systematic Expression Analysis of Mitochondrial Complex I Identifies NDUFS1 as a Biomarker in Clear-Cell Renal-Cell Carcinoma.Clin Genitourin Cancer. 2017 Aug;15(4):e551-e562. doi: 10.1016/j.clgc.2016.11.010. Epub 2016 Dec 1.
• [946] Quantitative Global Proteome and Lysine Succinylome Analyses Reveal the Effects of Energy Metabolism in Renal Cell Carcinoma.Proteomics. 2018 Oct;18(19):e1800001. doi: 10.1002/pmic.201800001. Epub 2018 Sep 5.
• [947] Thymoquinone inhibits metastatic phenotype and epithelialmesenchymal transition in renal cell carcinoma by regulating the LKB1/AMPK signaling pathway.Oncol Rep. 2018 Sep;40(3):1443-1450. doi: 10.3892/or.2018.6519. Epub 2018 Jun 25.